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Abstract 
 
Despite the ongoing political debate regarding the legality of medical marijuana, clinical 
investigations of the therapeutic use of cannabinoids are now more prevalent than at any 
time in history. Cannabinoids have been shown to have analgesic, anti-spasmodic, anti-
convulsant, anti-tremor, anti-psychotic, anti-inflammatory, anti-oxidant, anti-emetic and 
appetite-stimulant properties. There are mainly two well-known cannabinoid receptors, 
CB1 and CB2, located in the central (CB1) and peripheral (CB2) nervous systems as well 
as the immune system. More recently, endocannabinoids (ligands) and their receptors 
have also been found in the skeleton which appear as the main body system and 
physiologically regulated by CB2. 
This study aimed to examine the effect of both CB1 and CB2 receptor stimulation on 
wound closure response of MG-63 osteoblast bone cell monolayers using different 
treatments with cannabinoid such as Winn55,212-2, URB602 and HU308. Also, cell 
adhesion, cell proliferation and cell length was investigated. The study also aimed to 
examine the effect of HU308 treatments in combination with TGF-β3 (transforming 
growth factor beta -3) on wound healing, cell adhesion and extracellular matrix up 
regulation (collagen type I, fibronectin and protien S-100A6) as well as other biological 
factors such as secretion of matrix metalloproteinase (MMP-2) and nitric oxide (NO). 
Finally, this study investigated HU308/TGF-β3 combination treatment on the regulation 
of extracellular matrix (collagen type I, fibronectin and protien S-100A6) in a 3D 
multilayer system of MG-63 osteoblast bone cells. 
Wound healing assays of MG-63 monolayers revealed accelerated wound repair as well 
as increased cell proliferation mainly regulated through CB2 receptors, and that 
treatments with HU308 and HU308/TGF-β3 achieved minimum closure timings 
compared with control groups (P<0.05). Our finding suggested that proliferation rate 
with 500nM HU308 was significantly higher than control and TGF-β3/HU308 
combination groups (P<0.05). Interestingly, percentage of wound remained open after 
15 hours for combination groups was 17.6%±1.32 whereas treatment with 500nM 
HU308 had 20%±2.25 indicating that the combination groups took the lead throughout 
v 
 
wound healing. It was also observed that bridge formation in all treatment groups was 
taking place between 15 to 20 hour periods whereas within control treatments bridge 
formation started to take place after 25 hours.  
Cell surface attachment was examined via the trypsinization assay in which the time 
taken to trypsinize cells from the surface provided a means of assessing the strength of 
attachment. The results indicated that higher concentrations of HU308 (2μM), induced 
significant force of cell attachment compared with control and concentrations of 500nM 
and 1μM (P<0.05). However, groups treated with TGF-β3 and combination 
HU308/TGF-β3 indicated reduced cell surface attachment compared with control 
groups, indicating enhanced cell migration. 
Immunofluorescence staining as well as Elisa based semi-quantification technique 
indicated that both collagen type I and fibronectin were unregulated using higher 
concentrations of HU308 with decreased cell proliferation compared to lower 
concentrations. Nevertheless, protein S-100A6 was up-regulated in treatments with 
HU308, TGF-β3 and their combination HU308/TGF-β3 (P<0.05), indicating the 
positive role of these treatments in promoting cell differentiation. MMP-2 levels in the 
current study were also shown to be concentration-dependent, i.e. higher concentrations 
of HU308 significantly reduced MMP-2 secretion leading to decreased cell migration, 
while HU308/TGF-β3 combination treatment increased MMP-2 levels, indicating an 
increase in cell migration. The current study also examined levels of nitric oxide 
synthesis in relation to different treatments with HU308, TGF-β3 and HU308/TGF-β3 
combination. It was found that nitric oxide up-regulation influences rate of MG-63 
osteoblast wound healing in a concentration dependent manner.   
Lastly, UpCell culture dishes proved to have efficacy in obtaining a multilayer model of 
MG-63 osteoblast system in-vitro through changes in cell morphology. It was also 
found that treatments with HU308, TGF-β3 and HU308/TGF-β3 combination 
influenced collagen type I, fibronecton and protein S-100A6 secretion. These findings 
supported the earlier Elisa based semi-quantification results obtained for monolayer 
cultures. 
 
 
 
 
 
 
vi 
 
List of Associated Publications: 
 
1-The Effect of HU308/TGF-β3 Combination on Wound healing, Cell Proliferation 
and Protein Secretion of MG-63 Osteoblast Monolayers 
M. Genedy, M. Youseffi, and M.C.T. Denyer 
IOSR Journal of Pharmacy and Biological Sciences, accepted in press September 2013. 
(Impact factor 1.7) 
2- The effect of TGF-β3, HCl, HCl/BSA and pH on wound healing of cultured 
osteoblast monolayers 
M. Genedy, M. Ahmed, F. Sefat, M.C.T. Denyer and M. Youseffi 
7th United Kingdom (UK) & Republic of Ireland (RI) Postgraduate Conference on 
Biomedical Engineering and Medical Physics, University of Surrey in Guildford, 
Surrey, 9th -11th July 2013  
3- The Effect of Synthetic Cannabinoid HU308 on Fibronectin and Collagen Type 
I Expressions in MG-63 Osteoblast Cells  
M. Genedy, M. Youseffi, A. Abdeldayem  and M.C.T. Denyer 
7th United Kingdom (UK) & Republic of Ireland (RI) Postgraduate Conference on 
Biomedical Engineering and Medical Physics, University of Surrey in Guildford, Surrey 
from 9th -11th July 2013  
4- The synthetic cannabinoid WIN55, 212-2 encourages chondrocytes 
dedifferentiation 
A. Abdeldayem,  M. Youseffi, M. Genedy and M.C.T. Denyer 
7th United Kingdom (UK) & Republic of Ireland (RI) Postgraduate Conference on 
Biomedical Engineering and Medical Physics, University of Surrey in Guildford, 
Surrey, 9th -11th July 2013 
5- The Effect of Cannabinoid on healing of Scratched HaCaT cell monolayer 
Nina Hönig, M. Genedy, A. Abdeldayem, M.C.T. Denyer  and M. Youseffi 
The 23rd Annual International Cannabinoid Research Society Symposium on the 
Cannabinoids June 21 - 26, 2013 UBC Campus Vancouver, BC Canada 
 
 
 
vii 
 
6- The Effect of Monoglycerol lipase inhibitor (URB602) on the acceleration of 
MG-63 osteoblast wounded monolayers 
M. Genedy, M. Youseffi, A. Abdeldayem  and M.C.T. Denyer 
The 23rd Annual International Cannabinoid Research Society Symposium on the 
Cannabinoids June 21 - 26, 2013 UBC Campus Vancouver, BC Canada 
7- The Effect of HU308/TGF-β3 combination on MG-63 osteoblast wound healing, 
proliferation and migration 
M. Genedy, M. Youseffi, A. Abdeldayem  and M.C.T. Denyer 
The 23rd Annual International Cannabinoid Research Society Symposium on the 
Cannabinoids June 21 - 26, 2013 UBC Campus Vancouver, BC Canada 
8- The Effect of Different Concentrations of URB602 on Healing of scratched 
Chondrocyte Monolayers 
A. Abdeldayem , M. Genedy , M. Yousseffi  and M.C.T. Denyer 
The 23rd Annual International Cannabinoid Research Society Symposium on the 
Cannabinoids June 21 - 26, 2013 UBC Campus Vancouver, BC Canada 
9- The Effect of Different Concentrations of synthetic Cannabinoid receptor 2 
agonist (HU-308) on Healing of scratched Chondrocyte Monolayers 
A. Abdeldayem , M. Genedy , M. Yousseffi  and M.C.T. Denyer 
The 23rd Annual International Cannabinoid Research Society Symposium on the 
Cannabinoids June 21 - 26, 2013 UBC Campus Vancouver, BC Canada  
10- Cell Traction Force Mapping in MG63 and HaCaTs  
Chin Fhong Soon, M. A. Genedy, M. Youseffi, Morgan C. T. Denyer 
International Conference on Nanoscience and Nanotechnology 2013 (NANO-SciTech 
2013) Grand Blue Wave Hotel Shah Alam, Malaysia March 1-4, 2013 
11- Effect of CB 2 Selective agonist on wounded bone cell monolayers   
M. Genedy, M. Youseffi and M.C.T. Denyer 
22ND Annual Symposium Of The International Cannabinoid Research society 
Konzerthaus Freiburg Im Breisgau July 22-27,2012 
12- Effect of cannabinoids (WIN55,212-2) in acceleration of wound healing in bone 
cell monolayer  
M. Genedy, N. Hoenig, M. Youseffi and M.C.T. Denyer 
22ND Annual Symposium Of The International Cannabinoid Research society 
Konzerthaus Freiburg Im Breisgau July 22-27,2012 
viii 
 
13- The Effect of Different Concentrations of (R)-(+)-WIN 55,212-2 on Wound 
Healing of Chondrocytes Monolayer 
A. Abdeldayem, M. Yousseffi, S.A. Khaghani, M. Genedy  and M.C.T. Denyer 
 14th International Conference on AEROSPACE SCIENCES & AVIATION 
TECHNOLOGY, May 24 - 26, 2011, ASAT - 14 – Military Technical College, Cairo, 
EGYPT 
14- Effect of Different Concentrations of (WIN55,212-2)  in Acceleration of MG-63 
cell monolayer Wound Healing  
M. Genedy, M. Youseffi, F. Sefat, A abdeldayem  and M.C.T Denyer 
14th International Conference on AEROSPACE SCIENCES & AVIATION 
TECHNOLOGY, May 24 - 26, 2011, ASAT - 14 – Military Technical College, Cairo, 
EGYPT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
List of Abbreviations 
 
3D  three dimensional  
ATP adenosine triphosphate 
BSA bovine serum albumin 
DNA deoxyribonucleic acids 
Dthiol  1,6-Hexanedithiol 
ER  endoplasmic reticulum 
EM  electron microscope 
ECM extra-cellular matrix 
ELISA  enzyme linked immunoabsorbant assay  
FCS foetal calf serum 
FGF fibroblastic growth factor 
FIB  fibronectin 
GAGs glycosaminoglycans 
HOBs human osteoblast 
HaCaT Human Keratinocytes 
HBSS Hank’s balanced salt solution 
HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
IgG  immunoglobulin 
LAM laminin 
MRI magnetic resonance imaging 
mRNA messenger ribonucleic acids 
NA  numerical aperture 
OWLS optical waveguide lightmode spectroscopy 
PCL polycaprplactone 
PEG poly (ethylene glycol) 
PHA polyhydroxylkanoate 
PHB polyhydroxybutyrate 
PLA poly(lactic acid) 
PLG poly(glycolic acid) 
PPF  poly(propylene fumarate) 
PPO polypropylene oxide 
PDGF platelet derived growth factor 
PDMS polydimethylsiloxane  
PLGA poly(DL- lactic -co- glycolic acid) 
PLLA Poly (L-lactic acid) 
PHSRN Pro-His-Ser-Arg-Asn  
PDLLACL Poly (D, L-lactic acid-co-ε-caprolactone)  
RER rough endoplasmic reticulum  
RGD Arg-Gly-Asp 
RNA ribonucleic acids  
RRETAWA (Arg-Arg-Glu-Thr-Ala-Trp-Ala) 
SAM self-assembled monolayer 
SEM scanning electron microscope 
SCOM scanning confocal optical microscope 
TGF-β transformation growth factor beta 
x 
 
EGF          Epidermal growth factor  
Β2AR       β2-Adrenergic receptors 
    TIMP-1     Metallopeptidase inhibitor 1 
NO           Nitric oxide  
NOS         Nitric Oxide Synthase 
FN            Fibronectin  
Col-I         Collagen type I 
OPN         (bone sialoprotein) Osteopontin 
NF-KB       Nuclear factor kappa-light-chain-enhancer of activated B cells 
BGLAP     Osteocalcin 
MMP-2      Matrix metalloproteinase-2    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
 Table of Contents 
STATMENT OF ORIGINALITY: ................................................................................... ii 
ACKNOWLEDGEMENTS ............................................................................................. iii 
Abstract ............................................................................................................................ iv 
List of Associated Publications: ....................................................................................... vi 
List of Abbreviations........................................................................................................ ix 
LIST OF FIGURES: ...................................................................................................... xiii 
LIST OF TABLES: ....................................................................................................... xvii 
Chapter I ............................................................................................................................ 1 
1.1 Introduction and critical literature review ................................................................... 1 
1.2 Motivation behind bone tissue engineering ................................................................ 2 
1.3 Bone structure and function ..................................................................................... 3 
1.4 Cellular structure of bone ............................................................................................ 6 
1.5 Molecular structure of bone ...................................................................................... 11 
1.6 Non-collagenous matrix proteins .......................................................................... 13 
1.7 Stages of bone formation .......................................................................................... 14 
1.8 Cell and bone development ....................................................................................... 15 
1.9 Skeletal remodelling.............................................................................................. 17 
1.10 Basic principles of bone healing ............................................................................. 17 
1.11 Signals that initiate and maintain the bone-forming mechanisms .......................... 19 
1.12 Scaffolds and Tissue Engineering ........................................................................... 21 
Bioresorbable materials: ............................................................................................ 22 
Bioerodible materials: ................................................................................................ 22 
Bioabsorbable materials: ............................................................................................ 22 
1.13 Tailoring scaffold-cell interactions ......................................................................... 24 
1.14 Biomolecules used to augment bone cell reaction .............................................. 29 
1.15 Limitations that face cell-substrate interactions .................................................. 30 
1.16 Importance of cytokines in Bone repair .................................................................. 31 
1.17 Cannabinoids and bone cells ................................................................................... 36 
1.18 Overall aims and objectives .................................................................................... 46 
Chapter II ........................................................................................................................ 48 
xii 
 
2 The Effect of selective and non-selective CB receptor agonists Winn55,212-2, 
URB602 and HU308 on MG-63 osteoblast monolayer .................................................. 48 
2.1 Introduction to the mechanisms of action and function of cannabinoids.................. 48 
2.2 Aims & objectives ..................................................................................................... 49 
2.3 Materials and methods .......................................................................................... 50 
2.4 Statistical analysis ................................................................................................. 57 
2.5 Results and Brief Discussion .................................................................................... 58 
2.6 Discussion & conclusion ........................................................................................... 98 
2.7 Chapter summery .................................................................................................... 106 
Chapter III ..................................................................................................................... 107 
The effect of HU308 and TGF-β3 combinations on wound healing of MG-63 osteoblast 
monolayers .................................................................................................................... 107 
3.1 Introduction ............................................................................................................. 107 
3.2 Aims and objectives ................................................................................................ 109 
3.3 Material and Methods ............................................................................................. 110 
3.4 Statistical analysis ................................................................................................... 113 
3.5 Results and brief discussion .................................................................................... 114 
3.6 Discussion & conclusion ......................................................................................... 126 
3.7 Chapter summery .................................................................................................... 131 
Chapter IV ..................................................................................................................... 132 
Effect of TGF-β3 and HU308 and their combination on ECM-proteins, MMP-2 and 
nitric oxide regulation during wound repair of MG-63 bone cell monolayers ............. 132 
4.1 Introduction ............................................................................................................. 132 
4.2 Aims and Objectives ............................................................................................... 135 
4.3 Material and Methods ............................................................................................. 135 
4.4 Statistical analysis ................................................................................................... 140 
4.5 Results and brief discussion .................................................................................... 140 
4.6 Discussion & conclusion ......................................................................................... 153 
4.7 Chapter summery .................................................................................................... 161 
Chapter V ...................................................................................................................... 162 
Multilayer models of MG-63 osteoblast cells and the effects of HU308, TGF-β3 and 
their combination on ECM regulation........................................................................... 162 
5.1 Introduction ............................................................................................................. 162 
xiii 
 
5.2 Aims and Objectives ............................................................................................... 165 
5.3 Materials and methods ............................................................................................ 165 
5.4 Statistical analysis ................................................................................................... 168 
5.5 Results and brief discussion .................................................................................... 168 
5.6 Discussion & conclusion ......................................................................................... 175 
5.7 Chapter summery .................................................................................................... 179 
Chapter VI ..................................................................................................................... 180 
6 Overall Conclusion..................................................................................................... 180 
6.2 Future Work ............................................................................................................ 187 
Chapter VII.................................................................................................................... 190 
References: .................................................................................................................... 190 
Chapter VIII .................................................................................................................. 203 
Appendix ....................................................................................................................... 203 
 
 
LIST OF FIGURES: 
Figure1.1 An overview diagram of tissue engineering (Liu, 2007) .................................. 1 
Figure1. 2 General schematic of long bone illustrating the basic anatomy, differences in 
cortical and cancellous bone and micro-structural features in bone (Mackie, 2003, 
Porter et al., 2009) ............................................................................................................ 4 
Figure1. 3 Haversian canal lined by several layers of osteocytes in their lacunae.  The 
entire unit is called an osteon (Boyan, 2003) ................................................................... 8 
Figure1. 4 Ossification centres from within thickened regions of mesenchyme 
(Bradshaw, 2003) .............................................................................................................. 8 
Figure1. 5 Ossification centres from within thickened regions of mesenchyme 
(Bradshaw, 2003) .............................................................................................................. 8 
Figure1.6 Histology of Osteoclast cells (Bradshaw, 2003) ............................................ 11 
Figure1. 7 A florescent staining of mesenchymal stem cells (Meyer, 2006)................... 16 
Figure1. 8 A florescent staining of mesenchymal stem cells (Meyer, 2006)................... 16 
Figure1. 9 Representation of the cell proteins involved in cell adhesion on biomaterial 
(Anselme, 2000)............................................................................................................... 26 
Figure1.10 Two different pathways characterized for Runx2 activation via BMP’s 
(Meyer, 2006) .................................................................................................................. 36 
Figure1.11 Model of CB2 mitogenic signalling in osteoblasts. Gi protein activation is 
followed by enhanced ERK1/2 phosphorylation and accumulation of Mapkapk2. P 
xiv 
 
Mapkapk2 phosphorylates and activates CREB, resulting in transcriptional activation 
of cyclin D1 and cell proliferation. ................................................................................. 43 
Figure1.12 Model of CB1 regulation of bone formation by modulating adrenergic 
signalling. Activation of CB1 cannabinoid receptors in bone sympathetic nerve 
terminals by bone cell-derived 2-AG restrains NE release, thus alleviating the tonic 
suppression of bone (Joseph, 2008) ................................................................................ 44 
Figure2.1 Optical Images showing increase in cell length after 30 hours of cell culture 
(A) MG-63 osteoblast cells with no treatment (B) carrier control group (0.1% ethanol) 
(C) with 500nM winn55,212-2 (D) with 1μM winn55,212-2 (E) with 2μM winn55,212-2 
(scale bar=100μM) 59 
Figure2.2 MG-63 osteoblast proliferation factor with different concentrations of 
Winn55,212-2 synthetic cannabinoid. Standard error bars are shown. ......................... 60 
Figure2.3 MG-63 Cell length measurements after 30 hours of Winn55,212-2 addition 
with different concentrations (N=30). Standard error bars are shown. ......................... 61 
Figure2.4 Optical Images showing increase in cell length after 30 hours of cell culture 
(A) MG-63 osteoblast cells with no treatment (B) carrier control group (0.1% ethanol) 
(C) with 500nM URB602 (D) with 1μM URB602 (E) with 2μM URB602 (scale 
bar=100μM) ................................................................................................................... 62 
Figure2.5 MG-63 osteoblast proliferation factor with different concentrations of 
URB602. Standard error bars are shown. ...................................................................... 63 
Figure2. 6 Cell length measurements after 30 hours of URB602 addition with different 
concentrations (N=30). Standard error bars are shown. ............................................... 64 
Figure2.7 Optical Images showing increase in cell length after 30 hours of cell culture 
(A) MG-63 osteoblast cells with no treatment (B) carrier control group (0.1% ethanol) 
(C) with 500nM HU308 (D) with 1μM HU308 (E) with 2μM HU308 (scale 
bar=100μM) ................................................................................................................... 65 
Figure2.8 MG-62 osteoblast proliferation factor with different concentrations of 
HU308. Standard error bars are shown. ........................................................................ 66 
Figure2.9 Cell length measurements after 30 hours of HU308 addition with different 
concentrations (N=30). Standard error bars are shown. ............................................... 67 
Figure2.10 Wound healing of control and carrier control groups of 0.1% ethanol (scale 
bar=100μm) .................................................................................................................... 70 
Figure2.11 Graph of wound closure width against time for wounded culture flask with 
and without addition of WINN55,212-2 synthetic cannabinoid. Standard error bars are 
shown. ............................................................................................................................. 72 
Figure2.12 Images of wound healing process for the bone cell monolayers with 
WINN55,212-2 over a period of 30 hours (Scale bar=100μm). WINN55,212-2 
concentrations of 1μM/ml promoted the fastest wound closure ..................................... 73 
Figure2.13 Images of wound healing process for the bone cell monolayers using CB1 
and CB2 selective antagonist over a period of 30 hours (Scale bar=100μm) ............... 75 
Figure2. 14 Images of wound healing process for the MG-63 bone cell monolayers with 
different concentrations of URB602 over a period of 30 hours (Scale bar=100μm) ..... 77 
xv 
 
Figure2.15 Graph of % wound closure width against time (hrs) for wounded MG-63 
osteoblast monolayers with the addition of URB602. Standard error bars are shown. . 78 
Figure2.16 Rate of wound closure (μm/hr) for treatments of URB602 with different 
concentrations. ................................................................................................................ 79 
Figure2.17 Graph of % wound closure width against time for wounded MG-63 
monolayers with treatments of HU308 at different concentrations. Standard error are 
shown. ............................................................................................................................. 81 
Figure2.18 Images of wound healing process for the bone cell monolayer (HU308) over 
a period of 30 hours (Scale bar=100μm) ....................................................................... 82 
Figure2.19 Rate of wound closure (μm/hr) for treatments of HU308 with concentrations 
500nm, 1μM and 2μM concentrations compared to control .......................................... 84 
Figure2.20 Trpsyinization assay of MG-63 osteoblast cells in the presence of 
Winn55,212-2 at different concentrations (scale bar=100μm) ...................................... 88 
Figure2.21 Percentages of cell surface reduction after treatment with winn55,212-2 at 
concentrations of 500nM,1μM and 2μM. Standard error bars are shown. ................... 89 
Figure2.22 Trpsyinization assay of MG-63 osteoblast cells in the presence of URB602 
(scale bar=100μm) ......................................................................................................... 91 
Figure2.23  Percentage cell surface reduction vs. time with different concentrations of 
URB602 treatments. Standard error bars are shown. .................................................... 92 
Figure2.24  Percentage cell surface area reduction vs. time with different 
concentrations of HU308 treatments. Standard error bars are shown. ......................... 93 
Figure2.25 Trpsyinization assay of MG-63 osteoblast cells in the presence of HU308 
(scale bar=100μm) ......................................................................................................... 95 
Figure2.26 Comparison between wound closure width against time for control, Ethanol, 
Winn55,212-2, URB602 and HU308 test groups. Standard error bars are shown. ....... 97 
Figure2.27 Rate of wound closure for optimum concentrations treatment groups of 
control, carrier, Winn55,212-2,URB602 and HU308) ................................................... 98 
Figure3.1 Graph of MG-63 osteoblast proliferation factor with different treatments. 
Standard error bars are shown. 115 
Figure3.2 Cell length measurements after 30 hours for treatments control, carrier, 
HU308, TGFβ3 and HU308/TGFβ3) (N=30). Standard error bars are shown. .......... 116 
Figure3.3 Optical Images showing increase in cell length after 30 hours of cell culture 
(A) MG-63 osteoblast cells with no treatment ;(B) carrier control group (0.1% ethanol); 
(C) with 500nM HU308; (D) with 2μM HU308 ;(E) 8nMTGF-β3 and (F) TGF-
β3/HU308(scale bar=100μM) ...................................................................................... 117 
Figure3. 4 Graph of % wound closure width against time for wounded MG-63 
osteoblast monolayers with different treatments. Standard error bars are shown. ...... 119 
Figure3. 5 Images of wound healing process for the bone cell monolayers with different 
treatments compared with control throughout 30 hours (Scale bar=100μm) .............. 120 
Figure3.6 Rate of wound closure for different treatments control, carrier, HU308, TGF-
β3 and HU308/TGF-β3 ................................................................................................. 121 
xvi 
 
Figure3.7  Percentage cell surface reduction vs. time with different treatments. 
Standard error bars are shown. .................................................................................... 123 
Figure3. 8 Images showing the effect of trypsinaization on MG-63 osteoblast cells for 
control and 0.1% ethanol carrier groups (scale bar=100μm) ..................................... 124 
Figure3. 9 Images showing the effect of trypsinaization on MG-63 osteoblast cells with 
different treatments (scale bar=100μm) ....................................................................... 125 
Figure 4.1 Immunofluorescence staining for collagen type I (A) control groups, (B) 
500nMHU308, (C) 2μMHU308, (D) TGF-β3 and  (E) HU308/TGF-β3 treatment groups 
(scale bar=25μm) 143 
Figure 4.2 Immunofluorescence staining for fibronectin, (A) control groups, (B) 
500nMHU308, (C) 2μMHU308, (D) TGF-β3 and (E) HU308/TGF-β3 treatment groups 
(scale bar=25μm) ......................................................................................................... 144 
Figure 4.3 Immunofluorescence staining for protein S-100A6, (A) control groups, (B) 
500nMHU308, (C) 2μMHU308,(D) TGF-β3 and (E) HU308/TGF-β3 treatment groups 
(scale bar=25μM) ......................................................................................................... 145 
Figure 4.4 Negative control groups (no treatment), (A) light images of MG-63 cells, (B) 
Dapi staining of cell’s nucleus and  (c) immunofluorescence staining of MG-63 (scale 
bar=25μM) ................................................................................................................... 146 
Figure4.5 Optical density readings (630nm) following immunoperoxidase staining of 
deposited collagen type I. Standard error bars are shown, N=9. Standard error bars 
are shown. ..................................................................................................................... 148 
Figure 4.6 Optical density readings (630nm) following immunoperoxidase staining of 
deposited fibronectin. Standard error bars are shown, N=9. Standard error bars are 
shown. ........................................................................................................................... 148 
Figure 4.7 Optical density readings (630nm) following immunoperoxidase staining of 
deposited protein S-100A6. Standard error bars are shown, N=9. Standard error bars 
are shown. ..................................................................................................................... 149 
Figure 4.8 Optical density readings (570nm) following immunoassay staining of nitric 
oxide expression. Standard error bars are shown, N=9. Standard error bars are shown.
 ....................................................................................................................................... 151 
Figure 4.9 Optical density readings (630nm) following immunoassay staining of matrix 
metalloproteinase-2. Standard error bars are shown, N=9 ......................................... 152 
Figure 51 (a) At 37 °C, cells adhere on dehydrated PIPAAm layer; (b) At 20 °C, cells 
detach from hydrated PIPAAm layer, and form an intact cell sheet. 164 
Figure 5.2 Images of cell sheet detachment and transfer for UpCell culture dishes.... 167 
Figure5.3  3D cultures of MG-63 osteoblast cells throughout 72 hours (left), 2D 
monolayer cultures at 0 min and 72 hours (right) (scale bar =100μM) ...................... 170 
Figure 5.4 Reduction of mean cell surface area of MG-63 osteoblast in monolayer and 
multilayer cultured environments. Standard error bars are shown. ............................. 171 
Figure 5.5 Multilayer cultured MG-63 osteoblast cells showing nodule formation (scale 
bar =100μM) ................................................................................................................ 171 
xvii 
 
Figure5.6 Optical density readings (630nm) following immunoperoxidase staining of 
deposited collagen type I. Standard error bars are shown, N=9. Standard error bars 
are shown. ..................................................................................................................... 173 
Figure5.7 Optical density readings (630nm) following immunoperoxidase staining of 
deposited fibronectin. Standard error bars are shown, N=9. Standard error bars are 
shown. ........................................................................................................................... 173 
Figure5.8 Optical density readings (630nm) following immunoperoxidase staining of 
deposited protein S-100A6. Standard error bars are shown, N=9. Standard error bars 
are shown. ..................................................................................................................... 174 
 
LIST OF TABLES: 
Table1. 1 Non-collagenous matrix proteins of bone (Hollinger, 2004) .......................... 13 
Table1. 2 Signals involved in bone repair throughout different remodelling stages 
(Lieberman et al., 2002) .................................................................................................. 20 
Table1. 3 some of the integrin family of adhesion receptors (Saito, 1994) .................... 28 
Table1. 4 Biomolecules used to augment bone cell reaction (Hogan, 1996) ................. 29 
Table1. 5 Different synthetic CB receptor ligands and their antagonists....................... 41 
Table2.1 MG-63 osteoblast proliferation factors with different concentrations of 
Winn55,212-2 60 
Table2.2 MG-63 osteoblast proliferation factors with different concentrations of 
URB602 ........................................................................................................................... 63 
Table2.3 MG-63 osteoblast proliferation factors with different concentrations of HU308
 ......................................................................................................................................... 66 
Table2.4 Percentages of wound remained open throughout 30 hours for control and 
carrier group ................................................................................................................... 69 
Table2. 5 Percentages of Wound remained open throughout a 30 hour period for 
WINN55,212-2 and control groups. Standard error are shown. .................................... 72 
Table2.6 Percentages of wound closure remained open throughout a 30 hour period for 
URB602 groups. Standard error are shown. .................................................................. 78 
Table2.7 Percentages of wound closure remained open throughout a 30 hour period for 
control; 0.1%Ethanol, URB602 and LY320135 test groups. Standard error are shown.
 ......................................................................................................................................... 80 
Table2. 8 Percentages of wound remained open throughout a 30 hour period for 
HU308 groups with different concentrations. Standard errors are shown. ................... 83 
Table2. 9 Percentages of wound remained open throughout a 30 hour period for 
control, pure Ethanol, HU308 and AM630 test groups. Standard error are shown. ..... 85 
Table2.10 Percentage of MG-63 osteoblast cell surface reduction during 270 seconds 
with treatments of Winn55,212-2 at different concentrations. Standard error are shown.
 ......................................................................................................................................... 87 
xviii 
 
Table2.11  Percentage of MG-63 osteoblast cell surface reduction during 270 seconds 
with different concentration of URB 602. Standard error are shown. ........................... 90 
Table2.12  Percentage of MG-63 osteoblast cell surface reduction during 270 seconds 
with different concentration of HU308. Standard error are shown. .............................. 94 
Table3.1 MG-63 osteoblast proliferation factors with different treatments 116 
Table3.2 Percentages of wound closure remained open throughout a 30 hour period for 
different treatments. Standard error are shown. ........................................................... 119 
Table3.3  Percentage cell surface reduction throughout 270 seconds with different 
treatments. Standard error bars shown. ....................................................................... 123 
 1 
 
Chapter I 
1.1 Introduction and critical literature review 
The field of tissue engineering emerged more than two decades ago to address the acute 
shortage of organ transplants. The initial vision for the field was to isolate living cells 
from the relevant organs of patients or other human donors, culture them in polymer 
scaffolds that function as substitutes for the body's natural extracellular matrix (ECM), 
and then to re-implant the cell-laden scaffolds into the patient in an attempt to replace or 
restore damaged tissues (Vacanti, 1998 ). In theory after in-vivo implantation a natural 
tissue regeneration processes would take place, allowing blood vessel infiltration into 
the structure. Associated with this would be the steady degradation of the synthetic 
scaffold and replacement by native connective tissue and extracellular matrix 
molecules. A general yet simple illustration of such a process is shown in the following 
diagram (Figure 1.1) (Liu, 2007). 
 
 
Figure1.1 An overview diagram of tissue engineering (Liu, 2007)  
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1.2 Motivation behind bone tissue engineering 
Bone is a remarkable organ playing key roles in critical functions in human physiology 
including protection, movement and support of other critical organs, blood production, 
mineral storage and homeostasis, blood pH regulation, and a source of mesenchymal 
and hemopoietic stem cells (Ammar, 2011). The importance of bone tissue engineering 
becomes clear in the case of diseases such as osteogenesis imperfecta, osteoarthritis, 
osteomyelitis, and osteoporosis in which bone does not function properly (Parsh and 
Wilson, 2012, Byers and Steiner, 1992). These diseases along with traumatic injury, 
orthopedic surgeries (i.e., total joint arthroplasty, spine arthrodesis, implant fixation) 
and primary tumour resection lead to or induce bone defects. Therefore, the clinical and 
economic impact in treatments of bone defects is crucial, as many bone diseases that 
affect people require treatment which involve bone repair or replacement (Porter et al., 
2009). 
In critical-sized bone defects host bone is removed from another site (typically from the 
pelvis or iliac crest) and used to fill the defected area (Nakajima et al., 2007). However, 
the complication rate in autogenously bone grafting is as high as 30% and may include 
donor site morbidity, pain, paraesthesia, prolonged hospitalization and rehabilitation, 
increased risk of deep infection, hematoma, inflammation, and restricted availability 
(Gitelis and Saiz, 2002). 
Summing this together show the importance of bone tissue engineering as 
‘‘interdisciplinary field that applies the principles of engineering and the life sciences 
toward the development of biological substitutes that restore, maintain, or improve 
tissue function’’(Langer and Vacanti, 1993) 
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1.3 Bone structure and function 
Bones are the principle support for the body. They provide a rigid structure for muscle 
attachment and constitute a system of levers that turn muscle contraction into 
purposeful movements (Buckwalter et al., 1996).  
Bone is a living tissue that makes up the body's skeleton. Bones are classified by their 
anatomical shape, long (e.g. femur, humerus), short (e.g.tarsals in the foot, carpals in the 
hand), flat (e.g. membrane bone), and irregular (e.g. vertebra). Bone is a specialised 
form of connective tissue derived from mesoderm like other connective tissues such as 
cartilage. Excluding teeth and sesamoid bones that are embedded in tendons, there are a 
total of 206 bones in the adult human body, they are normally separated by various 
types of cartilages to provide support to the skeletal system and facilitate joint 
movement (Hollinger, 2004). The outer surface of bones, except those at the joints is 
covered with a membrane consisting of dense irregular connective tissue known as the 
periosteum (Netter, 1997). There are three gross types of bone in the human body; 
compact (cortical), spongy (trabecular or cancellous) and subchondral bone which can 
be distinguished by their appearance (Bilezikian, 2002). Bone cells receive their 
nutrients through a 3D network of blood vessels. All types of bone have an identical 
microscopic structure at comparable stages of maturity of bone tissue (Figure 1.2). The 
difference between them lies in the relationship of each bone type to the blood supply. 
Cancellous bone is bony tissue surrounded by blood vessels; compact bone is blood 
vessels surrounded by bony tissue; and subchondral bone is more vascularised than 
compact bone and less vascularised than cancellous bone. Compact bone makes up 80% 
of the skeleton and has a solid, compact structure and 80-90% of its volume is calcified. 
Spongy bone makes up 20% of the skeleton. This type of bone has more surface area 
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compared to compact bone but it is less dense. It is typically located at the end of long 
bones and is highly vascularised. It also contains red bone marrow where the production 
of blood cells (hematopoiesis) occurs (Hollinger, 2004). 
 
Figure1. 2 General schematic of long bone illustrating the basic anatomy, differences 
in cortical and cancellous bone and micro-structural features in bone (Mackie, 2003, 
Porter et al., 2009) 
 
 
The difference between cortical bone and cancellous bone is not only structural but also 
functional. The differences in their histologic and ultra-structural appearance are related 
to their primary functions: the cortical part of bone provides mechanical and protective 
functions, whereas the cancellous part is more involved in the metabolic functions (e.g. 
calcium homeostasis) (Mackie, 2003). Both aspects (structural and metabolic) are 
closely related to the features of the mineralised extra cellular matrix ECM. It can be 
concluded that in order to engineer a bone-like tissue in vitro in an attempt to mimic the 
natural tissue structure (biomimetics), understanding of hard tissue formation and the 
mineralisation processes in bone are fundamental. Additionally, as the ex-vivo grown 
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tissues interacts with the host cells and the ECM at the implantation site, normal repair 
mechanisms have to be considered and even enhanced to accelerate the defect repair 
(Bradshaw, 2003). 
The microscopic structure of bone varies according to its maturity; there are three forms 
of immature bone cells: woven, laminar, and fine cancellous. Woven bone is found 
initially in the fetus or where rapid bone is needed. Laminar bone is composed of sheets, 
or laminae, of bony tissue separated from each other by intervening networks of blood 
vessels. Thirdly, a more rapidly growing bone, i.e. fine cancellous bone, is found in 
places where transient reinforcement of the extant bone is needed (Bilezikian, 2002). 
The differences between immature and mature bones lie mainly in the relationships 
between the vascular canals and the bony tissue. Mature or adult bone is called lamellar 
which is arranged in thin sheets or lamellae that are roughly 3-7 microns thick. In each 
lamella, the bundles of collagen fibres are arranged parallel to one another. This 
arrangement gives lamellar bone a layered appearance in cross section. A group of 
lamellae may be organised in one of two ways, depending upon its location within the 
whole bone. The basic unit of lamellar bone is the osteon (Hollinger, 2004), in which 
sets of 15-20 lamellae are arranged in concentric tubes around an opening for a blood 
vessel (see Figure 1.2). The placement of vascular canals within these rings of bone 
differentiates mature from immature bone. Surrounding each osteon is a cement line, a 
dense ring that demarcates its boundaries and surrounds the outer lamella throughout 
the entire length of the osteon. Osteons are formed by remodelling either immature bone 
or older mature bone, adjacent osteons may cut across each other, may touch each other 
at their cement line, or may be separated by regions of less organised bone tissue. These 
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intervening regions of bone, called interstitial bone, are irregular in shape (Bilezikian, 
2002). 
The vascular canal at the centre of each osteon is part of a network of canals, the 
Haversian system which brings nourishment to the bone tissue. Within this system are 
two types of canals, Haversian and Volkmann‟s. Haversian canals are oriented more or 
less longitudinally within the bone. They are connected to each other, to the marrow 
cavity, and to the surface of the skeletal element by a complex system of oblique and 
transversely oriented canals, or Volkmann‟s canals. Volkmann‟s canals are not 
surrounded by concentric lamellae and in fact frequently cut through lamellae. Not all 
mature bone is organised into osteons. Near both the inner and outer surface of long 
bones, this organisation of bone tissue is replaced by several large-scale lamellae that 
encircle the entire perimeter of the shaft; these are called outer and inner circumferential 
lamellae (Bilezikian, 2002). 
1.4 Cellular structure of bone 
 
1.4.1.1 Osteoblast and osteocytes 
Bone contains four different types of cells including osteoprogenitor cells, osteocytes, 
osteoblasts and osteoclasts. In general osteoprogenitor cells can be considered as bone 
stem cells and they are located in the inner portion of periosteum and in endosteum. 
These cells have the capacity to divide and differentiate into osteoblast bone cells. 
Osteoprogenitor cells are immature progenitor cells and are induced to differentiate into 
osteoblasts under the influence of growth factors mainly bone morphogenetic proteins 
(BMP) (Agata et al., 2007). Bone tissue is formed by osteoblasts, maintained by 
osteocytes and broken down by osteoclasts (Lee and Taylor, 1999). Osteoblasts are 
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epithelial-like cells with cuboidal or columnar shapes, forming a monolayer covering all 
the sites of active bone formation. Osteoblasts are highly polarized cells: they deposit 
osteoid which is the non-mineralized organic matrix of the bone; osteoblasts initiate and 
control the subsequent mineralization of the osteoid. 
Osteoblasts display the typical features of a cell actively engaged in protein synthesis, 
glycosylation as well as secretion. Their specific products are type I collagen, 
osteocalcin, osteopontion and bone sialoprotein. Osteoblasts give a strong cytochemical 
reaction for alkaline phosphatase which is an enzyme that is plentiful in osteoblasts and 
this enzyme is important in the formation of mineral deposits in the matrix and 
disappears when the cells become embedded in the matrix as osteocytes. Osteoblasts 
also secrete growth factors and eventually flatten and transform onto osteocytes after 
bone formation is completed. Osteoblasts originate in the bone marrow and are derived 
from mesenchymal stem cells (Mundy and Yang, 2008). 
 
1.4.1.2 Osteocytes  
They are the most mature or terminally differentiated cells of the osteoblast lineage; 
they maintain the ECM of bone. They are highly branched cells with their body 
occupying small spaces called lacunae between the lamellae (Figures 1.3, 1.4 and 1.5). 
Small channels called the canaliculi course through the lamellae and interconnect 
neighbouring lacunae via gap junctions. Nutrients diffuse from a neighbouring blood 
vessel within the haversian cannal through canaliculi into the lacunae. 
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Figure1. 3 Haversian canal lined by several layers of osteocytes in their lacunae.  The 
entire unit is called an osteon (Boyan, 2003) 
 
 
Figure1. 4 Ossification centres from within thickened regions of mesenchyme 
(Bradshaw, 2003) 
 
 
Figure1. 5 Ossification centres from within thickened regions of mesenchyme 
(Bradshaw, 2003) 
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The life of an osteocyte depends on the nutrient diffusion process and the life of the 
bone matrix depends on the osteocyte. Osteocytes can remain alive for years provided 
vascularization. Osteocytes have been shown to die by apoptosis due to lack of 
oestrogen or high levels of glucocorticoids (Bradshaw, 2003). They are actively 
involved in the routine turnover of bony matrix, through various mechanosensory 
mechanisms.  
 
1.4.2 Clinical significance of osteoblast differentiation 
Osteoblasts are derived from pluripotent mesenchymal stem cells that function as the 
precursor cells of muscle cells, adipocytes, fibroblasts, and chondroblasts. 
The differentiation of the osteoblast is controlled by growth and transcription factors. 
Several members of the bone morphogenetic protein (BMP) family and transforming 
growth factor β can regulate the embryonic development and differentiation of the 
osteoblast. 
An osteoblast undergoes three major phenotypically identifiable stages of 
differentiation, proliferation, matrix production, and maturation in which mineralization 
occurs. During the proliferation phase, high-level expression of c-fos and histone H4 
occurs, and during matrix production, transforming growth factor β type 1 (TGF-β1) 
and type 1 collagen are up-regulated and synthesised, during the maturation phase these 
proteins decrease and the expression of alkaline phosphatase, osteopontin, and core 
binding factor 1 (Cbfa1) increases. Finally, during the mineralization phase, these 
previous proteins decline in expression (Mackie, 2003), whereas proteins such as 
osteocalcin increase with increased mineralized bone formation. Osteoblast cells in each 
of these phases are often described as early preosteoblasts, proliferating osteoblasts, 
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mature osteoblasts, and finally preosteocytes/osteocytes within the mineralized matrix, 
respectively (Bradshaw, 2003). 
1.4.3 Osteoclasts 
The osteoclasts do not belong to the osteoprogenitor cell lineage. Instead osteoclasts are 
derived from the monocyte-macrophage progenitor cell lineage in the bone marrow 
which diverges into the osteoclast progenitor pathway. 
The osteoclast precursor cells are monocytes which reach the bone through the blood 
circulation and fuse into multinucleated cells with as many as 30 nuclei to form 
osteoclast by a process regulated by osteoblasts and stromal cells of the bone marrow 
(Mundy and Yang, 2008). After attachment to the target bone matrix, osteoclasts 
generate a secluded acidic environment required for bone resorption. Bone resorption 
involves first the dissolution of the inorganic components of the bone (bone 
demineralization) mediated by H-ATPase (adenosine triphosphatases) within an acidic 
environment, followed by enzymatic degradation of the organic component by 
lysosomal protease, cathepsin K.  
One key mechanism by which osteoblasts work in part with osteoclasts is remodelling. 
After osteoblast differentiation, the cell presents a transmembrane protein, receptor 
activator of NF-kB ligand (RANKL), which binds to its receptor (RANK) on 
osteoclasts. Osteoblasts can down-regulate osteoclast activity through the presentation 
of a transmembrane decoy receptor for RANKL which inhibits osteoclasts binding. 
However, hormonal control can promote osteoclast activity through elevating RANKL 
expression on osteoblasts. In this way, osteoblasts play a critical role in both bone 
formation and the regulation of plasma calcium levels (Mackie, 2003). 
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The osteoclast is a large (up to 100 μm in diameter) and highly polarized cell that 
occupies a shallow connectivity called howship’s lacuna or the subosteoclastic 
compartment. The cell domain facing the lacuna has deep in folding’s on the cell 
membrane which is called the ruffled border (Figure 1.6). When the cell is not active the 
ruffled border disappears and the osteoclast enters a resting phase. However, when 
osteoclasts are active the circumference of the ruffled boarder at the point where the cell 
membrane is closely applied to the bone just at the margins of the lacuna actin filaments 
accumulate and participate to adhere to  α,β integrins  to form a sealing zone which 
seals of the bone resorption lacuna (Bradshaw, 2003). 
 
Figure1.6 Histology of Osteoclast cells (Bradshaw, 2003) 
1.5 Molecular structure of bone 
Human bone is composed of bone cells and a matrix of collagen fibres impregnated 
with bone salts (Sasano et al., 2012). The Extracellular Matrix (ECM) makes up 60% of 
bone and consists of organic and inorganic parts. The inorganic component (bone 
minerals) consists of calcium phosphate and hydroxyapatite [Ca10 (PO4)6(OH)2]. Water 
makes up 5-8% of bone’s composition. The organic component of matrix consists of 
type I collagen fibers (90%), proteoglycan, osteopontin, osteocalcin, osteonectin, bone 
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sialo protein, alkaline phosphatise, regulatory factors such as cytokines and growth 
factors (Hollinger, 2004, Ferreira et al., 2012). Proteoglycan helps the calcification of 
bone. The organic matrix consists of a highly vascular connective tissue enclosed by a 
fibrocellular layer, the periosteum. 
One of the main functions of most cells is to produce their own extracellular matrix 
(ECM). ECM components consist of the mixture of collagens, fibronectin and 
individual proteoglycans. This is an interactive natural scaffold that provides 
mechanical stability and cell anchorage, and also controls cell functions. In order to 
manufacture the ECM, cells synthesise mainly high-molecular-weight fibrous proteins. 
This protein is secreted out of the cell and builds up in the surrounding environment to 
form an insoluble network. In some tissues like skin and muscle the ECM is soft and 
elastic, whereas mechanically strong structures are formed in tendon, cartilage and 
bone. The ECM plays an important role in the human body and some of its functions are 
to provide structural support and tensile strength. It also provides substrates for cell 
adhesion and cell migration as cells cannot survive without any type of attachment. The 
ECM also regulates cellular differentiation and metabolic functions. Collagen is the 
most important structural protein of the extracellular matrix (Ferreira et al., 2012). The 
collagens are large families of proteins, comprising of at least 19 different members. 
Collagen is synthesized by an extensive number of cell types such as fibroblasts, 
osteoblasts, chondroblasts, odontoblasts, reticular cells, epithelial cells, endothelial 
cells, smooth muscle cells, Schwann cells. Collagen type I is the main component of 
bone. Osteocalcin, osteonectin, osteopontin and bone sialoprotein are four major non-
collagenous bone proteins. Both osteopontin and bone sialoprotein are necessary for the 
initiation of bone mineralisation (Roach, 1994). Osteocalcin is secreted by osteoblasts 
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and plays a role in the body's metabolic regulation and is found in bone and dentin. It is 
also used as a biochemical marker for the bone formation process. Osteonectin is a 
glycoprotein in the bone which is secreted by osteoblasts during bone formation, 
initiating mineralisation and promoting mineral crystal formation. It is an acidic, 
secreted ECM glycoprotein that plays a major role in bone mineralisation, cell-matrix 
interactions, and collagen binding (Guweidhi et al., 2005). Osteopontin is a glycoprotein 
that was first identified in 1986 in osteoblasts. It is also known as an important factor in 
bone remodelling. 
1.6 Non-collagenous matrix proteins 
Fibrillar network within the non-collagenous matrix proteins give rise to a structure 
configuration that is necessary for the process of mineralisation. The non-collagenous 
matrix proteins found in mineralised matrices are members of diverse types of 
molecules. Table 1.1 shows the non-collagenous matrix proteins of bone. 
Glycoproteins Gla proteins Proteoglycans 
Ostepontin osteocalcin Decorin 
Osteonectin Matrix Gla protein Biglycan 
Bone sialoprotein Protein S Fibromodulin 
Fibronectin Alkaline phosphatase Vitronectin 
Table1. 1 Non-collagenous matrix proteins of bone (Hollinger, 2004) 
There are three different non-collagenous matrix proteins of special relevance in bone 
formation: osteocalcin, osteonectin, and bone sialoprotein (Bini et al., 1999). 
 
1.6.1 Osteocalcin 
They are members of the Gla protein family with a molecular weight: 11KDa, most 
abondant non-collagenous matrix protein in bone, bind tightly to hydroxyapatite and 
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regulate apatite crystal growth and synthesised specifically by osteoblasts (Hollinger, 
2004).  
1.6.2 Osteonectin 
Single chain polypeptide of molecular weight: 32KDa, present in a number of tissues, 
expressed early in bone development, high concentration in sites of bone remodelling, 
binds to hydroxyapatite, and involved in osteoblast adhesion (Hollinger, 2004).  
1.6.3 Bone sialoprotein 
Single chain polypeptide of molecular weight: 32KDa, comprises predominantly 
glutamic acid, aspartic acid and glycine, present in bone and mineralised connective 
tissue, deposited mainly at sites of de novo bone formation, promotes cell attachment 
via integrin binding, and tightly connected to hydroxyapatite (Hollinger, 2004). 
1.7 Stages of bone formation 
There are two types of Osteogenesis: intramembranous ossification in which formation 
of bone occurs directly within the early development of connective tissue and 
endochondral ossification in which cartilage develops into bone. Both require a solid 
base and a well-developed vascular supply for the elaboration and mineralization of the 
extracellular matrix. Intramembranous ossification occurs during embryonic 
development by the direct transformation of mesenchymal cells into osteoblast (Parsh 
and Wilson, 2012, Bilezikian, 2002). It takes place by the formation of bone initially 
appearing as flat, membrane-like layers of early connective tissue arranging themselves 
among the layers and then differentiating into bone-forming cells called osteoblasts. On 
the other hand, endochondral ossification is present were unique properties of cartilage 
and bone are exploited to provide a mechanism for formation and growth of the 
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skeleton (Glorieux, 2011). Bone formation by intramembranous ossification is primarily 
fibrous and begins through the adhesion of cells into clusters or condensations. Early in 
the embryonic period, cells with oval or round nuclei are packed together in 
mesenchymal condensations; their cytoplasm appears to have a syncytcial arrangement. 
SOX 9, a transcriptional control factor for chondrocyte differentiation, are expressed in 
mesenchymal condensations before and during chondrogenesis. A runt related 
transcription factor 2 isoform, Runx2-I (also known as Cbfa1, Osf2, and AML3) 
(Bronckers et al., 2003), has an exclusive role in the early commitment stage of 
intramembranous or endochondral bone-forming processes. Colony bone factor beta 
(Cbfβ, or poly- mavirus enhancer binding protein 2β (PEBP2B)) is expressed in 
developing bone and forms a functional interaction with Runx2 (Choi et al., 2002). 
Their concerted activity contributes to the differentiation of cells into chondroblasts and 
osteoblasts. An intercellular matrix is formed containing compounds characteristic of 
cartilage matrix. The intercellular matrix appears first at the centre of the mesenchymal 
condensation then cells become separated by a matrix (Kundu et al., 2002),(Francis-
West et al., 2003). 
1.8 Cell and bone development 
To extra-corporally fabricate a bone like tissue, different cell sources and different cell 
types are principally suited to tissue like substitution. The different cell types are 
believed to originate from common progenitor pluripotent stem cells. These progenitors 
acquire specific phenotypes depending on their maturation during differentiation. 
Mesenchymal stromal stem cells serve as the major reservoir for different classes of 
stem cells (Meyer, 2006). Stromal cells have multilineage differentiation capacity, 
 16 
 
thereby generating progenitors with restricted developmental potential, such as 
fibroblasts, osteoblasts, and chondrocytes and adipocyte progenitors. 
The florescent staining (Figure 1.7) shows mesenchymal stem cells differentiated to 
osteoblasts for collagen type I (on the left) and fibronectin (on the right)       
 
Figure1. 7 A florescent staining of mesenchymal stem cells (Meyer, 2006) 
 
On the other hand, Figure 1.8 shows a florescent staining of mesenchymal stem cells for 
the osteoconductive markers osteonectin (left) and bone sialoprotein (right). 
 
Figure1. 8 A florescent staining of mesenchymal stem cells (Meyer, 2006) 
 
 
 
 17 
 
1.9 Skeletal remodelling 
Bone structure displays sequential stages throughout life, comprising: 
 1) A rapid skeletal growth phase accompanied by accrual of peak bone mass;  
 2) A steady state phase whereby bone mass remains constant;  
 3) Age-related bone loss 
These changes are the consequence of a continuous process of resorption and formation 
of the mineralized matrix, referred to as bone remodelling (BAB, 2009 ). 
However, the bone remodelling cycle is composed of two sets a relatively rapid 
processes (i.e. few weeks) including the resorption of pre-existing mineralized matrix 
by osteoclasts, followed by a slower phase (few months) that includes the bone 
formation by the osteoblasts (BAB, 2009 , Kalfas, 2001). The significance of 
imbalances in bone remodelling are demonstrated by conditions such as osteoporosis 
which is considered the most common metabolic bone disease in developed societies 
which in turn increases skeleton weakening and the risk of bone fracture (Unnanuntana 
et al., 2011) 
1.10 Basic principles of bone healing 
Generally, the process of wound healing is thought to occur in three phases that follow 
in both a sequential and simultaneous fashion. These phases are the inflammatory, 
proliferative, and remodelling phases (Kalfas, 2001). In the inflammatory stage, a 
hematoma develops within the fracture site during the first few hours and days. 
Inflammatory cells (macrophages, monocytes, lymphocytes, and polymorphonuclear 
cells) and fibroblasts infiltrate the bone under prostaglandin mediation (Dimitriou et al., 
2011). This results in the formation of granulation tissue, ingrowth of vascular tissue, 
and migration of mesenchymal cells. The primary nutrient and oxygen supply of this 
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early process is provided by the exposed cancellous bone and muscle. The use of anti-
inflammatory or cytotoxic medication during this 1st week may alter the inflammatory 
response and inhibit bone healing. During the repair stage, fibroblasts begin to lay down 
a stroma that helps support vascular ingrowth. It is during this stage that the presence of 
nicotine in the system can inhibit this capillary ingrowth (Kalfas, 2001). A significantly 
decreased union rate had been consistently demonstrated in tobacco abusers. As 
vascular ingrowth progresses, a collagen matrix is laid down while osteoid is secreted 
and subsequently mineralized, which leads to the formation of a soft callus around the 
repair site. In terms of resistance to movement, this callus is very weak in the first 4 to 6 
weeks of the healing process and requires adequate protection in the form of bracing or 
internal fixation. Eventually, the callus ossifies, forming a bridge of woven bone 
between the fracture fragments. Alternatively, if proper immobilization is not used, 
ossification of the callus may not occur, and an unstable fibrous union may develop 
instead (Kalfas, 2001). Fracture healing is completed during the remodeling stage in 
which the healing bone is restored to its original shape, structure, and mechanical 
strength. Remodelling of the bone occurs slowly over months to years and is facilitated 
by mechanical stress placed on the bone (Kalfas, 2001). As the fracture site is exposed 
to an axial loading force, bone is generally laid down where it is needed and resorbed 
from where it is not needed. Adequate strength is typically achieved in 3 to 6 months. 
Although the physiological stages of bone repair in the spinal fusion model are similar 
to those that occur in long bone fractures, there are some differences. Unlike long bone 
fractures, bone grafts are used in spinal fusion procedures. During the spinal fusion 
healing process, bone grafts are incorporated by an integrated process in which old 
necrotic bone is slowly resorbed and simultaneously replaced with new viable bone. 
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This incorporation process is termed "creeping substitution (Kalfas, 2001). Primitive 
mesenchymal cells differentiate into osteoblasts that deposit osteoid around cores of 
necrotic bone. This process of bone deposition and remodelling eventually results in the 
replacement of necrotic bone within the graft. The most critical period of bone healing 
is the first 1 to 2 weeks in which inflammation and revascularization occur. The 
incorporation and remodeling of a bone graft require that mesenchymal cells have 
vascular access to the graft to differentiate into osteoblasts and osteoclasts. A variety of 
systemic factors can inhibit bone healing, including cigarette smoking, malnutrition, 
diabetes, rheumatoid arthritis, and osteoporosis, in particular during the 1st week of 
bone healing. Additionally, it has been shown that Irradiation of the fusion site within 
the first 2 to 3 weeks can inhibit cell proliferation and induce an acute vasculitis that 
significantly compromises bone healing (Kalfas, 2001). 
1.11 Signals that initiate and maintain the bone-forming 
mechanisms 
A multitude of signal factors have been associated with the bone-forming mechanisms. 
They are summarised in the following table 1.2, their existence are indicated in initial, 
early, late and remodelling stages. The presence and timing of the expression of these 
signal molecules is of special relevance, since such molecules can be used in tissue 
engineering approaches to improve tissue formation in-vitro and in-vivo (Lieberman et 
al., 2002). 
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Table1. 2 Signals involved in bone repair throughout different remodelling stages 
(Lieberman et al., 2002) 
 
Recent evidence has shown that the specific members of the transforming growth factor 
β superfamily, including multiple BMPs, GDFs, and TGF-β1-3, act in combinations 
with other factors (e.g. metalloproteases) to promote tissue repair (Cho et al., 2002). 
However, bone regeneration is dependent on the formation of new vessels that assumed 
to be regulated by two separate pathways: a vascular endothelial growth factor (VEGF)-
dependent pathway and an angiopoietin-dependent pathway (Sittichockechaiwut et al., 
2009). The VEGF related family of molecules are essential endothelial-cell-specific 
mediators of neo-angiongenesis, whereas angiopoietin 1 and 2 are molecules that 
directly control vascular growth, the latter pathway stimulant is assumed to act during 
the whole period of new bone tissue formation. Thus it can be concluded that these 
different pathway stimulants play a crucial role in regeneration of bone tissue. However, 
it is not certain that full regeneration of bone relies entirely on those two signalling 
pathway stimulant parameters only, since there are number of boundary conditions that 
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should be considered as well in the processes of bone regeneration (e.g. defect size, 
tissue biomechanics, host conditions) (Sittichockechaiwut et al., 2009). 
In order to fully understand and control bone regeneration, different proteins that 
contribute in this process should be very carefully understood and studied, this would in 
turn identify the possible roles of each protein and the degree of contribution in bone 
regeneration.    
1.12 Scaffolds and Tissue Engineering 
Scaffolds form a framework and provide support for cells to attach, proliferate and 
differentiate, and form an extracellular matrix (ECM) (Agrawal and Ray, 2001). It is 
this ECM which provides the structural integrity of tissue. The scaffold also serves as a 
reservoir for cells, growth factors and cytokines (Chan and Leong, 2008). Synthetic 
scaffolds have been developed in order to aid tissue repair. 
In order to select appropriate scaffolds for bone repair several factors should be taken 
into consideration in order to achieve desirable responses from cells seeded in them 
either in-vitro or in-vivo.  
These factors include: 
An extensive network of interconnecting pores so that cells can migrate, multiply and 
attach deep within the scaffolds, channels through which oxygen and nutrients can pass 
to cells deep inside the scaffold, and the waste products can be easily carried away, 
biocompatibility of a biomaterial to perform its desired function with respect to a 
medical therapy without eliciting any undesirable local or systemic effects in the 
recipient or beneficiary of that therapy and appropriate mechanical strength 
(Hutmacher, 2000).  
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Biomaterials used in tissue engineering scaffold fabrication can be divided into broad 
categories of either synthetic Polycaprolactones or naturally derived (i.e. Collagen), 
with an emerging middle ground of semisynthetic materials such as HA/PCL 
hydroxyapatite Polycaprolactones (Griffith, 2002). 
1.12.1 Definitions given by Vert for materials behaviour (Vert, 1992) 
Biodegradable materials:  
Are solid polymeric materials and devices which break down due to macromolecular 
degradation with dispersion in vivo but no proof for the elimination from the body (this 
definition excludes environmental, fungi or bacterial degradation). Biodegradable 
polymeric scaffolds or substrates can be attacked by biological elements so that the 
system integrity as well as the macromolecules themselves is affected inducing 
fragments or other degradation by-products. Such fragments can move away from their 
site of action but not necessarily from the body. 
Bioresorbable materials:  
Are solid polymeric materials and devices which show bulk degradation and further 
resorb in vivo; i.e. polymers which are eliminated through natural pathways either 
because of simple filtration of degradation by-products or after their metabolization 
with no trace in the body. 
Bioerodible materials:  
Are solid polymeric materials or devices, which show surface degradation and further, 
resorb in vivo. 
Bioabsorbable materials:  
They are solid polymeric materials or devices, which can dissolve in body fluids 
without any polymer chain cleavage or molecular mass decrease. For example, it is the 
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case of slow dissolution of water-soluble implants in body fluids thus a bioabsorbable 
polymer can be bioresorbable if the dispersed macromolecules are excreted. 
 
1.12.2 Most popular biodegradable materials used in scaffold fabrication 
(Liu, 2007):  
They are as follows: Polylacticacid (PLA), Poly (DL-lactic acid-co-glycolicacid) 
(PLGA), Polyglycolic acid (PGA), Polyanhydrides, Polyfumarates (PF), 
Polyorthoesters, Polycaprolactones (PCL) and Polycarbonates. Synthetic materials such 
as PLA, PGA, PLLA and PLGA undergo bulk degradation throughout the cycle of 
implantation inside the human body as the molecular weight of the polymer starts to 
decrease upon placement in an aqueous media. However, the mass loss does not start 
until the molecular chain is reduced to a size which allows them to diffuse out of the 
polymer matrix. This mass loss is accompanied by a concentration gradient (often 
referred to as a release gradient) of acidic by-products which decrease the local pH of 
the wound site. To decrease the impact of this on repairing tissue, drainage systems 
should be engineered to prevent the accumulation of by-products. Failure to do this in 
poorly vascularised tissue such as bone will result in acidic degradation and resorption 
which could lead to temporary disturbances as well as inflammatory reactions and 
implant failure (Peter, 1998), (Anderson, 2001), (Hutmacher, 2000). To overcome such 
outcomes the scaffold/cell construct should be perfused with sufficient tissue fluid to 
neutralise the acidity especially during the phase where the mass loss of the synthetic 
implant occurs (Hutmacher, 2000). 
In order to alleviate the local inflammatory response occurring at the targeted site 
incorporation of ceramics such as TCP (Tricalcium phosphate), HA (hydroxyapatite) 
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powders can be introduced into a synthetic polymer matrix to produce a composite 
polymer scaffold that can buffer the acidic resorbation by-products of the synthetic 
polymers and therefore help prevent the unfavourable decrease in the pH (Kempen, 
2006).   
1.13 Tailoring scaffold-cell interactions 
The success of the scaffold depends on the ability of the implanted cells to attach to the 
surrounding environment and to stimulate angiogenesis (new blood vessel formation). 
The combination of high cell density and an appropriate substrate are needed to induce 
cooperative cell–cell and cell–matrix interactions. A cellular scaffold may be difficult to 
populate with cells (Tsang and Bhatia, 2004). However, it is important to program 
scaffolds with biological instructions, cells and growth factors which need to be 
integrated into the scaffold fabrication for tissue engineering purposes so that the 
bioactive molecule can be released from the scaffold and trigger or modulate new tissue 
formation. 
A study  (Koh, 2002,Tsang, 2004 ) have proposed the combination of photolithographic 
techniques with PEG-based (Polyethylene glycol) cell encapsulation chemistries to 
build a structural feature within a 3D cell/hydrogel network. As a result of using this 
method live cells were suspended in polymer solution and were photoimmobilized 
locally in multiple cellular domains in controlled hydrogel architecture to create 3D 
cellular hydrogel tissue constructs. Similarly (Vacanti, 1998 ) reported another 
technique to fabricate a cell-scaffold composite in vitro for subsequent implantation to 
produce a functional tissue in vivo. 
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1.13.1 Bone cell adhesion 
The term adhesion in the biomaterial domain covers different phenomena: 1) the 
physicochemical linkages between cells and materials involving ionic forces, Van der 
walls forces, and others which are considered short term events. 2) Cell adhesion 
occurring in longer term process and involving various biological molecules: 
extracellular matrix proteins, cell membrane proteins, and cytoskeleton proteins which 
interact together to induce signal transduction, promoting the action of transcription 
factors and consequently regulating gene expression (Vacanti, 1998 , Anselme, 2000).  
1.13.2 ECM adhesion proteins 
It was reported (Anselme, 2000) that some bone proteins have chemotactic or adhesive 
nature due to the existence of Arg-Gly-Asp (RGD) sequence which is specific to the 
fixation onto cell membrane receptors (integrin), e.g. fibronectin, osteopontin, bone 
sialoprotein, thrombospondin, type I collagen and vitronectin. Similarly, human 
osteoblasts adhere preferentially to fibronectin as compared to type I, type IV collagen, 
and vitronectin, but weakly to laminin and type V collagen. On the other hand, 
artificially synthesized peptides like GRGDS (Gly-Arg-Gly-Asp-Ser) or RGDS (Arg-
Gly-Asp-Ser) demonstrated an inhibitory effect in cell attachment after mixing with 
culture medium compared with control groups (without medium mixing) (Anselme, 
2000). 
 
In the external faces of focal contacts specific receptor proteins such as integrin are 
present. Similarly in the internal face there are some proteins like talin, paxillin, 
vinculin, tensin which are known of mediating interactions between actin filaments and 
membrane receptor proteins (integrin) as indicated in Figure 1.9. Many proteins localize 
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with vinculin and talin in the adhesion plaque: integrin, cytoskeletal proteins, proteases, 
protein kinases and phosphatases, signalling molecules all are involved in the signal 
transduction.  
The formation of focal contacts occur essentially in less motile cells rather than highly 
motile cells and they are promoted in-vitro by the use of ECM proteins like fibronectin 
or vitronectin (Alberts et al., 2002). However, the architecture of the actin cytoskeleton 
is essential to the maintenance of cell shape and cell adhesion, for example if they 
assemble in long bundles, F-actin supports finger-like protrusions of the plasma 
membrane known as filopodia similarly, if they are assembled in the form of a mesh, it 
supports sheet-like protrusions known as lamellipodia (Wu et al., 2012). In addition, if 
they are present in bundles coupled with adhesion plaques, actin ‘’stress fibers'’ may 
transmit forces to the substrate (Anselme, 2000).  
 
Figure1. 9 Representation of the cell proteins involved in cell adhesion on 
biomaterial (Anselme, 2000) 
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1.13.3 Adhesion molecules  
Adhesion molecules are characterized by their capacity to interact with a specific 
ligand. These ligands may be situated on the membrane of neighbouring cells or may be 
extracellular matrix proteins. The main two adhesion molecules family that are of 
interest in the area of tissue engineering are cadherins for cell-cell adhesion and 
integrins for cell-ECM adhesion. Integrins are transmembrane heterodimers consisting 
of noncovalently associated α and β sub-units. Each sub-unit is made up of a large 
extracellular domain, a transmembrane domain and a short cytoplasmic domain. 
Interestingly, there are various subunits of α and β integrins, they work together and are 
responsible for mediating both cell–cell and cell–matrix interactions which act as an 
interface between the intra- and extra-cellular compartments and can translate the 
attachment of external ligands to internal information which induces adhesion (Hynes, 
1992), spreading, or cell migration, thus ECM integrin interactions play a part in 
regulating cell growth and differentiation (Gronthos et al., 1997).  
Cultured human osteoblasts express high levels of α1β1, α3β1, α5 β1 and α7 β5 and much 
lower levels of α2 β1, α 4β1, α 7β1 and α 7 β3 integrin’s (Saito, 1994, Gronthos et al., 
1997, Ruoslahti and Pierschbacher, 1987), Thus it can be concluded that β1 sub-unit 
appears to be the predominant receptor involved in osteoblast adhesion to collagen and 
laminin and is partially involved in fibronectin, as indicated in Table 1.3 with different 
integrin subunits and their ligands.   
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Table1. 3 some of the integrin family of adhesion receptors (Saito, 1994) 
 
1.13.4 Cadherin for cell-cell adhesion 
As there are integrin (proteins) responsible for the adhesion of cell-ECM, there are also 
adherans junctions that mediate cell-cell adhesion called cadherins (CAM). Osteoblastic 
cells express different types of CAM’s, e.g. E-cadherins and cadherin-11 (or OB-
cadherin) as well as mRNA expression of N-cadherin and low levels of cadherin-4. 
Although expression of cadherin-4 is modulated by bone morphogenetic protein-2 
(BMP-2), cadherin-11 and N-cadherin expressions are not (S-L, 1998, Alberts et al., 
2002).  
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1.13.5 Gap-junctions 
Cell recognition and adhesion precede and control cell-cell communication via gap 
junctions. Intercellular communications occur through direct exchange of ions via gap 
junctions or through signals produced by the action of CAM (cell adhesion molecules). 
Gap junctions are constituted by homohexamus derived from a family of proteins called 
connexins. When the connexin of one cell (composed of six connexin molecules) is in 
register with a similar structure on a neighbouring cell, a transcellular channel is formed 
(Overholtzer and Brugge, 2008). Tight and adherens junctions or desmosomes provide 
anchorage to surrounding cells and allow direct exchange of ions or small molecules 
between cells (Chiba, 1994). 
 
1.14 Biomolecules used to augment bone cell reaction 
Evidence from a variety of studies indicates that the exposure to osteoinductive growth 
factors can promote new bone formation. However, different healing environments 
require different types of bone tissue to be engineered. Thus for bone regeneration and 
construction it is suggested that it should be accomplished using various bioactive 
factors with varying potency and efficacy (Stevenson, 1992), (Hogan, 1996), (Dimitriou 
et al., 2011). The following Table 1.4 summarizes the biomolecules that have been used 
recently to engineer new bone. 
Transforming growth factor beta (TGFβ) 
Bone morphogenic proteins (BMPs) 
Insulin-like growth factors (IGFs) 
Platelet-derived growth factors (PDGFs) 
Fibroblast growth factors (FGFs) 
Table1. 4 Biomolecules used to augment bone cell reaction (Hogan, 1996) 
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1.14.1 Modulation of TGF-β in collagen substrates used for bone tissue 
engineering 
A novel study undertaken by (Keogh, 2010) investigated the osteogenesis of collagen 
scaffolds and how it may be accomplished via two TGF-β dosage methods: either low 
continuous dose, e.g.0.2 ng/ml, or one containing a single high dose, e.g. 10 ng/ml. The 
study revealed that osteoblast cell lines were found to attach and infiltrate the scaffold 
leading to confluence at 35 days in both the periphery and centre of the construct. 
However, treatment with high levels of TGF-β resulted in greater mineral staining at 
low continuous treatment. Furthermore collagen type I and alkaline phosphate activity 
(markers of early stage osteogenesis) expressions were increased when treated with low 
levels of TGF-β when compared with high level treatment. In contrast, it was found that 
ostocalcin which is responsible for bone mineralisation (marker of late osteoblast 
differentiation) was more responsive to the higher dose treatment (Keogh, 2010). Thus 
it was concluded that for obtaining optimum effect, modulation of transforming growth 
factors should be used at low concentrations at the 1st stages of osteogenesis followed 
by high dosage concentrations in later stages.           
1.15 Limitations that face cell-substrate interactions 
Disadvantages of synthetic biodegradable polymers used in tissue engineering scaffold 
materials develop a lack of biological recognition on the material surface as they may 
not interact with the cells in a desired fashion and lead to unfavourable surface 
chemistry that will not provide a suitable environment for the tissue and may result in 
cell apoptosis (Anselme, 2000). One of the challenges that have to be faced by tissue 
engineers is how to integrate growth factors into fabricated scaffolds to achieve a 
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homogenous distribution of cell attachment and proliferation, moreover to control 
required dosage of biochemical stimuli in vitro (Luu, 2003, Lo, 2010). There is 
evidence that differentiation and organization of human embryonic cells (hES) can be 
influenced by the scaffold and directed by different stimuli such as retinoic acid, 
transforming growth factor β, activin-A, or insulin-like growth factor. These stimulants 
induce formation of human 3D structures with characteristics of developing neural 
tissues, cartilage, or liver, respectively. It remains a challenge in the development of 
tissue engineering scaffolds to control the architecture and the overall surface chemistry 
to precisely regulate cell behaviour (Annabi et al., 2010).  
1.16 Importance of cytokines in Bone repair 
To give an overview on bone repair and regeneration one should understand that bone 
tissue engineering takes place in a series of events that are affected by various biological 
and mechanical factors. Overall, it means that the bone healing responses starts when 
newly developed bone is integrated into the surrounding tissue and in response starts 
expressing extra cellar matrix (ECM) that supports cell attachment, proliferation and 
differentiation. This ECM can either be natural or synthetic (incorporated) 3D scaffolds 
(Hutmacher, 2000). 
Growth factors and adhesion molecules can be incorporated in the surface of the 
implanted matrix as they are secreted by cells in a natural response. These growth 
factors control the behaviour of the cells by controlling cell migration and 
differentiation and subsequent tissue formation (Ramoshebi et al., 2002). Stimulation of 
growth factors in relation to cell behaviour on cells is known as the osteoinductive 
process via signalling pathways. 
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There are various techniques to enhance tissue regeneration and one of them is by 
applying growth factors at the site of regeneration which is the simplest method for 
inducing cell migration and proliferation as well as differentiation. However, direct 
application of growth factors has little effect on cells because they tend to diffuse out 
from the site of regeneration very quickly (Khan et al., 2000). 
This problem can be solved by the controlled release of growth factors at the site of 
action over a long period of time using bio-absorbable scaffolds. 
1.16.1 Mechanisms of cytokine action: 
Autocrine effect (growth factors act directly on the cell that produced them), paracrine 
effect (growth factors act on neighbouring cells surrounding the growth factor 
producing cell), juxtacrine effect (growth factor communication signal received by one 
cell to neighbouring cells due to cell-cell interaction), endocrine effect (growth factors 
act on a cell in distance from where the growth factor producing by travelling through 
the blood stream). Growth factors have an important role in growth, development, day-
to-day maintenance, mobilised remodelling and injury (Kaplan et al., 2007). 
1.16.2 Transforming growth factor β 
The transforming growth factor-β (TGf-β) super-family encompasses various different 
proteins which includes the bone morphogentic protein (BMP). These different proteins 
play different processes in cell development stages. 
TGF-β exists as 3 isoforms in mammals: TGF-β1, 2 and 3 (Kingsley, 1994); and act in 
either a paracrine or autocrine manner (Krasagakis et al., 1994), (Kaplan et al., 2007). 
Different cell types, including epithelial, endothelial, lymphoid and mesenchymal cells, 
produce TGF-β. Characteristics of cells under the influence of TGF-β include down-
regulation of cell-cell junctions, increased motility and decreased proliferation. In 
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mesenchymal cells, however, TGF-β stimulates cell growth (Shipley et al., 1986). Also, 
the influence of TGF-β on cell activity can be affected by the physiologic state of the 
target cell and its environment, i.e. receptor expression and the presence of other growth 
factors. For example, when fibroblasts are grown in monolayers in the presence of 
epidermal growth factor (EGF), TGF-β causes a decrease in proliferation. Conversely, 
when these cells are grown in serum, the inhibitory effects of TGF-β are overcome by 
EGF (Roberts et al., 1985) 
The transforming growth factor family include different proteins such as BMB’s, 
nodals, activins, inhibins and TGF-β. However, TGF-β exists inside the body in three 
different isomers which are TGF-β1, 2 and 3, and their actions can be either paracrine or 
endocrine. They have different response according to the site and environment. For 
example, in skin cells when fibroblasts are grown in monolayers in the presence of 
epidermal growth factor (EGF), TGF-β causes a decrease in proliferation. In opposition, 
when these cells are grown in semi-solid medium, TGF-β induces growth (Border and 
Noble, 1994). 
Previous studies have been less conclusive with respect to TGF-β3 as an in-vitro 
treatment as compared to TGF-β1 and 2 (Khan et al., 2000) and also as compared to 
other growth factors such as Bone Morphogenetic Protein (BMP) (Croteau et al., 1999), 
Platelets-Drived growth factor (PDGF), Insulin-Like growth factor (IGF) (Thaller et al., 
1993) and Fibroblast growth factors (FGF) (Hurley et al., 1993). This study investigates 
the effect of TGF-β3 in combination with cannabinoid on bone cell detachment via a 
trypsinization process as well as its effect on the wound closure response in cultured 
bone monolayers. A Lack of research on TGF-β3 is the main reason to use using this 
cytokine in combination with cannabinoids.  
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1.16.3 TGF-β signalling 
The effects of TGF-β1, 2 and 3 are mediated by a range of signalling pathways (Kale, 
2004, Aoudjit and Vuori, 2012). Activation of the same signalling cascade follows 
ligand-receptor interactions at the cell surface. The TGF-β receptor complex is made up 
of serine-threonine kinase receptor types I and II. These bind to a third receptor, type 
III; also known as betaglycan. This membrane-anchored proteoglycan binds to the TGF-
β ligand and presents it to the type I/II receptor complex allowing signal transduction to 
occur (Shi and Massague, 2003). This betaglycan also known as the TGF-beta type III 
receptor has been shown (Lopez-Casillas et al., 1994) to act as dual modulator of TGF-β 
activity. The soluble form of this protein, no longer anchored to the cell membrane, acts 
as an inhibitor of TGF-β signalling (Shi and Massague, 2003). Furthermore, all TGFβ 
superfamily members bind to heterodimeric receptor isomers that belong to the same 
family, i.e. dimeric complexes of various type I receptor serine/threonine kinases (ALK 
1-7) and type II receptor proteins (5 isoforms)(Euler-Taimor and Heger, 2006). These 
receptors subsequently activate different intra-cellular SMAD proteins to elicit various 
biological responses. Besides activation of Smads, TGF-β mediates its effects via 
activation of a number of signals including mitogen-activated protein kinases (p38 
MAPK), extracellular-signal-regulated kinases (Erk), c-Jun N-terminal kinase (JNK), 
and Transforming growth factor β–activated kinase 1 (TAK1) (Bujak and 
Frangogiannis, 2007). Interestingly, BMP’s share the same signalling cascades as TGF-β 
(Hollinger, 2004). 
To initiate intracellular signalling, BMP binds as a dimer to a complex of two 
transmembrane receptors (type I and II) and starts a phosphorylation cascade 
upregulating bone-specific differentiation genes (e.g., runx2, osteocalcin, bone 
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sialoprotein, type I collagen, and alkaline phosphatase). BMP-2 receptors type I and II 
are activated by two independent signalling pathways (Hollinger, 2004); The first 
pathway involves BMP-2 dimerization and binding to a preformed receptor complex, 
initiating a phosphorylation cascade. The type I receptor phosphorylates Smad1, Smad5, 
and Smad8. A complex of these three is formed with Smad4 in the cytoplasm. The 
complex translocates to the nucleus and functions as a transcriptional regulator of bone-
specific genes. In contrast Smad6 and Smad 7 have an inhibitory effect for such 
formation by bending to type I receptor and blocking the phosphorylation of Smad1, 
Smad5, and Smad8 as indicated in Figure 1.10, (Chen et al., 2012).  
The second signalling pathway is activated when the BMP-2 dimer binds to receptor 
type II only. This binding event recruits receptor type I and initiates a phosphorylation 
cascade via the MAPK pathway involving p38 and Erk1/2. This pathway culminates 
with activation of AP-1 in the nucleus (figure 1.10).  
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synthetized endocannabinoids such as anandamide and endocannabinoid 2-
arachidonoylglycerol due to expression of CB2 cannabinoid receptor. Although the CB2 
receptor has been implicated in pathological processes in the central nervous system and 
peripheral tissues, the skeleton appears to be a system physiologically regulated by 
CB2. It is believed that CB2 related cannabinoids driven processes play an important 
role in the mediation and the setting off of bone remodelling (BAB, 2009 ).  
Locally, osteoblasts are regulated mainly by bone morphogenetic proteins. Systemically 
different factors control bone formation for example parathyroid hormone, calcitonin, 
insulin-like growth factor I and osteogenic growth peptide. More recently, it has been 
reported that bone remodelling is also subject to a hierarchically superior central control 
by hypothalamic leptin and neuropeptide Y signalling as well as downstream 
sympathetic signalling through osteoblastic β2 adrenergic receptors which is negatively 
regulated by CB1 receptor agonists (Takeda et al., 2002).  
The actions of cannabinoids and endocannabinoids are mediated mainly by G protein-
coupled cannabinoid receptors type 1 (CB1) and type 2 (CB2) (Howlett, 2002).  
CB1 is perhaps the most abundant cannabinoid G protein-coupled receptor expressed in 
the CNS. It is also present in peripheral neurons and the gonads and to some extent in 
several other peripheral tissues. CB2 is expressed in the immune system, cirrhotic liver, 
arteriosclerotic plaques, inflamed gastrointestinal mucosa and brain inflammation (Bab 
and Zimmer, 2008). However, CB1 and CB2 are not functionally identical as 
demonstrated by the presence of cannabinoid agonists and antagonist with distinct 
binding specificities to either receptor. 
A rather striking observation (BAB, 2009 , Di Marzo et al., 2001) stated that bone 
formation and bone mass as well as central production of at least one major 
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endocannabinoid are subject to negative control by leptin, that is involved in regulating 
energy intake and energy expenditure It was also stated that traumatic brain injury 
enhances both bone formation (Orzel, 1985a, Di Marzo et al., 2001) as well as central 2-
Arachidonoylglycerol (2-AG) production which is considered one of the main CB1 
endogenous ligand (Qian et al., 2009). However, the importance of endocannabinoid 
studies in human skeleton arose from the identification of higher magnitudes of 
anandamide and 2-AG found in skeleton with higher level of magnitudes compared 
with those in blood. Thus it was concluded that these endocannabinoid are locally 
synthesized in the skeletal system (Bab, 2008).  Both CB1 and CB2 receptors contribute 
to the action of cannabinoids and endocannabinoids and they both represent a 
distinctive role in the mediation and regulation of cannabinoid response in bone 
regeneration (BAB, 2009 , Hanus et al., 1999). Both receptors are thought to be 
involved in the signalling cascade associated with p38 mitogen-activated protein kinase 
activation (Derkinderen et al., 2001) along with the activation of p42/44 mitogen-
activated protein kinase. These are also pathways thought to be involved in BMP’s and 
TGFβ mediated processes in osteoblasts thus raising the hypotheses of fine tuning 
between growth factors as well as cannabinoid receptor agonists and their activation and 
response in the modulation of bone formation. Interestingly, the importance of 
cannabinoid agonist response in cells may be linked in relation to preosteoblastic cells 
such as MC3T3-E1 which express low levels of CB receptors. However, when they are 
cultured in osteogenic medium they express high levels of CB2 receptor mRNA in 
parallel with the increase of ALP activity as well as RUNX2. This response was also 
indicated in parallel with the use of osteogenic promoters such as BMP’s and TGF-β 
which are involved in ossification and mineralization of osteoblast bone cells (Orzel, 
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1985b, Panikashvili, 2001, Wildburger, 1998). Furthermore, indicating the positive 
effect cannabinoid agonists could make on osteoblastic cell-line. 
One of the various cannabinoid types that has been established is the specific CB2 
agonist HU-308 which triggers a Gi protein-mediated mitogenic effect and consequent 
expansion of the preosteoblastic pool in early osteoblast progenitors (Bab, 2005) 
1.17.1 CB1 and its role in increasing osteoblast formation 
Recent findings suggested that CB1 controls osteoblast function by negatively 
regulating norepinephrine (NE) release from sympathetic nerve terminals in the 
immediate vicinity of these cells. NE suppresses bone formation by binding to 
osteoblastic β2AR, this suppression is further alleviated by activation of sympathetic 
CB1 (BAB, 2009 ). 
However, findings indicated that CB1 null receptor mice express a high bone mass 
phenotype suggesting that their activation down-regulates bone mass (Tam et al., 2006) 
and that CB1 inverse agonist would suppress bone resorption by inhibiting osteoclast 
formation. In contrast other paradoxical findings indicate  that CB1 null receptor mice 
develop low bone mass (Bab and Zimmer, 2008) and that deficiency in CB1 is 
associated with a defect in bone formation in a mouse model of traumatic brain injury 
(Idris, 2011). 
 
1.17.2 Psycho activity effects and their relation to CB1 
One of the major drawbacks with cannabinoid treatments is the induced Psycho-activity 
effect. Therefore, it is necessary to consider this in treatment selection especially when 
dealing with bone to avoid the psychological side effects that could be endured on both 
the brain and the body. CB2 selective targeting is important to overcome complications 
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associated with the cannabinoid psychoactive effects such as catalepsy, 
hypolocomotion, and disruptions in the memory which are mainly mediated by 
cannabinnoid receptor CB1. One synthetic cannabinoid (CB2 receptor agonists) that has 
been validated being non-psychoactive is the HU-308 which has been found to attenuate 
bone loss induced by oestrogen depletion in ovariectomized (OVXed) animals (Bab.I, 
2007).   
 
1.17.3 Importance of CB2 induced bone formation for potential wound 
healing  
Recent studies indicate different findings on the effect of CB2 selective agonists on 
bone formation, while some findings indicate that CB2 selective agonists such as 
JWH133 and HU308 promote osteoclast formation (Idris, 2011), others indicate that 
CB2 selective agonist HU308 increase bone formation markers and stimulates bone 
nodule formation (Ofek et al., 2006). 
A CB2-specific agonist has been shown to enhance osteoblast number and activity and 
restrained trabecular osteoclastogenesis. In a recent study it was indicated that CB2 
agonist inhibits proliferation of osteoclast precursors and receptor activator of NF-kB 
ligand expression in bone marrow-derived osteoblasts-stromal cells (Bab.I, 2007). 
There is also evidence that endocannabinoids specifically CB2 agonists are essential for 
the maintenance of osteoblastic and osteoclastic mediation via CB2 signalling response 
(Bab.I, 2007). Unlike the neuronal CB1 cannabinoid receptor, CB2 is expressed 
predominantly in non-neuronal cells and has no psychoactivity. In bone, CB2 is 
expressed by osteoblast, osteocytes and osteoclasts (Ofek et al., 2011), notably the 
effect of CB2 activation in osteoblast is due to its mitogenic response of the endogenous 
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endocannabinoid present in osteoblasts such as (anadamide) which stimulates osteoblast 
proliferation in vitro (Ofek et al., 2011). 
1.17.4 Cannabinoids and non psycho activity for potential therapeutic 
treatments 
Overall the psychotropic effect of cannabinoids is due to the presence of 
tetrahydrocannabinol (THC), as this is the major element that is responsible for the 
psycho activity in cannabinoid. If a cannabinoid extract is made without THC analogues 
it may prohibit the negative psycho-active effect making it useful and efficient as a 
potential drug in testing of 3-D culture systems (Burstein, 1999 ). ∆9-THC is lipophilic 
having the  ability to dissolve in fats, oils, lipids, and non-polar solvents such as hexane 
or toluene and is relatively non selective for both receptor subtypes CB1 and CB2 
(Porter, 2001 ). Table 1.5 shows both cannabinoid receptors CB1 and CB2 and their 
synthetic an non synthetic agonists and antagonists used in research (Porter, 2001 ). 
 CB1 CB2 
Endogenous agonists  Anandamide Anandamide  
Receptor selective agonists  2-arachidonylglycerol palmitoylethanolamide 
 Δ9 -THC Δ9 -THC 
 Winn55,212-2 Winn55,212-2 
 HU210 HU210 
Receptor selective antagonists  SR141716A SR144528 
 LY320135 AM630 
Table1. 5 Different synthetic CB receptor ligands and their antagonists 
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1.17.5 Cannabinoids and their anti-inflammation effect 
As defined earlier in the literature, the existence of two cannabinoid receptors, namely 
CB1 and CB2, are both responsible for cannabinoid response on different cells 
behaviour and type, e.g. osteoblasts and osteoclasts. CB1 receptor mediates most of the 
psychoactive effects of cannabinoid in the human body whereas the CB2 receptor is 
principally involved in the anti-inflammatory and immuno-suppressive actions. 
Therefore, selective targeting of cannabinoid receptor CB2 by their agonist has the 
potential of providing an anti-inflammatory effect of cannabinoids without its 
psychoactivity response (Ashton and Glass, 2007).  
There is also evidence that cannabinoid CB2 receptors are up-regulated during the 
activation of microglia (glial cells or macrophages of the brain and spinal cord) 
following brain injury, more specifically it was indicated that CB2-postive cells 
appeared in the rat brains following hypoxia-ischemia  as feedback mechanism to 
reduce inflammation (Ashton and Glass, 2007). This finding raises the hypothesis that 
CB2 receptor plays an important and distinct role in the process of anti-inflammation 
response. Further, indicating a potential use in diseases that are characterized by 
inflammation such as arthritis and different degenerative joint diseases in order to 
induce inflammation in the pro-inflammatory phases. Some studies also indicate that 
CB2 agonist treatment on human CD40 ligand expressions in cell cultures of microglial 
cells significantly reduced pro-inflammatory mediators such as THF-α and NO (nitric 
oxide) (Ehrhart et al., 2005).      
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1.17.6 CB2 signalling cascades in regulation of bone proliferation 
It has been established from the literature that CB2 activity is mitogenic in osteoblast 
culture, and that the mitogenic activity of CB2 signalling stimulation downstream is 
independent of the type of the agonist used. Evidence shows that stimulation of CB2 is 
regulated downstream through the Erk1/2 signalling pathway (Figure 1.11) ruling out 
the possible involvement of p38 signalling pathway, which is responsible for osteoblast 
undergoing differentiation after stimulation with transforming growth factors (Ofek et 
al., 2011).  
 
 
Figure1.11 Model of CB2 mitogenic signalling in osteoblasts. Gi protein activation is 
followed by enhanced ERK1/2 phosphorylation and accumulation of Mapkapk2. P 
Mapkapk2 phosphorylates and activates CREB, resulting in transcriptional activation 
of cyclin D1 and cell proliferation. 
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1.17.7 Presence of 2-AG in bone 
From the previous literature it was made clear that traumatic brain injury acutely 
stimulates central production of the major endocannabinoid (2-AG), and recent studies 
also show the presence of (2-arachidonoylglycerol alongside) 2-AG in osteoblast cells 
(Figure 1.12) are with the same magnitude as those expressed in brain, which in turn 
indicates a major role for this endocannabinoid in osteoblasts and potentially in bone 
formation (Joseph, 2008). 2-AG is also found in the MC3T3-E1 osteoblast cell line. 
Nevertheless, the 2-AG synthesizing enzymes DAGLα and DAGLβ are expressed in 
bone cells and 2-AG level in blood is minimal thus local skeletal production appears to 
be the main source of these high levels of 2AG. Together with the expression of the two 
cannabinoid receptors in bone, these findings indicate the complexity of skeletal 
endocannbinoid system.  
 
Figure1.12 Model of CB1 regulation of bone formation by modulating adrenergic 
signalling. Activation of CB1 cannabinoid receptors in bone sympathetic nerve 
terminals by bone cell-derived 2-AG restrains NE release, thus alleviating the tonic 
suppression of bone (Joseph, 2008) 
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1.17.8 Cannabinoids and inhibition of tumour invasion  
Along with various advantages in cannabinoid use there is increasing evidence that 
suggest cannabinoid compounds are useful for tumour cell growth inhibition through 
their modulation of several cell survival pathways. For example, in many clinical 
studies cannabinoid administration has been shown to induce regression of different 
diseases such as Gliomas, thyroid epitheliomas, and lung adenocarcinomas (Galve-
Roperh et al., 2000, Hinz et al., 2004). Furthermore, several in vitro studies have 
confirmed proapoptotic and antiproliferative effects on cancer cells by mechanisms 
involving the de novo synthesis of ceramide (responsible for cell differentiation, 
proliferation and programed cell death) and/or the activation of mitogen activated 
protein kinases (MAPKs) (Galve-Roperh et al., 2000, Hinz et al., 2004). Even though 
the majority of these and other cannabinoid effects are mediated by two Gi/0 protein 
coupled receptors CB1 and CB2, there is also experimental data that suggest a 
stimulatory effect of the endocannabinoid annadamide on transient receptor potential 
vanilloid 1 (TRPV1), a nonselective cation channel. However, several cannabinoid 
effects, including induction of apoptosis and cell death in several cell types, release of 
arachidonic acid and intracellular calcium, stimulation of MAPKs, and inhibition of 
interleukin 2 releases have been associated with molecular events that are independent 
of either CB 1 /CB 2 or TRPV1 activation (Ramer and Hinz, 2008). 
Cancer cell invasion is one of the most crucial events in local spreading, growth, and 
metastasis of tumours. Matrix metaloproteinases (MMPs) have emerged as a group of 
enzymes that exert an important function during tumour invasion, causing degradation 
of collagen and proteoglycans (Ramer and Hinz, 2008). To find a link between 
cannabinoid and MMP’s, various studies have been carried out to indicate a dosage 
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relation between tetrahydrocannabinol (THC) and TIMP-1 metallopeptidase inhibitor 1 
which is demonstrated to be a potent MMP inhibitor that suppresses tumour growth. 
Interestingly it has been observed that after treating HeLa cells with increasing dosage 
of THC no alterations were observed on MMP-9 levels. By contrast, concentrations of 
MMP-2 were decreased upon treatment of cells with increasing concentrations of THC 
and this was observed by the alterations in TIMP-1.  
In order to identify the involvement of different pathways for cannabinoid action HeLa 
cells were pre-treated with SB203580 and PD98059 which were inhibitors of P38 and 
P42/44MAPK activity, respectively. It was found that these inhibitors prevented the 
effects of THC which led to the decrease in TIMP-1 levels which in response increased 
the level of MMP’s preventing the action of cannabinoids on cell tumour growth 
(Ramer and Hinz, 2008). This seems to be contradicting to the earlier findings and 
therefore mechanisms, of action via CB1 and CB2 receptors and their binding ligands, 
works through different pathways depending on many factors including type of cells, 
tumours, signals and interactions (Ofek et al., 2011). 
1.18 Overall aims and objectives 
 
To elect the optimum concentration for synthetic cannabinoids that promotes better 
wound healing and to investigate which CB receptor mainly contributes to the process 
of MG-63 osteoblast monolayer wound healing. Examination of Cellular responses such 
as proliferation, cell behaviour and morphology (cell size, cell number) during wound 
healing. 
To investigate CB agonist response on bone cell monolayer detachment via 
trypsinization to indicate cell migration. 
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Furthermore finding the effect of transforming growth factor β3 in combination with 
CB2 receptor agonist HU308 on MG-63 osteoblast wound healing, proliferation and 
trypsinziation alongside their role in regulating collagen type I, fibronectin, protein S-
100A6, MMP-2 and Nitric oxide during MG-63 monolayer wound healing. In addition, 
the effect of different treatments of TGFβ3, HU308 and TGF-β3/HU308 combinations 
in the regulation of collagen type I, fibronectin and protein S-100A6 in MG-63 
osteoblast multilayers was investigated. 
This work provides a first insight in the clinical significance of using synthetic 
cannabinoids in fields such as tissue engineering in order to accelerate bone formation 
and bone wound healing without the disadvantages of psychoactivity, furthermore 
provides a first insight on the use of combination treatments of growth factors and 
cannabinoids in treatments of osteoblast monolayer wound healing and protein 
regulation in multilayer models.  
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Chapter II 
2 The Effect of selective and non-selective CB receptor agonists 
Winn55,212-2, URB602 and HU308 on MG-63 osteoblast 
monolayer  
2.1 Introduction to the mechanisms of action and function of 
cannabinoids 
A functional endocannabinoid system is present in several mammalian organs and 
tissues. Recently, endocannabinoids and their receptors have been identified and 
reported in the skeleton. Osteoblasts, the bone forming cells, and osteoclasts, the bone 
resorbing cells, produce endocannabinoids anandamide and 2-arachidonoylglycerol and 
express CB2 cannabinoid receptors. Actions of cannabinoid and endocannabinoids are 
mediated mainly through cannabinoid receptor types CB1 and CB2 (Howlett, 2002). 
Both receptors are not functionally identical and this is demonstrated by the presence of 
cannabinoid agonist and antagonists with distinct binding specifications to either 
receptor (Hanus et al., 1999).  
More interestingly, anandamide and 2-Arachidonoylglycerol (2-AG) are present in bone 
at levels similar to those in the brain. Both CB-receptor ligands are produced by 
osteoblastic cells in culture. In addition, DAGLα and DAGLβ, enzymes that are 
critically involved in the 2-AG biosynthesis, are expressed in osteoblasts, osteocytes 
and bone-lining cells. Although various studies have indicated that both 2-AG and 
anandamide are perceived as non-selective agonists of CB1 and CB2, findings indicate 
that in bone and bone cell cultures 2-AG activates CB1 receptors in the sympathetic 
nerve terminals, whereas anandamide affects bone cells directly by binding to CB2 
receptors (Bab and Zimmer, 2008). 
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MG-63 osteoblast bone cells used in the present study express both CB1 and CB2 
receptors (Lu et al., 2002), and it was also shown that osteoblast cultures of MC3T3-E1 
pre-osteoblast cells exhibit low levels of neuronal CB1 receptor and peripheral CB2 
receptor (Maccarrone and Finazzi-Agro, 2002). However, when these cells are grown in 
osteogenic medium for 2-4 weeks they express higher levels of CB2 receptors (Bab, 
2005), indicating that more differentiated MC3T3-E1 osteoblast cells express more CB2 
receptors.      
There is also evidence that CB1 receptors control osteoblast functions and that mice 
with null CB1 receptors exhibited a decrease in bone density and low bone mass with 
increase in osteoclast count (Tam et al., 2006).  It also seems that bone resorption can be 
modulated by cannabinoid agonists (Idris AI et al., 2005). Interestingly, not only CB1 
receptors were responsible for the increase in bone mass and bone density, it has also 
been found that CB2 receptor agonists had the ability to prevent and to reverse bone 
loss without the association of the psychoactive effects of CB1 selective agonists.  
2.2 Aims & objectives 
 
In the present chapter the effect of CB receptor agonists on wound healing of MG-63 
osteoblast cell monolayers was investigated. Using the non-selective CB receptor 
agonist Winn55,212-2 and by blocking CB1 and CB2 receptor with the specific 
antagonist, it can be shown which CB receptor mainly regulate Winn55,212-2 actions. 
Individual CB selective receptor agonists were also compared in relation to healing a 
MG-63 wound model. To examine the effect of CB1 receptors, monoglycerol lipase 
inhibitor URB602 was used to indirectly up regulate CB1 endogenous agonist 2-AG, 
furthermore CB2 selective agonist HU308 was used to investigate the effect of CB2 
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receptors on MG-63 osteoblast wound healing. This was carried out to further validate 
the significance of each receptor in wound healing of MG-63 osteoblast monolayer.  
Cell attachment was also investigated, as cell spreading and adhesion is associated with 
cell survival, growth and proliferation (Folkman and Moscona, 1978, Chen et al., 1997).  
The aim of this chapter was therefore, to identify the optimum concentration of 
synthetic cannabinoid that promotes better wound healing, and then identifying which 
CB receptor mainly contributes in the process of wound healing by treatment with the 
non-selective CB1/CB2 receptor agonist Winn55,212-2 and the blockage of individual 
receptors. Further investigation was carried out to examine the role of each specific CB 
receptor by either indirectly up regulating CB1 endogenous receptor agonist 2-AG or by 
treatments of CB2 selective receptor agonist HU308. Further investigations were also 
carried out to identify the different roles of each CB1 and CB2 receptors in relation to 
MG-63 osteoblast cell proliferation and attachment.                                                                                  
2.3 Materials and methods 
  
2.3.1 Cell culture 
MG-63 osteoblast-like cells, originally isolated from human osteosarcoma were 
acquired from ECACC (European Collection of Cell Cultures) and used in this study.  
The MG63 osteoblasts are a widely used cell line (Morris et al., 2006) because of their 
ability to retain a differentiated phenotype in culture conditions (Declercq et al., 2004) 
and because they can be grown for an infinite number of passages. MG63 cells have 
also been used previously in the study of the integrin-mediated cell-matrix interactions 
regulated by cytokines and hormones (Broberg and Heino, 1996, Riikonen et al., 1995). 
Moreover, the MG63 cell line has been used as a convenient source for purification and 
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identification of known and novel osteoblast transcription factor complexes (Newberry 
et al., 1997). 
In the present study, MG-63 osteoblast cells were cultured in a low glucose (1g/L-D-
Glucose) HEPES (25mM) buffered DMEM (Dulbecco's Modified Eagle Media, Sigma 
Aldrich) culture medium supplemented with L-glutamine (2.5 mM U/mL), Penicillin 
(100 U/mL), Streptomycin (0.1 mg/mL), Amphotericin B or a fungizone (250μg/ml), 
(Sigma Aldrich-UK)  and 10% FCS v/v (fetal calf serum- PromoCell - UK). Routine 
sub-cultures were carried out upon reaching 80% confluency in sterile environment 
using a laminar flow hood by washing cells three times with Hank’s Balanced Salt 
Solution (HBSS) each time for five minutes, and by adding 1ml of 0.25% Trypsin-
EDTA (Sigma Aldrich, UK) to detach cells. Once cells became rounded, detachment 
was stopped by the addition of 2ml medium containing 10% FCS. Cells were 
centrifuged at 1500 R.P.M, and then diluted using complete medium and counted using 
a haemocytometer. Cells were plated of an initial cell density of 100,000 cell/ml, culture 
flaks were always incubated in a 5 %CO2 air jacket controlled incubator at 37oC.  
Prior to experimentation of different treatments, it was made sure that the same 
conditions were applied for all experiment groups, in terms of using the same osteoblast 
cell patch, same culture medium and the same conditions throughout this work. 
Experiment were repeated three times for every treatment and were all carried out with 
the same stock solutions under the same conditions of cell culture; therefore a common 
control group was used for all treatments.   
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2.3.2 Preparation of treatments 
2.3.2.1 Non-selective CB receptor agonist Win55212-2  
2.09mg of the synthetic cannabinoid Win55212-2 (Sigma-Aldrich, 522.6138g/mol) was 
dissolved in 2ml of 100% ethanol (stock solution A) out of which 5μl was diluted in 
5ml medium to reach a final concentration of 2μM. 1ml of stock solution (A) was then 
diluted with 1ml of 100% ethanol to make sock solution (B) out of which 5μl was 
diluted in 5ml medium to reach a final concentration of 1μM. Out of the stock solution 
(A) another 0.5ml was taken out and was diluted to 1.5ml in 100% ethanol to make 
stock solution (C) out of which 5μl was further diluted in 5ml medium to reach a final 
concentration of 2μM. Samples were kept in the fridge as recommended by the supplier 
at 2-8°C. This process ensured that the concentration of ethanol applied to the cells was 
constant in all experiments.  
2.3.2.2 Preparation of Monoglycerol lipase inhibitor URB602 
URB601 CB1 agonist (Molecular weight 295.38g/mol) was obtained from Sigma-
Aldrich (U3010). Dilution was carried out according to supplier’s instruction, into three 
different concentrations of 2μM, 1μM and 500nM. 1.181mg was dissolved into 2ml 
100% ethanol to gain a stock solution (D), out of which 5μl was diluted in 5ml medium 
to reach a final concentration of 2μM. Out of the stock solution (D) 1ml was further 
added to 1ml of 100% ethanol to make stock solution (E) out of which 5μl was further 
diluted in 5ml medium to reach a final concentration of 1μM. Out of stock solution (D) 
another 0.5ml of stock solution was added to 1.5ml of 100% ethanol to make stock 
solution (F) out of which 5μl was further diluted in 5ml medium to reach a final 
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concentration of 500nM. All three samples were stored according to suppliers 
instructions at 2-8°C fridge for further use.   
2.3.2.3 Preparation of HU308 CB2 selective agonist (Hebrew university) 
HU308 CB2 agonist with a molecular weight of 414.62g/mol (supplied by Tocris 
bioscience) was diluted according to the suppliers instruction into three different 
concentrations of 2μM,1μM and 500nM. First 1.66mg was dissolved in 2ml of 100% 
ethanol to make stock solution (G) out of which 5μl was further diluted in 5ml medium 
to reach a final concentration of 2μM. Out of stock solution (G) 1ml was further added 
to 1ml of 100% ethanol to make stock  solution (H). out of which 5μl was diluted in 5ml 
medium to reach a final concentration of 1μM. 0.5ml of stock solution (G) was added to 
100% ethanol to gain stock solution (I) out of which 5μl was diluted in 5ml medium to 
reach a final concentration of 500nM. Samples were then stored at -20°C freezer 
according to suppliers instructions. 
2.3.2.4 Preparation of CB1 selective antagonist 
CB1 selective antagonist (LY320135, sigma Aldrich) with molecular weight of 
383.4g/mol was prepared by addition of 0.383mg of the CB1 antagonist with 1ml of 
100% ethanol to obtain a stock solution (K), out of which 5μl was diluted in 5ml 
medium to reach a final concentration of 1μM. Out of stock solution (K) 0.5ml was 
taken out and was further diluted by the addition of extra 0.5ml of sterilized 100% 
ethanol to obtain stock solution (L) out of which 5μl was diluted in 5ml medium to 
reach a final concentration of 500nM. 
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2.3.2.5 Preparation of CB2 selective antagonist: 
CB2 selective antagonist (AM630, Tocris, molecular weight of 504.37g/mol) was 
prepared by the addition of 0.5mg of the CB2 antagonist with 1ml of 100% ethanol to 
obtain a stock solution (M), out of which 5μl was diluted in 5ml medium to reach a final 
concentration of 1μM. Out of stock solution (M) 0.5ml was taken out and was further 
diluted by addition of extra 0.5ml of 100% ethanol to obtain stock solution (N) out of 
which 5μl was diluted in 5ml medium to reach a final concentration of 500nM. 
 
2.3.3 Cell proliferation assay 
The effect of synthetic cannabinoids on MG-63 osteoblast bone cells proliferation was 
assessed and cells were grown and sub-cultured as explained earlier according to their 
confulency. Prior to each experiment cells were counted using a haemocytometer and 
seeded with initial seeding density of 10×104 cells/ml and treatments were added and 
cells were left in the incubator. After 30 hours in culture, cells were trypsinized as 
indicated earlier. Cells were counted using a haemocytometer. Cell densities were 
compared with the initial plating densities and a proliferation factor was calculated by 
dividing cell density in cells/ml after 30 hours in culture by the plating cell density 
100,000 cells/ml. The experiments were repeated three times for consistency and the 
mean proliferation factors were calculated were (N) is the number of experiment 
repeats.  
2.3.4 Analysis of cell size (Cell Length) 
For every treatment used (Winn55,212-2, URB602 and HU308), cell size was 
determined after 30 hours via the acquisition of photomicrographs and measurement 
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using Image J software (NIH). The experiment was repeated three times, mean cell sizes 
were normalized for all groups and presented in percentage increase or decrease as 
compared to final cell size in control groups and (±SE) were calculated and (N) is the 
number of cells measured. 
2.3.5 Monolayer wound closure assay  
The capacity of osteoblast cell monolayer to repair in the presence of different receptor 
agonists was assessed by means of creating a sample wound via scratching a confluent 
bone cell monolayer.  
The wound scarring technique was first adopted in an experiment with NIH/3T3 cells in 
order to examine wound closure (GREEN, 2004), and wounds were initiated using a 
piece of Mylar film. The NIH/3T3 cells used in these experiments took 300 minutes for 
total wound closure. However, in the current investigation, surgical plastic pipettes were 
used instead of Mylar film to reduce the possibility of contamination, and the timing 
window for total wound closure of a 300μm width wound in MG-63 bone cell 
monolayer was found to be ~30 hours (Youseffi et al., 2010). A wound was made by 
scratching through the middle of the monolayer using a disposable long nosed plastic 
pipette. The tip was bent downwards so that it could be inserted into the flasks and 
sterilized in 70% ethanol and allowed to dry in air within the culture cabinet. The tip 
was then drawn across the cells on the cultured surface creating the wound. The scratch 
markings facilitated orientation while imaging, a marker was applied at 900 angle to the 
initial scratch and pictures were also taken at the cross points. Thus the same points 
were always photographed which gave more accurate data for analysis. 
After infliction of the wounds the culture flasks were inserted horizontally inside the 
incubator and photographs were taken every five hours for a period of 30 hours. The 
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cells were photographed using a light microscope and a digital camera. Pictures were 
captured and stored as ‘tif’ images using sicon Image Visi capture from Scion 
Corporation. 
Using ‘Image J’ software the distance between the wound edges was measured. Ten 
vertical lines were drawn and the distances between the intersections of the lines and the 
wound edges were measured Present data was acquired every 5 hours and data analysis 
consisted of a set of ten measurements of the wound width from each culture flask at 
each time point, and each experiment was repeated three times with a set of 30 
measurements in total (N=30) for each time point. Normalized wound width for each 
treatment was plotted against time. 
The first parts of the study were to culture MG-63 cell monolayers in normal culture 
flasks and create a model wounds. These cultures were used to investigate three 
different treatments WINN55,212-2, URB602 and HU308 at different concentrations of 
500nM, 1μM and 2μM also used by others (Bab, 2005, Bab and Zimmer, 2008, Bab, 
2008). This allowed the optimum concentration for establishing the fastest wound 
closure to be identified. All wound closure rates associated with each treatments of 
WINN55,212-2, URB602 and HU308 were compared against control cultures (no 
treatment) and negative control cultures (carrier treatment).  
2.3.6 Cell detachment analysis (trpsinization assay)  
Osteoblast cell attachment in both control and treatment groups were assessed at room 
temperature using a trypsinization assay. Trypsin is a temperature dependant enzyme 
(Kuzmina and Pervushina, 2004) that digests proteins by cleaving the peptide chains at 
the carboxyl side of amino acids (Olsen et al., 2004, Miyata et al., 2000, Khaghani, 
2012). This effect causes breakage of cell-cell and cell-extracellular environment 
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adhesion releasing the cells from the culture flask and/or dissociation from each other. 
The time taken for detachment of osteoblasts from the surface allows evaluation of the 
strength of cell attached to the extracellular environment.  
In this study MG-63 osteoblast bone cells were grown in complete culture medium with 
and without the addition of different treatments for a period of 30 hours. After 30 hours 
in culture and prior to starting the trypsinization assay cells were rinsed 3 times with 
Hank’s Balanced Salt Solution (HBSS) and then 2ml of 0.25% Trypsin-EDTA (Sigma 
Aldrich, UK) was added to the cells in each culture flask while cultures were present 
under the microscope. As soon as trypsin was added to the culture flask, the cells started 
to round up. Preliminary experiments indicated that it took 6 minutes for osteoblast cells 
to completely detach after culturing in medium without the presence of any treatment. 
Therefore in order to examine treatment related differences in cell detachment time 
experiments were carried out in a window of 4.5 minutes by obtaining a sequence of 10 
images at 30 second intervals. During trypsinization a digital camera connected to a 
phase contrast microscope and associated image J software was used. The cell 
detachment (rounding) rate was measured by determining the percentage reduction in 
cell surface area during 4.5 minutes based on individual cell morphology and the time 
taken for this reduction to occur. The same 20 cells were measured per frame, and 
experiments were repeated in triplicates and means were calculated (±SE), with total 
number of cell counted N=60.                                                                                                                 
2.4 Statistical analysis 
Mean % of wound remained open was tested for normality using a Kolmogorov 
Smirnov test. Normally distributed data (p > 0.05) were analysed using SPSS via a 
Oneway Analysis of Variance (ANOVA) followed by a post Hoc Bonferroni test. 
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Kruskal-Wallis test and serial Mann Whitney tests were used for non-normally 
distributed data (p<0.05).  Statistical tests were performed such that a p value of P< 0.05 
was considered as indicating a significant difference. There was some variability in 
initial wound widths therefore, % wound closure was normalised by computing zero 
minute of wound gap to be 100% and wound closure width during 30 hours is 
represented in correspondent percentages.     
2.5 Results and Brief Discussion 
 
2.5.1 The effect of Non CB-selective agonist Winn55,212-2 on MG-63 
Cell proliferation 
 Experiments examining the effect of Winn55,212-2 on osteoblastic bone cell 
proliferation (Figure 2.1 and 2.2) showed that the proliferation rate of the cells with 
Winn55,212-2 treatments was noticeably higher than those seen in control and carrier 
control cultures (see Table 2.1). It was clearly noted that proliferation rate of MG-63 
osteoblast cells was significantly high with concentrations of 1μM compared to 
concentrations of 500nM and 2μM of Winn55,212-2 with a proliferation factor of PF=2 
meaning treatment with 1μM induced doubling of the cell population. 
.                             
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Osteoblast MG-63 
with/without 
supplementation 
Proliferation factor   
Control 1.25 
Negative control (carrier) 1.274 
Winn55,212-2 500nM 1.44 
Winn55,212-2 1μM 2 
Winn55,212-2 2μM 1.38 
Table2.1 MG-63 osteoblast proliferation factors with different concentrations of 
Winn55,212-2 
 
 
Figure2.2 MG-63 osteoblast proliferation factor with different concentrations of 
Winn55,212-2 synthetic cannabinoid. Standard error bars are shown. 
 
Statistical analyses using a one-way ANOVA showed a significant increase (P<0.05 for 
N=15) in proliferation rate in treatment groups with 1μM concentrations compared to 
all other concentrations of winn55,212-2 and control groups, indicating that using 
Winn55,212-2 at 1μM concentration had a significantly positive effect in increasing 
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MG-63 osteoblast  proliferation rate in comparison to all of the other groups after 30 
hours. Interestingly, changes in cell morphology were also evident between 
Winn55,212-2 with 2μM concentration compared with the rest of cultures (Figures 2.1 
and 2.3). Winn55,212-2 2μM seemed to  induce a less elongated osteoblast phenotype 
with a non-significant increase in cell size compared to controls. In contrast, cell 
morphology of carrier groups looked more elongated and more spread out. Cell length 
measurements indicated that treatment groups of carrier controls induced a percentage 
increase in cell size to nearly 186%±5.23 (P<0.05).    
 
Figure2.3 MG-63 Cell length measurements after 30 hours of Winn55,212-2 addition 
with different concentrations (N=30). Standard error bars are shown. 
 
2.5.2 The Effect of Monoglycerol lipase inhibitor URB602 on MG-63 
Cell proliferation 
This current experiment investigated the proliferation rate of MG-63 osteoblast cells in 
response to treatment with monoglycerol lipase inhibitor URB602 (Figure 2.4). 
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Osteoblast MG-63 with/without 
supplementation 
Proliferation factor 
30hrs 
Control 1.25 
Negative control (carrier group) 1.27 
URB602 500nM 1.11250 
URB602 1μM 1.62 
URB602 2μM 1.58 
Table2.2 MG-63 osteoblast proliferation factors with different concentrations of 
URB602 
It can be clearly noted (Figure 2.5) that treatments of URB602 with concentrations 1μM 
and 2μM had induced similar proliferation rates after 30 hours in culture, although  they 
were significantly higher than control groups (p<0.05, N=15), were (N) is the number of 
repeats. 
 
Figure2.5 MG-63 osteoblast proliferation factor with different concentrations of 
URB602. Standard error bars are shown. 
 
Cell length measurements indicated that all treatments with URB602 (Figure 2.6) 
induced an increase in cell length. However, carrier groups of 0.1% ethanol had the 
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highest increase in cell length compared to other groups with approximately 86%±4.16 
increase of cell length compared to control groups (p<0.05, N=30), were (N) number of 
cells. On the other hand treatment groups with higher concentrations of URB602 (2μM) 
showed 50%±3.45 increase in cell length measurements compared to control. This 
increase in cell size might aid in accelerating wound closure by filling the wound gaps 
faster than control.          
 
Figure2. 6 Cell length measurements after 30 hours of URB602 addition with 
different concentrations (N=30). Standard error bars are shown. 
 
2.5.3 The effect of CB2 selective agonist HU308 on MG-63 osteoblast 
Cell proliferation  
It was found that HU308 of 500nM concentration induced the highest proliferation 
factor (PF=2.47) after 30 hours compared with control, HU308 1μM and HU308 2μM 
treated cells (Figure 2.7 and 2.8). HU308 treated cells after 30 hours in culture with 
both 1μM and 2μM concentrations had similar proliferation factors at PF=1.74 and 
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Osteoblast MG-63 with/without 
supplementation 
Proliferation factor  
Control 1.25 
Negative control (carrier groups) 1.27 
HU308 500nM 2.47 
HU308 1μM 1.74 
HU308 2μM 1.77 
Table2.3 MG-63 osteoblast proliferation factors with different concentrations of 
HU308 
 
 
Figure2.8 MG-62 osteoblast proliferation factor with different concentrations of 
HU308. Standard error bars are shown. 
 
Statistical analysis using one-way ANOVA showed that MG-63 osteoblast treatment 
groups with 500nM of HU308 concentration, Figure 2.8, had significantly higher 
proliferation rate than other concentrations and also control groups  (P<0.001, N=15). 
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It was found that cell length of HU308 treated cells with both concentrations of 1μM 
and 2μM induced approximately 50% increase as compared with control cells (Figure 
2.9). Also, 500nM HU308 treatment cells not only achieved the fastest wound closure 
rates but also displayed a significant increase in MG-63 osteoblast cell size by 
173%±5.64 SE compared to controls (P<0.05). On the other hand, cells in the carrier 
control groups of 0.1% ethanol displayed a significant increase in cell size of 
186%±4.16 SE (P<0.05) compared to control groups.  
 
Figure2.9 Cell length measurements after 30 hours of HU308 addition with different 
concentrations (N=30). Standard error bars are shown. 
 
2.5.4 The effect of Winn55,212-2 on wound healing of MG-63 osteoblast 
monolayer  
Results for the in-vitro monolayer wound repair assay of osteoblastic MG-63 bone cell 
monolayers showed healing response in the presence of three different concentrations of 
synthetic cannabinoid Winn55,212-2, as compared with cannabinoid carrier groups 
(0.1% ethanol) as negative control and control culture groups with no treatments.  
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Figure 2.10 shows the wound healing of control and negative control culture groups for 
the osteoblastic MG-63 bone cell monolayers. In control groups, the average scratch 
width was ~300μm±20-40μm. It was seen in control groups that after 10 hours, cells 
started to change at the wound edge. After 15 hours cells started to change their 
morphology clearly and elongated with slight migration to the wound site and at hour 
20, cells started to migrate into the wound site with further elongation in their 
morphology, at hour 25 cells started making bridges with maximum elongation in the 
osteoblastic pool. It became clear that 80% of the wound still remained open after 10 
hours decreasing to only 45% after 25 hours. 
Negative control culture carrier groups (0.1% ethanol) were investigated using the same 
methodology of wound initiation. Again average starting wound width was 300μm± 30-
50μm. It was found (Figures 2.10) that after five hours the morphology of the cells at 
the wound edges changed and that the cells had elongated, spread, replicated and 
migrated into the wound site perpendicularly to the wound axis. Cells near the wound 
edge looked more elongated, whereas the cells distant from the wound edges were more 
rounded. Furthermore, the cells at the edge of the wound site had a tendency to be less 
dense and more spread out. Cells distant from the wound edges start to align behind 
bridges formed at hour 25. From Table 2.4 it can be seen that 45% of the wound 
remained open after 25 hours in non-treated cells compared to 32% of wound remained 
open in 0.1% Ethanol carrier treatment groups. Statistical analysis showed that 
significant differences between control and carrier groups only appeared after hour 15 
(p<0.05).  
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Time 
 
(%) wound remained open 
Control  
 
(%) Wound remained 
open, 
0.1% Ethanol  
0 min 100%±1.84462 100%± 1.9745 
5 hrs 89.969%±1.5080 87.14%±2.6459 
10 hrs 80.37%±1.968 78.19%±2.789 
15hrs 68.360%±2.0612 63.37%±3.1772 
20 hrs 57.687%±2.8144 45.0%±2.982 
25hrs 45.089%±3.286 32.67%±2.5518 
30 hrs 35.789%±3.4902 20.46%±2.1216 
Table2.4 Percentages of wound remained open throughout 30 hours for control and 
carrier group 
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 Control Negative control 
0 hrs 
  
5 hrs 
  
10 hrs 
  
15 hrs 
  
20 hrs 
  
25 hrs 
  
30 hrs 
  
Figure2.10 Wound healing of control and carrier control groups of 0.1% ethanol 
(scale bar=100μm) 
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In order to identify the most appropriate concentration of the synthetic cannabinoid 
Win55212-2, three concentrations were investigated: 500nM, 1μM and 2μM. The 
following images (Figures 2.11) show the three different test groups for all three 
different concentrations. It became clear that there is a dose threshold for concentrations 
above which cells tend to have a negative (slower) response in terms of wound healing, 
compared to lower concentrations. A comparison (Figure 2.12) between three different 
concentrations was tested and their effect on wound healing is indicated by the 
percentage of wound remained open. It was apparent that the most effective 
concentration for achieving higher percentage of wound closure was 1μM for which 
only 8% of the wound remained open after 20 as compared with 500μM and 2μM with 
20% and 40% of wound remained open, respectively. This finding matched the 
proliferation rates investigated earlier in this chapter were synthetic cannabinoid 
Winn55,212-2 at a concentration of 1μM increased cell density after 30 hours of 
treatment. Table 2.5 show the percentage of wound remained open at each time point 
throughout 30 hours for each concentration tested.  
Statistical analysis showed significant differences between control, ethanol and test 
groups. Significant differences (p<0.001) were found between fastest wound closure 
treatment groups and control groups starting from 5hrs up till 30hrs. However, 
significant difference between carrier groups and treatment groups only appeared after 
10 hours.  
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Time % wound remained 
open (500nM)  
% wound remained 
open (1μM)  
% wound remained 
open (2μM) )  
0 min 100±1.254 100±1.42116 100±1.5468 
5 hrs 75.71307±2.211 70.5298±1.10138 75.03849±1.365 
10 hrs 63.72542±1.121 48.7746±2.01385 63.78984±2.325 
15 hrs 44.19335±0.478 34.21226± 1.23876 52.04029±1.7532 
20 hrs 20.82383±1.879 8.726181±1.29129 39.98954±1.1127 
25 hrs 4.669415±2.124 1.229868±0.53683 29.71886±0.732 
30 hrs 2.785±2.30 0.765±1.59 11.25±1.8452 
Table2. 5 Percentages of Wound remained open throughout a 30 hour period for 
WINN55,212-2 and control groups. Standard error are shown.  
 
 
 
Figure2.11 Graph of wound closure width against time for wounded culture flask 
with and without addition of WINN55,212-2 synthetic cannabinoid. Standard error 
bars are shown.  
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Wound healing (WINN55212-2 test groups) 
                      500nM                                    1μM                          2μM                    
0 min                                 
5hrs                                   
10 hrs                              
15 hrs                              
20 hrs                             
25 hrs                             
30hrs                             
Figure2.12 Images of wound healing process for the bone cell monolayers with 
WINN55,212-2 over a period of 30 hours (Scale bar=100μm). WINN55,212-2 
concentrations of 1μM/ml promoted the fastest wound closure 
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 2.5.5 Effect of Winn55,212-2 on wound healing with CB1 (LY320135) 
and CB2 (AM630) selective receptor antagonists 
 
To further investigate the role of the synthetic cannabionoid Winn 55,212-2 in relation 
to which receptor contributes the most in the process of wound healing, three sets of test 
groups where treated with synthetic cannabinoid Winn55,212-2 at its optimum 
concentration of 1μM, and each set was then treated with either LY320135, a CB1 
selective receptor antagonist, or with AM630, a CB2 selective antagonist Figures 2.13. 
Cells treated with 1μM of CB2 specific receptor antagonist with addition of synthetic 
cannabinoid Winn 55,212-2 resulted in a slower wound closure response over 25 hours 
compared with those treated with CB1 specific receptor antagonist, indicating that the 
CB2 receptors in osteoblasts bone cells primarily contribute to the action of synthetic 
cannabinoid Winn 55212-2 in acceleration of bone monolayer wound healing. This 
indicates a further crucial role for CB2 receptors in MG-63 osteoblast cell proliferation 
and migration. Figure 2.13 shows the difference in wound healing of the two test 
treatment groups, first the 1μM Winn55212-2 and CB1 specific antagonist, second the 
1μM Winn 55212-2 and CB2 specific antagonist. 
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Wound healing of Winn55,212-2 CB1 and CB2 antagonists 
       LY320135                    AM630 
    (1μM – CB1 antagonist)  (1μM – CB2 antagonist) 
 
0 min       
5hrs       
10hrs         
15hrs          
 20hrs          
25 hrs          
Figure2.13 Images of wound healing process for the bone cell monolayers using CB1 
and CB2 selective antagonist over a period of 30 hours (Scale bar=100μm)   
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2.5.6 The effect of URB602 with different concentrations on wound 
healing of MG-63 osteoblast monolayers  
The effect of 500nM, 1μM and 2μM monoglycerol lipase inhibitor (URB602) was 
investigated in relation to wound closure of MG-63 osteoblast monolayers was found 
from the collected data examined over a period of 30 hours that the optimum 
concentration which promotes higher rate of wound healing was 1μM. Figures 2.14 and 
2.15) and Table 2.6 show that after 10 hours cells started to elongate and migrate into 
the wound bed to form pseudo-bridges. The percentage of wound remained open after 
10 hours was~40% in cells treated with 1μM concentration compared to a difference 
increase of 19% and 8% for the 500nM and 2μM treated cells, respectively. Similarly 
the rate of wound closure seen in Figure 2.16 shows that the rate of wound closure per 
hour was the highest in 2μM concentration groups in the first 5 hours. However, 
proceeding hours indicated higher rates among lower concentration groups, thus 
indicating wound closure acceleration during 30 hours using URB602 at lower 
concentrations. In fact, higher concentrations such as 2μM had a prohibiting effect on 
the acceleration of wound healing in later hours (e.g. after 15 hours). As a result it is 
suggested that the monoglycerol lipase inhibitor (URB602) induces a dose dependent 
response in MG-63 osteoblast monolayer wound healing.  
 
 
 
 
 
 

 78 
 
 
Figure2.15 Graph of % wound closure width against time (hrs) for wounded MG-63 
osteoblast monolayers with the addition of URB602. Standard error bars are shown. 
 
Time (%) wound 
remained 
open 
Control  
 
(%) Wound 
remained 
open, 
0.1% Ethanol  
% wound 
remained 
open (500nM)  
% wound 
remained open 
(1μM)  
% wound 
remained open 
(2μM)  
0 min 100%±1.844 100%± 1.97 100±2.3144 100±1.14874 100±2.2356 
5 hrs 89.96%±1.50 87.14%±2.64 84.99±1.2314 75.68±1.42598 75.12±1.6533 
10 hrs 80.37%±1.96 78.19%±2.78 59.13±1.8561 40.57±1.57872 48.00±2.3015 
15 hrs 68.36%±2.06 63.37%±3.17 42.00±2.3214 26.59±1.87080 31.41±3.2136 
20 hrs 57.68%±2.81 45.0%±2.98 26.53±3.7541 15.52±1.90393 19.37±1.0325 
25 hrs 45.08%±3.28 32.67%±2.55 15.00±4.2136 8.03±2.14483 11.47±2.4621 
30 hrs 35.78%±3.49 20.46%±2.12 4.41±2.3142 0.646±1.51419 2.708±0.9532 
Table2.6 Percentages of wound closure remained open throughout a 30 hour period 
for URB602 groups. Standard error are shown. 
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Figure2.16 Rate of wound closure (μm/hr) for treatments of URB602 with different 
concentrations.  
 
2.5.6.1 Effect of URB602 on wound healing with CB1 selective receptor 
agonist (LY320135) 
In order to further investigate the response acquired due to the addition of 1μM 
monoglycerol lipase inhibitor URB602 on wounded bone monolayers, 1μM of CB1 
selective receptor antagonist (LY320135) was added to study if the indirect up 
regulation of endocannabinoid 2-AG through URB 602 treatments act via CB1 receptor 
alone or if other signalling pathways are involved. Results were compared with control 
groups (non-treatment and negative control groups). It was found that the percentages of 
wound remaining open after using CB1 selective antagonist (LY320135) had similar 
responses to those of carrier groups (Table 2.7). This finding indicated that the selective 
CB1 antagonist totally blocked the effect of URB602 on wound healing of MG-63 
osteoblast monolayers and that the response obtained from URB602 treatments was 
modulated through CB1 receptors.    
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Time 
% wound 
remained open 
(Control)  
% wound 
remained open 
(0.1% Ethanol)  
 
% wound 
remained open 
(1μM URB602)  
 
% wound 
remained open 
(1μM 
URB602+1μM 
LY320135)  
 
0 min 100±1.84462 100± 1.9745 100±1.14874 100±1.236 
5 hrs 89.96939±1.5080 87.14868±2.6459 75.68627±1.42598 89.2269±1.5436 
10 hrs 80.3788±1.968 78.19793±2.789 40.57228±1.57872 75.51126±2.321 
15 hrs 68.36004±2.0612 63.37944±3.1772 26.5947±1.87080 61.93948±1.329 
20 hrs 57.68714±2.8144 45.06035±2.982 15.52094±1.90393 37.88424±2.658 
25 hrs 45.08918±3.286 32.67767±2.5518 8.03587±2.14483 26.0295± 2.6751 
30 hrs 35.78943±3.4902 20.46713±2.1216 0.646069±1.51419 17.257425±1.945 
Table2.7 Percentages of wound closure remained open throughout a 30 hour period 
for control; 0.1%Ethanol, URB602 and LY320135 test groups. Standard error are 
shown. 
 
2.5.7 The effect of HU308 with different concentrations on wound 
healing of MG-63 osteoblast monolayers  
Wound healing experiments were carried out using HU308 (Hebrew University) 
synthetic cannabinoid on MG-63 osteoblast monolayers. Three different concentrations 
were tested individually: 500nM, 1μM and 2μM and each group was repeated three 
times for consistency. It was found that all three concentrations accelerated wound 
closure (Table 2.8). However, 500nM seemed to induce faster wound closure. Early 
bridge formation was indicated after 10 hours (Figure 2.18). Seemingly there was only 
9±1.5% of wound remained open at hour 20 for 500nM treated cells. It was also evident 
from optical images that cells elongated earlier than controls and that migration took 
place in the first 10 hours. Figure 2.17 indicated that treatment groups with 
concentrations of 500nM had increased wound closure more than other concentrations 
used; it was also evident that the percentage of wound remained open for all tested 
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groups including control represented almost a linear distribution throughout the 30 hour 
period. The results also indicated that HU308 synthetic cannabinoid additions had 
higher wound closure compared to carrier and control groups.  
 
 
Figure2.17 Graph of % wound closure width against time for wounded MG-63 
monolayers with treatments of HU308 at different concentrations. Standard errors 
are shown. 
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                     Wound healing of MG-63 bone monolayers with different concentrations 
of HU 308 
 
                    500nM                              1μM   2μM 
 0min               
 5hrs               
 10hrs              
       15hrs              
 20hrs               
 25hrs              
 30 hrs            
Figure2.18 Images of wound healing process for the bone cell monolayer (HU308) 
over a period of 30 hours (Scale bar=100μm) 
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Time  % wound 
remained open 
(Control)  
% wound 
remained open 
(0.1% Ethanol)  
 
% wound 
remained open 
(500nM)  
% wound 
remained open 
(1μM)  
% wound 
remained 
open (2μM) )  
0 min 100±1.84462 100± 1.9745 100±1.89 100±1.2 100±2.65 
5 hrs 89.969±1.5080 87.148±2.6459 79.431±2.63 85.25±3.26 87.740±3.25 
10 hrs 80.37±1.968 78.197±2.789 40.163±3.123 49.961±2.32 52.137±1.35 
15 hrs 68.360±2.0612 63.379±3.1772 19.934±2.362 30.13±2.14 32.75±4.3 
20 hrs 57.687±2.8144 45.060±2.982 9.0720±1.567 17.64±1.23 18.656±6.23 
25 hrs  45.089±3.286 32.677±2.5518 4.99±1.35 9.656±1.78 9.437±1.23 
30 hrs  35.789±3.4902 20.467±2.1216 2.095±0.84994 5.973±0.65 6.312±1.01 
Table2. 8 Percentages of wound remained open throughout a 30 hour period for 
HU308 groups with different concentrations. Standard errors are shown. 
 
It can also be noted from the rate of wound closure per hour (Figure 2.19) that by using 
treatments of 500nM HU308, closure rates was induced in the first 10 hours of up to 
30μm per hour indicating to the higher positive effect of HU308 synthetic cannabinoid 
on wound healing especially at low concentrations. It was also found that the rate of 
wound healing between all three concentrations had the same line pattern throughout the 
30 hours. However, wound closure rates are different between each concentration. 
Nonetheless, closure rate response following 10 hours for concentration of 500nM 
HU308 plummeted to become the lowest rate per hour at 25 hours, which may be a 
result of cell contact inhibition due to the high proliferation rate.        
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Figure2.19 Rate of wound closure (μm/hr) for treatments of HU308 with 
concentrations 500nm, 1μM and 2μM concentrations compared to control  
 
2.5.7.1 Effect of HU308 on wound healing with CB2 selective receptor 
antagonist (AM630)  
CB2 selective receptor antagonist (AM630) was added to cultures treated with 500nM 
HU308 and were compared with control test groups (non-treatment and negative control 
groups). 
The percentages of wound remained open after 30 hours are given in Table 2.9 
indicated that cultures treated with HU308 and CB2 antagonist did not completely 
alleviate the effect of CB2 specific agonist HU308. In fact, it induced better wound 
closure response compared with control and carrier treatments. This suggests that 
treatments of HU308 do not only act via CB2 receptor signalling pathways, perhaps 
there are other signalling pathways involved and this is in complete agreement with 
literature as other signalling pathways have been identified that are responsive to CB2 
agonist stimulation. In addition, comparison between all four test groups (control, 
negative control, 500nMHU308 and 500nMHU308+AM630), Table 2.9, indicated that 
0
5
10
15
20
25
30
35
5H 10H 15H 20H 25H 30H
ra
te
 o
f w
ou
nd
 cl
os
ur
e 
μm
/h
r 
Time (hours) 
control
negative control
500nM HU308
1uM HU308
2uM HU308
 85 
 
after 25 hours both agonist groups and agonist/antagonist groups had similar wound 
closure width, indicating to a possible simultaneous and synergetic response through 
signalling pathway different to those of CB2 receptors .  
 
Time  % wound 
remained open 
(Control)  
% wound 
remained open 
(0.1% Ethanol)  
 
% wound 
remained open 
(500nM HU308)  
 
% wound 
remained open 
(500nM 
HU308+500nM 
AM630)  
0 min 100±1.84462 100± 1.9745 100±1.89707 100±1.7536 
5 hrs 89.96939±1.5080 87.14868±2.6459 79.43115±2.63308 75.8871±1.1286 
10 hrs 80.3788±1.968 78.19793±2.789 40.16313±3.12331 48.04969±3.2138 
15 hrs 68.36004±2.0612 63.37944±3.1772 19.93432±2.36227 33.12468±2.3654 
20 hrs 57.68714±2.8144 45.06035±2.982 9.072003±1.56720 21.28846±1.3252 
25 hrs  45.08918±3.286 32.67767±2.5518 4.999942±1.35393 8.010715±2.3654 
30 hrs  35.78943±3.4902 20.46713±2.1216 2.095635±0.84994 5.547063±2.1254 
Table2. 9 Percentages of wound remained open throughout a 30 hour period for 
control, pure Ethanol, HU308 and AM630 test groups. Standard error are shown. 
 
2.5.8 The effect of Winn55,212-2 with different concentrations on 
detachment of MG-63 osteoblast cells  
The trypsinization assay of MG-63 osteoblastic monolayers revealed that the 
detachment time of cells for different concentrations of Winn55,212-2 is significantly 
higher as compared with either control and the carrier control treatment cells, as can be 
seen from images in Figure 2.20. Table 2.10 shows the percentage cell surface area 
reduction following trypsinization. After 270 seconds the percentage decrease in cell 
surface area for control cells was 42.4%±1.95 as compared with cells treated with 
Winn55,212-2 concentrations (500nM,1μM and 2μM) which were 42.3% ,48% and 
47.9%, respectively. However, the percentage decrease in cell surface area was similar 
in the first 30 seconds in all groups. Figure 2.21 shows the percentage decrease in cell 
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surface area for treatment in relation to trypsinization. Although treatment with 500nM 
Winn55,212-2 induced the fastest reduction in cell area amongst all three 
concentrations, control and carrier treatment cultures remained to have the fastest 
overall detachment time. Furthermore, it was evident that cultures with treatment of 
synthetic cannabinoid Winn55,212-2 at 1μM and 2μM concentrations increased cell 
attachment significantly (P<0.05) compared with control, carrier and 500nM 
Winn55,212-2 treatment cultures. Interestingly, carrier treatments of 0.1% ethanol 
induced the most significant % of cell surface reduction indicating the role of ethanol in 
reducing cell adhesion. 
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Time 
% surface 
area Control 
 
% surface 
area Negative 
Control 
 
% surface 
area 
Winn55,212-2 
500nM 
 
% surface 
area 
Winn55,212-2 
1μM 
 
% surface 
area 
Winn55,212-2 
2μM 
 
0Sec 100±4.19 100±3.25 
 
100±4.65 
 
 
100±4.42 
 
 
100±2.81 
 
30Sec 
 
89.374±3.06 
 
88.260±5.26 
 
87.251±4.56 
 
 
89.802±3.92 
 
90.913±2.76 
60Sec 
 
77.251±1.97 
 
72.256±3.25 75.941±3.58 
 
84.852±3.78 
 
 
 
83.285±2.13 
 
 
90Sec 69.763±2.12 62.223±4.325 70.102±3.34 78.232±2.96 77.213±1.83 
120Sec 
 
62.764±1.94 
 
58.230±6.21 
 
65.513±3.55 
 
 
72.075±3.50 
 
 
72.770±1.56 
 
150Sec 
 
57.584±2.14 
 
53.265±4.23 60.151±3.71 65.177±3.19 66.333±1.25 
180Sec 
 
53.048±2.02 
 
49.326±6.23 
 
55.651±3.78 
 
 
59.161±2.60 
 
 
61.832±1.60 
 
210Sec 48.987±1.86 46.236±2.54 
 
52.028±3.47 
 
55.457±2.31 57.280±1.49 
240Sec 
 
46.163±1.87 
 
42.236±1.32 
 
48.464±3.61 
 
52.241±2.11 51.871±1.69 
270Sec 42.476±1.95 37.935±3.23 42.354±3.70 48.130±2.15 
 
47.950±1.76 
 
Table2.10 Percentage of MG-63 osteoblast cell surface reduction during 270 seconds 
with treatments of Winn55,212-2 at different concentrations. Standard error are 
shown. 
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Figure2.21 Percentages of cell surface reduction after treatment with winn55,212-2 
at concentrations of 500nM,1μM and 2μM. Standard error bars are shown. 
 
2.5.9 The effect of URB602 with different concentrations on cell 
detachment of MG-63 osteoblasts 
Trypsinization assay for MG-63 osteoblastic monolayers (Figure 2.22) revealed that the 
detachment time for cells using different concentrations of Monoglycerol lipase 
inhibitor URB602 is significantly lower (P<0.05) in all groups as compared with control 
and carrier groups (Table 2.11). The percentage decrease in surface area due to 
trypsinization after 270 sec reduced in control groups to 42.4% ±1.95% as compared 
with URB602 concentrations (500nM,1μM and 2μM) which were lower than controls, 
31.915%±1.78, 35.827%±2.00 and 29.871%±1.69, respectively. However, it was noted 
that 60 seconds after addition of trypsin, the percentage decrease in cell surface area 
was 14% greater in cells treated with 2μM URB602 compared with control groups. It 
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was also noted that percentage reduction in cell surface area in treatments of 1μM 
URB602 had a similar response to those of 0.1% ethanol carrier treatments. The 
percentage reduction in cell surface area (figure 2.23) was plotted against trypsinization 
time showed that overall, treatment with Monoglycerol lipase inhibitor URB602 at 
different concentration significantly reduced MG-63 cell area in less time than did 
control and carrier treatment cultures (P<0.05)(N=60) were N is the number of cells 
measured. 
Time 
% surface area 
Control 
 
% surface area 
Negative 
Control 
 
% surface area 
URB602 
500nM 
 
% surface area 
URB602 
1μM 
 
% surface area 
URB602 
2μM 
 
0Sec 100±4.19 100±3.25% 100±3.30 100±2.82 100±3.84 
30Sec 89.374±3.06 
 
88.260±5.26 78.983±2.93 82.612±2.8 79.674±2.90 
60Sec 77.251±1.97 
 
72.256±3.25 64.555±1.88 69.068±2.33 63.654±2.61 
90Sec 69.763±2.12 
 
62.223±4.325 56.217±1.82 62.844±2.00 52.822±2.52 
120Sec 62.764±1.94 
 
58.230±6.21 51.424±1.94 56.217±2.78 47.454±2.28 
150Sec 57.584±2.14 
 
53.265±4.23 48.238±1.77 52.066±2.72 42.511±1.94 
180Sec 53.048±2.02 
 
49.326±6.23 43.675±1.61 48.778±2.33 38.577±1.72 
210Sec 48.987±1.86 
 
46.236±2.54 40.288±1.57 44.007±2.43 35.712±1.77 
240Sec 46.163±1.87 
 
42.236±1.32 34.803±1.54 40.351±2.31 33.359±1.86 
270Sec 42.476±1.95 
 
37.935±3.23 31.915±1.78 35.827±2.00 29.871±1.69 
Table2.11  Percentage of MG-63 osteoblast cell surface reduction during 270 seconds 
with different concentration of URB 602. Standard error are shown. 
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Figure2.23  Percentage cell surface reduction vs. time with different concentrations 
of URB602 treatments. Standard error bars are shown.  
 
2.5.10 Effect of HU308 with different concentrations on cell detachment 
of osteoblasts  
Figure 2.24 and 2.25 show Cell detachment of MG-63 osteoblast monolayers after 
treatment with different concentrations of HU308. Groups treated with 1μM HU308 had 
a similar response to those of carrier groups. In contrast groups with higher 
concentrations of HU308 at 2μM showed the slowest detachment time amongst all 
groups indicating an increased cell surface adhesion. Table 2.12 shows the percentage 
decrease in cell surface area in HU308 at 500nM concentration and control groups. 
After 270 seconds the percentage decrease in cell surface area for control cells was 
42.4% as compared with HU308 at 500nM concentrations at 39.736%±1.7. On the other 
hand, significant differences were observed between higher concentrations of HU308 
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treatments compared with control and carrier treatment cultures (P<0.05). Overall, it 
can be concluded that decrease in percentage cell surface area over time was observed at 
concentrations of 1μM and carrier treatments of 0.1% ethanol which promoted faster 
detachment as compared with control and 2μMHU308 treatments. More interestingly, it 
can be suggested that MG-63 cell adhesion force induced by synthetic cannabinoid 
HU308 is concentration dependent.  
 
Figure2.24  Percentage cell surface area reduction vs. time with different 
concentrations of HU308 treatments. Standard error bars are shown. 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
0 30 60 90 120 150 180 210 240 270
Re
du
ct
io
n 
in
 c
el
l s
ur
fa
ce
 a
re
a 
 (%
) 
Time (s) 
Control (%)
negative control(%)
HU308 500nM (%)
HU308 1μM (%) 
HU308 2μM (%) 
 94 
 
 
 
Time 
% surface 
area Control 
 
% surface 
area Negative 
Control 
 
% surface 
area HU308 
500nM 
 
% surface 
area HU308 
1μM 
 
% surface 
area HU308 
2μM 
 
0Sec 100±4.19 100±3.25 100±3.45 100±2.85 100±3.45 
30Sec 
89.374±3.06 
 
88.260±5.26 86.267±3.37 89.406±3.01 93.855±3.27 
60Sec 
77.251±1.97 
 
72.256±3.25 75.962±2.48 79.710±3.43 84.368±3.22 
90Sec 
69.763±2.12 
 
62.223±4.325 67.885±1.56 64.671±2.82 74.215±2.96 
120Sec 
62.764±1.94 
 
58.230±6.21 63.333±2.06 57.155±2.63 68.816±2.98 
150Sec 
57.584±2.14 
 
53.265±4.23 59.181±2.15 51.513±2.23 64.125±2.38 
180Sec 
53.048±2.02 
 
49.326±6.23 55.240±2.14 48.908±2.33 59.730±2.57 
210Sec 
48.987±1.86 
 
46.236±2.54 50.614±2.07 43.289±2.46 56.157±2.57 
240Sec 
46.163±1.87 
 
42.236±1.32 45.883±2.21 39.566±2.22 52.611±2.37 
270Sec 
42.476±1.95 
 
37.935±3.23 39.736±1.77 34.360±1.53 48.038±1.65 
Table2.12  Percentage of MG-63 osteoblast cell surface reduction during 270 seconds 
with different concentration of HU308. Standard error are shown. 
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2.5.11 comparison between optimum concentrations of all three 
treatments used in relation to wound healing of MG-63 osteoblast 
monolayers  
In order to show the difference and the contribution that each type of treatment had on 
the acceleration of wound closure, Winn55,212-2, URB602 and HU308 at their 
optimum concentrations of 1μM, 1μM and 500nM, respectively, along with both 
control groups and negative control groups were statistically compared using SPSS 
statistical analysis.  
Figure 2.26 shows the percentages of wound remaining open throughout a period of 30 
hours between all 5 groups, i.e. control, negative control, Winn55,212-2, URB602 and 
HU308. Although, the percentage of wound remaining open after 25 hours was the least 
in Winn55,212-2 synthetic cannabinoid treated cells, it was found that HU308 synthetic 
cannabinoid at a concentration of 500nM induced the greatest increase in wound healing 
over 30 hours compared with all other tested treatments. This indicates that HU308 may 
be used to induce bone wound closure without evidence of any psychoactive responses. 
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Figure2.26 Comparison between wound closure width against time for control, 
Ethanol, Winn55,212-2, URB602 and HU308 test groups. Standard error bars are 
shown. 
 
It was also found (Figure 2.27) that HU308 synthetic cannabinoid treated cultures had 
the highest wound closure rate up to the 1st 10 hour as compared with the remaining 
culture treatments. Interestingly, WINN55,212-2 cannabinoid groups reached their peak 
wound healing rate at 20 hours indicating a  slow response to WINN55,212-2 
treatments on MG-63 osteoblast bone cells. On the other hand, carrier and control 
groups showed lower rates of wound healing throughout the 30 hours. Therefore, it can 
be suggested that the proposed treatments which affected either CB1 or CB2 or both 
had a positive effect in MG-63 osteoblast monolayer wound healing acceleration. It can 
also be suggested that the best response obtained amongst all tested groups was mainly 
regulated through CB2 receptors using HU308 in acceleration of wound closure, 
perhaps this could be due to the increase in wound healing rate per hour in the first 10 
hours of HU308 treatments.  
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Figure2.27 Rate of wound closure for optimum concentrations treatment groups of 
control, carrier, Winn55,212-2,URB602 and HU308)  
 
2.6 Discussion & conclusion    
Bone is a remarkable tissue playing key roles in critical functions in human physiology 
including protection, movement and support of other critical organs, blood production, 
mineral storage and homeostasis, blood pH regulation and multiple progenitor cell 
(mesenchymal, hemopoietic) housing. The importance of bone becomes clear in the 
case of diseases such as osteogenesis imperfecta, osteoarthritis, osteomyelitis, and 
osteoporosis in which bone does not function properly. These diseases along with 
traumatic injury, orthopaedic surgeries (e.g. total joint arthroplasty, spine arthrodesis, 
implant fixation) and primary tumour resection lead to, or induce bone defects or voids. 
As a result, the clinical and economic impact of treatments of bone defects is staggering 
(Tanaka, 2013, Pfeil et al., 2013, Parsh and Wilson, 2012).  
Different remedies in bone tissue engineering especially treatment of bone trauma or 
congenital defects have been put off for a variety of reasons such as bone defect size 
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and infection. Additionally, injured or diseased bone may not be capable of repairing 
itself by means of mechanical fixation alone resulting in non-union (Porter et al., 2009).  
The endocannabinoid system is now recognized as playing an important role in the 
regulation of bone mass and bone remodelling (Idris and Ralston, 2010). Bone cells 
have been reported to express type 1 cannabinoid receptor (CB1), type 2 cannabinoid 
receptor (CB2), and the orphan G protein coupled receptor 55 (GPR55), which has 
recently been found to be activated by some cannabinoid receptor ligands (Ross, 2009). 
However, GPR55 does not appear to play a role in regulating bone formation (Whyte et 
al., 2009). 
Recently, two observations have led to the study of cannabinoids and their effect on 
osteoblast bone cells. One is that of bone formation and increase in bone mass, as well 
as the central production of the endocannabinoid 2-arachidonoylglycerol (2-AG) which 
are subject to negative control by leptin (Marzo et al., 2001). The other is that traumatic 
brain injury stimulates both bone formation at distant skeletal sites and central 2-AG 
production (Panikashvili et al., 2001).  
This is in line with the occurrence of the endocannabinoid ligands in bone, and as 
indicated before the existence of CB1 and CB2 receptors in bone. However, their 
individual roles in the regulation of bone mass are not well defined. 
In spite of this, CB1 expression in osteoblasts and their precursors is low (Tam et al., 
2006). On the other hand, CB2 receptors have been reported in osteoblasts and 
committed osteoblast precursors, such as mouse bone marrow-derived stromal cells and 
MC3T3-E1 pre-osteoblasts, as well as in the osteocyte, the terminally differentiated cell 
in the osteoblastic lineage (Tam et al., 2006, Scutt et al., 2007). 
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In the present study, three concentrations of three different types of synthetic 
cannabinoids, i.e. non-selective CB receptor agonist, CB1 selective agonist and CB2 
selective agonist were investigated to assess the response they induce on MG-63 
osteoblastic cells. It was found that Winn55,212-2 which is a non-specific (non-
selective) CB1/CB2 receptor agonist induced a concentration dependant response on 
MG-63 osteoblast proliferation rate up to concentrations of 1μM. However, higher 
concentrations had an opposite effect, decreasing cell proliferation rate as well as 
wound closure. It was essential  for the cells to be incubated  left for 48 hours prior to 
scratching to reach a similar cell density (Bindschadler and McGrath, 2007) thus 
scratching assay would be carried out at the plateau of cell growth curve and cell 
densities prior to wound healing would not affect % of wound closure. The 
trypsinzation assay also revealed that all three concentrations of Winn55,212-2 (500nM, 
1μM and 2μM) induced enhanced  cell adhesion especially with concentrations 1μM 
and 2μM. in summery it can be suggested that the response seen in the model wound 
was mainly due to the increase in the proliferation rate and not cell migration owing to 
the high force of cell attachment. This was seen mainly with Winn55,212-2 at a 
concentration of 1μM which displayed increased proliferation rate amongest all 
concentrations.  
This dosage dependency response is also in complete agreement with a study that 
demonstrated that treatment of cultured cerebellar granule cells with synthetic 
cannabinoid Winn55,212-2 causes cell-body and nuclear shrinkage, as well as a 
concentration dependant decrease in cell viability with treatments of concentrations 
ranging from 1μM -10μM (Pozzoli et al., 2006). Another study investigated the effect 
of Winn55,212-2 on lymphocyte migration, which indicated that concentrations ranging 
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from 0.001-0.01μM and concentration as high as 10μM induced minimal cell migration 
(Tanikawa et al., 2011). It was also evident from the current investigation that 
Winn55,212-2 mediated its effect on MG-63 osteoblast cells mainly through CB2 
receptor signalling which has been identified by the blockage of CB1 receptor via the 
selective CB1 antagonist LY320135, either indicating that WINN55,212-2 acts via CB2 
receptor in bone cells or that MG-63 cells may have higher magnitude of CB2 receptor 
expression. This was recently confirmed in dorsal root ganglia cells which displayed 
increased CB2 mRNA levels in response to bone cancer (Hald et al., 2008), indicating 
that MG-63 cells being osteosarcoma derived cells might have influenced CB2 induced 
levels.  
Nevertheless, agonist also antagonist properties of a ligand can only be interpreted when 
a particular signal transduction pathway is defined, since the same ligand can behave as 
an agonist in one pathway, or antagonist in another (Kenakin, 2007).  Winn55,212-2 has 
been also identified as a full agonist for Gi1, Gi2 and Gi3 proteins in N18TG2 cells, 
whereas other receptor agonists are believed to be only agonists for Gi1, Gi2 and 
antagonist for Gi3 such as Desacetyllevonantradol (Turu and Hunyady, 2010).  
Experiments were therefore carried out using URB602, a monoglycerol lipase inhibitor. 
CB1 expression in osteoblasts is low (Tam et al., 2006), thus it was more appropriate to 
study the locally synthesized endocannabinoids 2-arachidonoylglycerol (2-AG) and its 
up-regulation effect on MG-63 osteoblast bone cells to understand the effect of CB1 
selective receptor agonist on MG-63 osteoblast cells. It was indicated that 2-AG 
synthesizing enzymes DAGLα and DAGLβ (Bisogno et al., 2003) are expressed in bone 
cells by various studies (Monteleone et al., 2005). This was further confirmed by 
demonstrating that blood 2-AG level is negligible compared to bone levels. As a result 
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it was found that local skeletal production appears to be the main source of these high 
levels of 2-AG (Tam et al., 2008). It was also indicated that (2-AG) is an endogenous 
agonist of the cannabinoid receptor 1 (CB1 receptor). It is present at relatively high 
levels in the central nervous system and is the most abundant molecular species of 
monoacylglycerol found in rat brain. On the other hand, monoglycerol lipase (MGL) 
hydrolyzes 2-AG to arachidonic acid and glycerol, thereby terminating its biological 
actions. URB602 is a selective inhibitor of MGL (Muccioli et al., 2007), thus it 
increased 2-AG endocannabinoid presence in bone, enabling the study of selective CB1 
receptor agonist (2-AG) on MG-63 wounded bone monolayers as well as cell 
detachment.  
It is suggested by the literature that traumatic brain injury (TBI) enhances peripheral 
osteogenesis and fracture healing and stimulates bone formation in the distant skeletal 
site, and that TBI stimulation of bone formation was absent in CB1-null mice (Tam et 
al., 2008). Although CB1 expression is extremely low in bone cells (Idris AI et al., 
2005), and that CB1-deficient mice, have low bone density, in part because of a 
substantial decrease in their bone formation, this decrease is also explainable by the 
absence of CB1 receptors which are normally expressed in bone sympathetic nerve 
fibers (Tam et al., 2006) and partially in osteoblast cells. Interestingly, in the present 
study it was found that the monoglycerol lipase inhibitor URB602 increased 
proliferation rate at higher concentrations and that, lower concentrations such as 500nM 
had minimal effect on proliferation rate. In contrast, this was not the case using the CB2 
selective agonist HU308 which induced the highest proliferation rate at concentrations 
as low as 500nM. However, higher concentrations of CB2 selective agonist HU308 
induced lower proliferation rates, although it was still higher than control (no treatment 
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groups), and therefore this finding is in complete agreement with the literature that low 
cannabinoid doses may enhance cell proliferation, whereas high doses usually induce 
growth arrest or apoptosis (Guzman et al., 2002).  
The trypsinization assay for treatment groups of URB602 showed that cell attachment 
was reduced by concentrations of 1μM, but increased with concentrations of 2μM and 
this can be related to the indirect effect of 2-AG endocannabinoid  on CB2 receptor 
especially at higher concentrations as it was previously indicated  that 2-AG may act as 
an agonist for CB2 receptors in some cell types such as microglia (Marrs et al., 2010) 
which may be the case with MG-63 osteoblast cells. On the other hand, the 
trypsinization results for the synthetic cannabinoid HU308 indicated that cell 
attachment decreased when cells were treated with concentrations of 500nM and 1μM, 
but that treatment with HU308 concentrations of 2μM increased cell attachment beyond 
that seen in control cells. This phenomenon may be due to the involvement of another 
subtype signalling pathway that may be regulated by CB2 specific receptors and this 
pathway could be stimulated due to the higher concentrations used and because same 
signalling pathways can be phosphorylated by different receptors having different 
affinities to treatments. This was further examined in a study that showed 
concentrations of HU308 as low as 10-30nM increased osteoblast cell migration 
(Sophocleous et al., 2011).  
There is evidence in the literature that HU-308 increases cell proliferation in MC3T3-E1 
osteoblast cells and also stimulated the activity of alkaline phosphate activity as an 
indicator for the onset of bone mineralization (Tam et al., 2008). There is also evidence 
that treatments with HU308 as low as 10-30nM activated osteoblast differentiation by 
increasing nodule formation and increasing ALP-activity (Sophocleous et al., 2011).  
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In conclusion it can be said that wound assay models for both treatments with URB602 
and synthetic cannabinoid HU-308 with concentrations of 1μM and 500nM, 
respectively, induced faster wound closure response indicated by the percentage of 
wounds remained open after 30 hours. Moreover, the rate of wound closure per hour 
was usually at its highest in the first five - ten hours for treatments with Winn55,212-2, 
URB602 and HU308 groups. This was not the case with control groups for which the 
rate of wound closure per hour was at its peak at hour 15 and 20. This discrepancy of 
wound closure rate response between different cannabinoid treatments and control 
relates to the initial increase in cell proliferation and cell migration displayed by cell 
detachment especially in treatment groups with URB602 and HU308 and as a result of 
contact inhibition experienced by cells and the initial increase in proliferation rates.    
While, all results in this chapter were compared with control groups with no treatment, 
experiments were also carried out to study the effect 0.1% ethanol (carrier groups). 
There is evidence that ethanol increases the permeability of cell membranes, affecting 
the functioning of intrinsic membrane proteins, such as ion and water channels, which 
regulate the chemical and physical balance in cells (Patra et al., 2006). This could 
explain their positive response on MG-63 cells with 0.1% ethanol, which increased 
membrane permeability allowing greater exposure to supplements in the culture 
medium thus enhancing wound closure.   
Interestingly, it has been stated that HU308 CB2 agonist stimulates wound closure in a 
model of MC3T3-E1 osteoblast cells mainly by migration not proliferation 
(Sophocleous et al., 2011). This is in contrast to the findings presented in this thesis 
were the results indicated a synergetic effect of proliferation and migration. Similar 
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findings have been reported elsewhere, for example, HU-308 treatment of MC3T3-E1 
osteoblast cells increase osteoblast cell number (Tam et al., 2008).  
In general, it is believed that, cells with low motility form strong focal adhesions while 
motile cells form less adhesive structures. However, intermediate level of attachment 
induces a maximal migration rate (Anselme, 2000). Thus it can be suggested 
conclusively that MG-63 cells in all three types’ of treatments used have shown 
increased wound closure either due to cell proliferation or migration indicated by cell 
detachment or by both. Additionally, it was noted when treating cells with HU308, the 
500nM HU-308 concentration did not have the same response as agonist/antagonist 
groups and this could be attributed to either the affinity of the CB2 antagonist to fully 
block selective CB2 receptors or it could be attributed to the existence of subtypes of 
CB2 receptor signalling pathways (Hanuš et al., 1999) and  that AM630 CB2 selective 
antagonist does not block all receptors acting on the same signalling pathway. 
In addition, several studies have also indicated that Ca2+ signalling was reported to take 
place after CB1 or/and CB2 receptor stimulation in insulinoma cells and was induced 
significantly after stimulation with JWH133 a CB2 receptor agonist (De Petrocellis et 
al., 2007).  
Other signalling pathways downstream have also been identified for both CB1 and CB2 
mechanism of action and it was found that stimulation of CB1 receptors both in vivo 
and in-vitro leads to the activation of ERK1/2 kinases in a variety of cell types 
(Howlett, 2005), CB1 receptor-mediated activation of ERK1/2 proteins can involve a 
number of mechanisms including activation of Gi/o proteins, transactivation of VEGF 
receptors through inhibition of adenylyl cyclase and protein kinase A and the Src 
tyrosine kinase FYN. In addition, it was also reported (Liu et al., 2000) that CB1 and 
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CB2 receptor stimulation in endothelial cells can also be activated via p38 MAPK and 
JNK signalling pathways which maybe the case for the synergetic effect of different 
signalling pathways in the present CB receptor agonists (Liu et al., 2000). A rather 
interesting remark have been reported in several studies (Bouaboula et al., 1997, Rajesh 
et al., 2008) that show CB receptor stimulation of MAPK pathway can be indirectly 
induced by insulin and growth factor receptors which also regulates cell proliferation 
and differentiation. Thus it was important to investigate the synergetic effect of growth 
factors in combination with the synthetic CB2 receptor cannabinoids that induced the 
fastest wound healing in this chapter. 
2.7 Chapter summery 
Overall it was found in the current chapter, that cannabinoids accelerate wound healing 
and induce cell proliferation mainly through CB2 receptors and that CB2 receptors have 
shown higher affinity to synthetic cannabinoids either Winn55,212-2 or HU308. It was 
also found that synthetic cannabinoid has a concentration dependent effect on MG-63 
osteoblast cell monolayer wound healing, cell proliferation and cell detachment, and 
that higher concentration of cannabinoids would increase cell attachment and reduce 
cell proliferation.   
 
 
 
 
 
 
 107 
 
Chapter III 
The effect of HU308 and TGF-β3 combinations on wound healing 
of MG-63 osteoblast monolayers  
3.1 Introduction 
 
Results acquired from Chapter 2 indicated that both CB1 and CB2 receptor agonists 
induced a positive effect on MG-63 osteoblast cell proliferation and monolayer wound 
closure, in addition, it was shown that CB receptor stimulation resulted in a 
concentration dependent increase in cell detachment rate. Furthermore, it was found that 
responses were mainly regulated through CB2 receptors. Therefore, CB2 specific 
agonist HU308 achieved faster wound healing compared with Winn55,212-2 and 
URB602 treatments at an optimum concentration of 500nM. However, there is evidence 
in the literature that growth factors and cytokines may also influence bone repair (Sefat 
et al., 2009). It was previously indicated that TGF-β isoforms modulate osteoblast 
differentiation and formation of bone as they activate smad-dependant pathways which 
are responsible for skeleton formation (Chen et al., 2012). In addition transforming 
growth factor-β3 was found to influence bone healing by regulating extracellular matrix 
synthesis and angiogenesis (Kalfas, 2001).  
In practice cytokines or biological regulators are not found in isolation in an in-vivo 
environment, thus they often act in combination with other regulators and mechanisms. 
Therefore, it was important in the current chapter to examine the effect of TGF-β3 in 
combination with HU308 on wound healing response.     
Bone healing occurs in three distinct but overlapping stages, the early inflammatory 
stage, the repair stage and the late remodelling stage (Bertone, 1989, Faler et al., 2006, 
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Kalfas, 2001). Therefore is advised  that anti-inflammatory or cytotoxic medication 
should not be used during the 1st stage of injury because that would delay the 
inflammatory response during the reactive phase which is responsible for the 
recruitment of cytokines to the site of injury (Faler et al., 2006). One major class of 
cytokines up regulated in this phase are the transforming growth factor-Betas (TGF-
β’s), suggesting that TGF-β functions in all three phases of wound repair (Faler et al., 
2006). In vivo studies of skin have shown that TGF-β3 promotes wound healing by 
recruiting inflammatory cells and fibroblasts to the wound site and by facilitating 
keratinocyte migration (Tyrone et al., 2000, Merwin et al., 1991). Transforming growth 
factors are also known to be a potent stimulant of neovascularization and vascular 
rearrangement. Additionally, observations indicate that TGF-β3 activation signals are 
responsible in stopping terminal differentiation in tissue cells (Graycar et al., 1989). It 
has also been indicated that unlike the role of TGF-βI and II in inducing scar formation, 
TGF-β3 was shown to reduce scarring and promote better collagen organization in vivo 
(Shah et al., 1995). There is limited research regarding the use of TGF-β isomers in 
bone cell engineering (Khan et al., 2000, Tosounidis et al., 2009) and in terms of 
healing compared to other cell types such as keratinocytes (Sun et al., 2009, Shirakata, 
2010). However, a recent study (Sefat et al., 2009) suggested repair in 2-D model of 
MG-63 bone cells, wound closure was accelerated by treatment with 50ng/ml of TGF-
β3. 
It is probable that if endocabinoids regulate bone cell replication and migration in bone 
fracture repair, they do this in combination with cytokines such as TGF-β3, thus it is 
important to study the effect of cannabinoids in a model wound system and compare the 
effects of such treatment with both TGF-β3 and the most potent cannabinoid identified 
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in Chapter 2. The rationale for combining CB-2 selective agonist with transforming 
growth factor- beta 3 arises from the idea that the cannabinoids that target CB2 receptor 
mainly act downstream through the MAP Kinase pathway which are a link between 
membrane-bound receptors and the terminal changes of gene expression. The MAP 
Kinase pathways are activated downstream by many types of receptors including 
tyrosine Kinase receptors, cytokine receptors and serpentine G-protein-coupled 
receptors. The MAP Kinase pathway consists of three subfamilies; the extracellular 
signal-regulated Kinases 1 and 2 (ERK1/2), c-Jun N-terminal Kinase/ stress-activated 
Kinase, and p38 MAP Kinase (Ofek et al., 2011). Furthermore, they regulate cell 
proliferation, differentiation and cell survival. The MAP Kinase pathway is also 
important in regulating the effect of transforming growth factors in cells (Ofek et al., 
2011). Therefore, it is possible that both CB-2 receptor agonists and transforming 
growth factors may have synergistic effect on cells signalling pathways.  
3.2 Aims and objectives  
The main objective of this chapter was to investigate the effect of TGF-β3 in 
combination with the optimum concentration (500nM, as indicated in Chapter 2) of the 
CB2 selective agonist HU308 to investigate wound closure in cultured monolayers of 
MG63 osteoblast bone cells. This work investigated and compared the wound closure 
properties of HU308/TGF-β3 combinations, TGF-β3 alone and HU308 treatments with 
both concentrations 500nM and 2μM. The higher concentration of 2μM was used to 
further show the significance of combination treatments between fastest and slowest 
treatments for wound healing in cultured MG-63 osteoblast monolayers. Additional 
experiments were performed to examine the effect of HU308/TGF-β3 combinations on 
cell proliferation, cell detachment and cell morphology during wound closure.    
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3.3 Material and Methods  
 
3.3.1 Cell culture 
MG-63 osteoblast bone cells were cultured in a low glucose (1g/L-D-Glucose) HEPES 
(25mM) buffered  DMEM (Dulbecco's Modified Eagle Media, Sigma Aldrich) culture 
media  supplemented with L-glutamine (2.5 mM U/mL), Penicillin (100 U/mL), 
Streptomycin  (0.1 mg/mL), Amphotericin B or a fungizone (250μg/ml), (Sigma 
Aldrich-UK)  and  10% FCS v/v (fetal calf serum- PromoCell - UK). The bone cells 
were plated in 25cm2 tissue culture grade cell culture flasks at a cell density of 100,000 
cells/ml cells/culture. All supplements and chemicals were purchased from Sigma 
Aldrich-UK, except those otherwise mentioned. 
 
3.3.2 TGF-β3 and its Solvent 
Transforming growth factor beta3 (TGF-β3) is a type of protein produced by almost all  
types of cells (Schwartz et al., 1993). It is soluble in an acidic environment in addition 
to being also soluble in water. One of the obstacles using water as a solvent is the 
development of a sticky jelly like material (Wallace and Rosenblatt, 2003). Hence, it is 
not appropriate to dissolve TGF-β in water and to aliquot in micro-litre scope, as the 
final solution is less than 1ml. As a consequence, hydrochloric acid was chosen as an 
appropriate solvent for all types of transforming growth factor and to provide a TGF-β3 
stock solution. The solvent also contained 1mg/ml bovine serum albumin (BSA) (Sigma 
Aldrich, UK) as a protein carrier. 
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3.3.3 Preparation of TGF-β3 
Human recombined transforming growth factor-beta 3 (Sigma Aldrich, UK) was diluted 
according to the suppliers recommendation in which 10mg bovine serum albumin was 
dissolved in 10ml of 4mM hydrochloric acid to obtain 1mg/ml HCl/BSA. This 1mg/ml 
HCl/BSA solution was sterilised, using a 0.22μm filter. 10μg/40ml of TGF-β3 was 
dissolved in 0.5ml of the sterile 1mg/ml HCl/BSA solution, aliquoted into fifty 10μl 
vials and stored at -20ºC, each with a concentration of 200ng/mL which was added to 
4mL media to reach a final concentration of 50ng/ml (8nM).  
3.3.4 Cell proliferation studies 
The effect of different treatments such as TGF-β3 and HU308 and their combinations 
on proliferation of MG-63 osteoblastic bone cells with fibroblastic like morphology was 
assessed. This was done by preparing culture flasks for each treatment group with initial 
cell densities of 10×104 Cell/ml, after 30 hours in culture. Cells were trypsinized as 
described Chapter 2, section 2.3.3; cells were counted using a haemocytometer; cell 
densities were compared with the initial plating densities and a proliferation factor was 
calculated by dividing cell density in cells/ml after 30 hours in culture by the plating 
cell density (10×104 Cell/ml). The experiments were repeated three times for 
consistency and the mean proliferation factors were calculated. 
3.3.5 Analysis of cell size (cell length) 
Cell length was measured for every treatment used i.e. control, TGF-β3, HU308 and 
HU308/TGF-β3 combined, via acquisition of photomicrographs and measurement using 
Image J software (NIH). The experiment was repeated three times, mean cell sizes were 
normalized for all groups and were presented in percentage increase or decrease from 
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the original cell size for control groups (±SE) were calculated and (N) is the number of 
cells measured. 
3.3.6 Wound closure assay  
Confluent cell cultures were wounded as described in chapter 2 and treated with either 
TGF-β3 or with combination of 500nM HU308/8nM TGF-β3. Combination treatment 
was compared against control groups (no treatment) and with 500nMHU308 and 2μM 
HU308 groups.   
After wounding the monolayers, the culture flasks were incubated at37°C and 
photographs were taken every 5hrs up to 30hrs starting with zero minute. The cells were 
imaged using a phase contrast light microscope and photographed with a digital camera. 
Pictures were captured and stored as tif images. Using ‘Image J’ software the distance 
between the wound edges was measured. Ten vertical lines at semi-random horizontal 
distances were drawn and the distances between the intersections of the lines with the 
wound edges were measured as described in chapter 2. Graphs of percentage wound 
closure width versus time were plotted for different treatments and controls. 
Comparisons were made in terms of percentage wound closure and closure rate. All 
experiments were repeated three times and the data acquired was combined to acquire 
mean percentage wound width at each time point. 
3.3.7 Cell detachment analysis (trypsinization assay)  
MG-63 Osteoblast cell attachment in both control and treatment groups of TGF-β and 
HU308/TGF-β3 combinations were assessed at room temperature using a trypsinization 
assay. Cells were grown in six-well culture plates in complete media supplemented with 
TGF-β3 and HU308/TGF-β3 combinations plus controls. After incubation for 30 hours, 
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cells were washed 3 times with Hank’s Balanced Salt Solution (HBSS) as described in 
Chapter 2. Cells were then treated with 2ml of 0.25% Trypsin-EDTA (Sigma Aldrich, 
UK) and detachment was monitored using time-lapse photomicroscopy. Images were 
taken at a sampling rate of 1 frame every 30 seconds over a total period of 4.5 minutes. 
As cells detach they round up and cell surface decreases. Thus cell detachment rate was 
measured by monitoring cell surface size reduction using ‘Image J’ software in the same 
way, i.e. 20 cells per frame per time point. Experiments were repeated in triplicates for 
consistency were N=60 (total number of cells measured per time point). 
3.4 Statistical analysis 
 
Collected data at different time points per treatment were tested for normality using a 
Kolmogorov Smirnov test. Normally distributed data (p > 0.05) were analysed using 
SPSS via a Oneway Analysis of Variance (ANOVA) followed by a post Hoc Bonferroni 
test. Kruskal-Wallis test and serial Mann Whitney tests were used for non-normally 
distributed results (p < 0.05).  Statistical tests were performed such that a p value of < 
0.05 was considered as indicating a significant difference. There was some variability in 
initial wound widths therefore, % wound closure was normalised by computing zero 
minute of wound gap to be 100% and wound closure width during 30 hours is 
represented is correspondent percentages.  
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3.5 Results and brief discussion 
 
3.5.1 Effect of TGF-β3 and TGF-β3/HU308 on MG-63 osteoblast 
proliferation 
 
The cell proliferation assay was carried out on cultures treated with 8nM TGF-β3 and 
8nM TGF-β3 in combination with 500nM HU308 and compared with controls. 
Treatment with 500nM HU308 (Figure 3.1) induced the highest proliferation rate (PF 
=2.47) amongst all treatment groups, whilst control groups displayed the lowest 
proliferation rate (PF = 1.25) after 30 hours in culture. In contrast, cell proliferation was 
reduced in treatments with 2μMHU308 (PF = 1.77) and similarly reduced in treatment 
with combination of 8nM TGF-β3 and 500nM HU308 (PF =1.735) in relation to 500nM 
HU308 treatments. This finding supports the view that HU308 at high concentrations 
inhibits cell replication and also indicates that TGF-β3 may inhibit the proliferative 
effect of HU308 treatment at lower concentrations of 500nM. 
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Figure3.1 Graph of MG-63 osteoblast proliferation factor with different treatments. 
Standard error bars are shown.  
 
Table (3.1) show proliferation factors with different treatments after 30 hours. Statistical 
analysis showed that proliferation rate with 500nM HU308 was significantly higher 
(P<0.05) than control and TGF-β3/HU308 combination groups. Figure 3.3 show the 
images of MG-63 osteoblast bone cells proliferation 30 hours after treatment indicating 
a more spread morphology. Figure 3.2 shows that treatments with TGF-β3 and HU308 
of concentrations 500nM and 2μM, respectively, and their combination HU308/TGF-
β3, significantly induced increase in cell length by an increment of 118%, 73%, 52% 
and 62% respectively compared to control groups.   
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Osteoblast MG-63 
with/without 
supplementation 
Proliferation factor  
After 30 Hours  
Control 1.25 
Carrier  1.27 
HU308 500nM 2.477 
HU308 2μM 1.77 
TGF-β3 1.85 
TGF-β3/HU308 1.73 
Table3.1 MG-63 osteoblast proliferation factors with different treatments 
 
 
 
Figure3.2 Cell length measurements after 30 hours for treatments control, carrier, 
HU308, TGFβ3 and HU308/TGFβ3) (N=30). Standard error bars are shown. 
 
 
 
 
 
 
0
50
100
150
200
250
%
 in
cr
ea
se
 in
 c
el
l 
le
ng
th
 

 118 
 
3.5.2 Effect of TGF-β3 and TGF-β3/HU308 combination on wound 
closure of MG-63osteoblast monolayer 
 
Wounded MG-63 osteoblast monolayers were either treated with 8nM TGF-β3 or CB2 
specific agonist HU308 at concentrations of either 500nM or 2μM, and combinations of 
8nM TGF-β3 with 500nM HU308. 
It was found that % wound width closure varied throughout the 30 hour period in 
relation to the applied treatment (Figure 3.4). After 5 hours, control treated cultures and 
cultures treated with 2μM HU308 groups had comparable percentages of wound closure 
of 89.96%±1.5080, 87.740%±3.25 (p>0.05), respectively, whereas all other treatments 
at the same point of time induced significant % wound closure width compared to 
control groups (P<0.001). However, at later time points significant difference between 
all groups including control groups were evident (P<0.01). After 10 hours, the % wound 
remained open for cultures treated with 500nM HU308 was 40%±3.12331 whilst the % 
wound remained open for cells treated with a combination of 500nM HU308/8nM TGF-
β3 was 47%±1.832. By the 15 hour time point, % wound remained open was 
17.6%±1.32 in the 500nM HU308/8nM TGF-β3 combination treated cultures compared 
to 20%±2.36227 in the 500nM HU308 treated cultures (Figure 3.4, 3.5 and Table 3.2). 
It was also noted that bridge formation in treatment groups started taking place between 
hours 15 to 20, whereas in control groups, bridge formation started to take place after 25 
hours, therefore accelerated wound closure was more evident in treatment groups, and 
this was further confirmed by increased rates of wound closure (Figure 3.6). 
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Time % wound 
remained 
open 
(Control)  
 
% wound 
remained    
open 0.1% 
Ethanol  
 
% wound 
remained open 
(500nM 
HU308)  
 
% wound 
remained 
open (2μM 
HU308)  
 
% wound 
remained 
open 
(8nMTGF-
β3)  
 
% wound 
remained 
open 
(8nMTGF-
β3/HU308)  
 
0 min 100±1.84462 100± 1.9745 100±1.89707 100±2.65 100±1.685 
 
100±1.282 
 
5 hrs 89.96±1.508 87.14±2.645 79.43±2.6330 87.740±3.25 75.423±1.9 
 
75.99±1.533 
 
10 hrs 80.37±1.968 78.19±2.789 40.16±3.1233 52.137±1.35 49.53±2.22 
 
47.231±1.832 
 
15 hrs 68.36±2.061 63.37±3.177 19.93±2.3622 32.753±4.32 30.01±2.34 
 
17.696±1.320 
 
20 hrs 57.68±2.814 45.0±2.982 9.072±1.5672 18.656±6.23 12.23±1.90 
 
5.899±0.748 
 
25 hrs 45.08±3.286 32.67±2.551 4.999±1.3539 9.4371±1.23 6.66±1.56 
 
2.1285±0.689 
 
30 hrs 35.78±3.4902 20.46±2.121 2.095±0.84994 6.3126±1.01 2.87±0.941 
 
0.497±0.217 
Table3.2 Percentages of wound closure remained open throughout a 30 hour period 
for different treatments. Standard error are shown. 
 
Figure3. 4 Graph of % wound closure width against time for wounded MG-63 
osteoblast monolayers with different treatments. Standard error bars are shown. 
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 The rate of wound closure per hour (Figure 3.6) for both synthetic cannabinoid groups 
HU308 500nM and 2μM concentrations and TGF-β3 and its combination groups TGF-
β3/HU308 compared with control (no treatment) groups show that during the first 10 
hours, both concentrations of HU308 induced higher closure rates reaching to 29μm/hr 
and 24μm/hr for both 500nM HU308 and 2μM HU308, respectively, whereas control 
groups had maximum wound closure rates of 8μm/hr at 25 hrs. Interestingly, TGF-β3 
and TGF-β3/500nMHU308 combination treatments had similar effects on wound 
healing rate throughout 30 hours although closure rate in combination treatment seemed 
higher than TGF-β3 groups by an increment of ~5μm/hr after 15 hours which was 
increased after 20 hours to ~6μm/hr and~9μm/hr for combination HU308/TGF-β3 and 
TGF-β3 groups, respectively.    
 
 
Figure3.6 Rate of wound closure for different treatments control, carrier, HU308, 
TGF-β3 and HU308/TGF-β3 
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3.5.3 Cell adhesion analysis 
The trypsinization assay revealed that treatment with TGF-β3 had the shortest time for 
% reduction in cell surface area, indicating that TGF-β3 reduced cell attachment as 
compared with the other treatments (Figure 3.7, Table 3.3). However, cells treated with 
2μM HU308 took the longest to detach as evidenced by a relatively low % decrease in 
cell surface area after 270 seconds. Treatments with combinations of TGF-β3/HU308 
altered the detachment time of MG-63 osteoblast cells compared to their individual 
treatments as can be seen from figure 3.7 and Table 3.3. It was found that the 
percentage decrease in cell surface area after three minutes was 45%±1.96 and 
47%±1.63 for TGF-β3 and 8nMTGF-β3/500nMHU308 combination groups 
respectively, while 500nMHU308 decreased by 55%±2.14. On the other hand, the 
percentage decrease in cell surface area after 270 seconds for all treatment groups, i.e. 
control, carrier groups, 500nMHU308, 2μMHU308, 8nMTGF-β3 and 
500nMHU308/8nMTGF-β3 were 42.4%±1.8, 37.9%±3.23, 39.7%±1.77, 48%±1.65, 
36.8%±2.2 and 35.4%±1.11, respectively. Statistical analyses showed that up to 90 
seconds there were no significant differences in detachment for all treatments. However, 
significant differences were observed (Table 3.4) between treatment groups after 120 
seconds. It was also apparent that there were no significant differences in detachment 
time between control groups and HU308 with concentration of 500nM. On the other 
hand, significant differences were identified between cells treated with 2μMHU308 and 
combination groups alongside groups treated with 500nMHU308 and TGF-β3, 
especially at 120, 150 and 180 seconds (P<0.01). The study also showed there were no 
significant differences in detachment time between cells treated with TGF-β3 and 
8nMTGF-β3/500nMHU308 combination groups (P>0.05). Overall all TGF-β3 
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treatments promoted cell detachment amongst all tested groups resulting enhanced cell 
migration as seen from images in Figure3.8 and 3.9. It was also noticeable that carrier 
treated cells (0.1% ethanol) elaborated faster cell detachment compared to HU308 (both 
concentrations) and control groups.  
 
Figure3.7  Percentage cell surface reduction vs. time with different treatments. 
Standard error bars are shown. 
 
Time % Cell surface 
area Control 
 
% Cell surface 
area Negative 
Control (0.1%) 
Ethanol 
 
% Cell surface 
area  HU308 
500nM 
 
% Cell surface 
area HU308 
2μM 
 
% Cell 
surface area 
TGF-β3 
 
% Cell 
surface area 
HU308/ 
TGF-β3 
 
0Sec 100±4.19 100±3.25 100±3.45 100±3.45 100±3.74 100±4.55 
30Sec 89.374±3.06 88.260±5.26 86.267±3.37 93.855±3.27 86.86±3.54 85.02±4.31 
60Sec 77.251±1.97 72.256±3.25 75.962±2.48 84.368±3.22 66.34±3.02 72.75±3.53 
90Sec 69.763±2.12 62.223±4.325 67.885±1.56 74.215±2.96 57.77±2.20 62.21±2.97 
120Sec 62.764±1.94 58.230±6.21 63.333±2.06 68.816±2.98 51.41±2.26 54.81±2.90 
150Sec 57.584±2.14 53.265±4.23 59.181±2.15 64.125±2.38 47.58±2.04 51.61±1.91 
180Sec 53.048±2.02 49.326±6.23 55.240±2.14 59.730±2.57 45.41±1.96 47.58±1.63 
210Sec 48.987±1.86 46.236±2.54 50.614±2.07 56.157±2.57 43.09±2.17 44.64±1.39 
240Sec 46.163±1.87 42.236±1.32 45.883±2.21 52.611±2.37 40.74±2.00 42.80±1.15 
270Sec 42.476±1.95 37.935±3.23 39.736±1.77 48.038±1.65 36.88±2.20 35.43±1.11 
Table3.3  Percentage cell surface reduction throughout 270 seconds with different 
treatments. Standard error bars shown. 
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 500nM HU308 2μM HU308 8nM TGF-β3 8nMTGF-β3/ 500nMHU308 
0 Sec 
    
30 Sec 
    
60 Sec 
    
90 Sec 
    
120 Sec 
    
150 Sec 
    
180 sec 
    
210 sec 
    
240 sec 
    
270 sec 
    
Figure3. 9 Images showing the effect of trypsinaization on MG-63 osteoblast cells 
with different treatments (scale bar=100μm) 
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3.6 Discussion & conclusion    
In the previous chapter it was found that treatment of MG63 osteoblast cells with CB2 
agonist HU308 at concentrations of 500nM promoted optimal model wound closure and 
induced maximum proliferation. In this chapter the effects on model wound closure of 
treating MG63 cells with 500nM HU308 were compared with the effects of treating 
cells with combinations of 500nMHU308 and 8nM (50ng/ml) TGF-β3 or 2μM HU308. 
These experiments were performed using a CB2 selective agonist rather than a CB1 or 
nonspecific synthetic cannabinoid because it is well known that endocannabinoid 
activation of pre-synaptic CB1 receptors is known to reduce neurotransmitter release 
and hence excite toxicity in postsynaptic neurons (Ashton and Glass, 2007). There is 
also evidence that CB1 receptors are involved in direct regulation of vasodilation 
through vascular CB1 receptors and indirectly by inhibition of vasoconstrictors (Ashton 
and Glass, 2007), and that CB1 receptors play a part in up regulating pro-inflammatory 
mediators such as nitric oxide (NO) and TNF-α in the acute phase of injury (Ashton and 
Glass, 2007). However, there is evidence that these effects do not directly influence 
osteoblasts, and if CB1 agonists on non-specific cannabinoids were used for bone 
wound repair they may induce serious side effects and complications such as catalepsy, 
increased body temperature, analgesia and hyper tension (Hanuš et al., 1999). In 
comparison, HU308 agonist specifically targets the CB2 receptors which are highly 
expressed in bone, liver and the immune system (Ofek et al., 2006). Furthermore, CB1 
and CB2 receptors are not functionally identical, CB1 is shown to activate potassium  
ion channels (Caulfield and Brown, 1992) in nerve terminals (Ofek et al., 2006) whilst 
CB2 receptor signalling contributes to the maintenance of bone mass by two 
mechanisms; (i) direct stimulation of stromal cells and osteoblasts and (ii) inhibition of 
 127 
 
monocytes/osteoclasts both directly and by inhibition of osteoblast stromal cell RANKL 
expression (Ofek et al., 2006). 
TGF-β3 is a member in the TGF-beta family; it was found to be a potent regulator in 
functions associated with bone formation, i.e. mitogenesis, collagen synthesis, and 
alkaline phosphatase activity. TGF-β isomers have also been found to influence cell 
morphology, for example TGF-β1 in chondrocytes plays a very important role in rapid 
formation of fibroblast like chondrocyte cells in vitro (Chi, 2004,Nakamura, 2007). A 
role for TGF-β3 in bone repair was also suggested after a direct comparison and 
analysis of receptor competition between TGF-β1 and TGF-β3. This combined with 
evidence of pico-molar concentrations of high-affinity binding sites for TGF-β3 in bone 
suggest that bone cells are more sensitive to TGF-β3 than they are to TGF-β1 (Dijke et 
al., 1990) 
In this study it was found that HU308 with 500nM concentration induced a higher 
proliferation rate than did combination treatments with HU308 and TGF-β3. The results 
also indicated that TGF-β3 treatment and combination treatments induced comparable 
reductions in proliferation rate as compared with 500nM HU308 treatment. This 
response can be explained by the cross and synergetic effect they both have on their 
signaling pathways further downstream which might have made the pathway less 
responsive to either or both stimulants. Support for this view comes from evidence that 
CB2 receptor and Type I and II TGF-β receptors both share one of the most important 
signalling pathways, i.e. P-38 pathway (Hocevar et al., 1999, Herrera et al., 2005), and 
that the response of either treatments could be controlled by receptor affinity to each 
treatment or by receptor saturation of each treatment. On the other hand, the wound 
closure assay indicated that treatments with combinations of TGF-β3 and HU308 had 
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significantly induced faster wound closure (P<0.001) than did treatment with 500nM 
HU308 alone and compared to control groups indicating that other factors may have 
contributed in the processes of wound healing other than the increase in cell number 
displayed in response to 500nM HU308 treatment cultures. It can also be noted that 
cannabinoid treatment groups with either 500nM or 2μM concentrations achieved an 
exponential increase in the rate of wound healing per hour in the first 10 hours, 
conversely this increase was not present in wound healing rates in the remaining 
cultures (control, carrier, TGF-β3 and combination HU308/TGf-β3). Moreover, the 
wound closure rate following HU308 treatments remained higher than those of TGF-β3 
and TGF-β3/HU308 groups for the first 17 hours. Subsequent to 17 hours wound 
closure rates levelled off and were similar in all treatment groups. The discrepancy in 
wound repair rates between cell treated with combinations of TGF-β3/HU308 and cells 
treated with TGF-β3 compared to those individual treatments of HU308 may be 
attributed to cell migration. Evidence supporting this was acquired from cell length 
measurements and trypsinistaion experiments in which it was found that TGF-β3 
reduced adhesion of MG-63 osteoblast cells. Decreased attachment is documented as 
being associated with better cell migration. This finding was in complete agreement 
with a study that showed that Mast cells exhibited enhanced chemotactic responses after 
treatment with TGF-β3 compared to treatment with TGF-β1 and 2 (Olsson et al., 2000). 
Even though, combination groups showed lower migration rates indicated by 
trypsinization with no significance in proliferation rate compared to TGF-β3 treatment 
groups, they still achieved accelerated wound closure which may have been as a result 
of cells having more time to replicate and multiply throughout bridge formation, 
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resulting in the minimizations of the wound gap formation during the 30 hour healing 
period. 
Interaction of cells (via membrane receptors) with ligands expressed by neighboring 
cells, and cell-cell signaling play an important role in stimulating or inhibiting cell 
proliferation (Fox et al., 2008). In this chapter the model wound assay revealed that 
increasing cell migration would increase the gap between cells therefore enhancing the 
process of bridge formation. Bridge formation allows cells distal to the wound edge to 
align behind those bridging cells and track into a wound site thus enhancing repair to 
organize the cell structure leading to changed morphology at the wound site with a more 
elongated phenotype, whereas cells away from the site were rounded and denser (Sefat 
et al., 2009). It was found that TGf-β3 influenced cell morphology and increased cell 
size by nearly a factor of 2 compared to control treatment cells. In fact, it was shown 
that almost all treatments used in the present study had increased cell length by nearly 
60-70%, therefore gap width during wound healing may have experienced variations in 
the percentage of the wound remained open especially in TGF-β3 treatment groups due 
to the increased cell size in combination with the effect of cell proliferation, furthermore 
influencing different responses in terms of wound closure rate. Interestingly, the 
increase in wound healing rate for cannabinoid treatment groups decreased after 
reaching the last 10 hours by either agonist receptor saturation or contact inhibition 
leading to the inhibition of cell proliferation.  
TGF-β production by almost all cell type was initially identified in 1978 (Derynck and 
Miyazono, 2008)  in an inactive/latent form (Schwartz et al., 1993) suggesting that it 
plays regulatory roles in most tissues. Although the function of TGF-β in various cell 
types has been investigated, their function in bone repair is as yet not fully understood. 
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There have been studies on the effect of TGF-β on bone yet the majority of these studies 
are not related to bone wound repair. In this study the results indicate that wounded 
bone monolayers treated with either TGF-β3 or synthetic HU308 cannabinoid or 
combinations of both demonstrated an enhanced ability to repair, in some cases during 
the first 20 hours following wounding. This may also be related to an increase in 
secretion of ECM molecules at the wound edge, which functions by capturing cells via 
the integrin ECM interactions, thus helping migration into the wound site (Nelson and 
Chen, 2002). This view was further supported by significant differences in cell 
detachment times between each treatment as cells have shown to establish different 
responses in relation to cell-ECM adhesion strength. This work is the first to examine 
the effect of synthetic HU308 cannabinoid in combination with TGF-β3 on MG-63 
wounded bone cell monolayers, therefore providing a potential insight into the 
mechanisms of wound repair whilst indicating that cell response may be related to the 
up-regulation of extracellular matrix secretion. The importance of invistigating the 
effect of combination treatments, allows better understanding of cell regeneration, as 
cell biological stimulants are not found selectively in practice or in-vivo. Interestingly, 
several of other studies have adopted similar approaches in testing drugs in 
combinations and have shown enhanced findings (Ackermann et al., 2011).  
Previous studies have also indicated that the rate and duration of monolayer cell 
migration is limited by the initial density of cells (Rosen and Misfeldt, 1980, 
Bindschadler and McGrath, 2007). However, this phenomenon was circumvented in the 
present study by plating MG-63 bone cells with an initial unified cell density and 
commencing the scratch assay after cells reached a plateau in their density after 48 
hours. 
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As a consequence, it is important to further examine the mechanisms of wound healing 
by understanding the effects of different treatments investigated in the current chapter 
on extracellular matrix regulations, and quantitatively identifying different factors that 
may influence MG-63 osteoblast wound healing and cell detachment by methods such 
as immunestaining and immuneperoxidase techniques.  
3.7 Chapter summery  
Overall, it was found that combination treatments of HU308/TGF-β3 had by far the 
most effective response in the acceleration of MG-63 osteoblast monolayer wound 
healing. Furthermore, combination treatments has also reduced cell attachment greatly 
due to the presence of TGF-β3 which resulted in enhanced cell migration leading to 
better wound closure. It was confirmed that combination treatments of HU308/TGF-β3 
may have had synergetic effects on MG-63 osteoblast wound healing, effecting both 
cell proliferation and cell morphology (cell length). However, further analysis on the 
mechanisms of wound repair would need to be investigated.    
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Chapter IV 
Effect of TGF-β3 and HU308 and their combination on ECM-
proteins, MMP-2 and nitric oxide regulation during wound repair 
of MG-63 bone cell monolayers 
4.1 Introduction 
In order to both qualitatively and quantitatively investigate the mechanisms of action in 
healing of wounded MG-63 monolayers, milestone changes had to be studied. Various 
studies have shown that collagen type I is the major organic component of bone. Studies 
have also shown that collagen type I influences the expression of the osteoblastic cell 
phenotype and also plays a role in the mineralization of the osteoblast derived matrix 
(Owen et al., 1990). Additionally, collagen type I was found to be directly associated 
with cell proliferation (Owen et al., 1990). There is also evidence that 1,25(OH)2-
vitamin D3 given during the proliferative phase down regulates collagen type I synthesis 
which in turns stops osteoblast maturation and differentiation (Owen et al., 1990). Thus 
it seems that collagen up regulation is driven by cell proliferation leading to the onset of 
matrix maturation. 
In consequence it is important to quantify the secretion of collagen type I in the present 
wound model and to assess influences of different treatments on collagen type I 
synthesis. 
As important as collagen type I is in defining the mechanisms of wound repair for MG-
63 osteoblast bone cells, there is also growing interest regarding the secretion of other 
ECM proteins which likewise may contribute to the process of wound healing. 
Numerous studies have indicated a primary role for fibronectin in osteoblast bone cell 
migration; there is evidence that the presence or absence of fibronectin deposited around 
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a given cell can determine whether that cell participates in migratory movements during 
development (Ruoslahti, 1984), (Owen et al., 1990). Thus it is important to characterise 
fibronectin secretion both qualitatively and quantitatively in order to determine how the 
modulation of fibronectin secretion influences bone repair.    
On the other hand, it is well recognized that Transforming growth factor-β3 is a 
hormonally active polypeptide that controls cell growth and differentiation (Sporn and 
Roberts, 1985). It is present in normal tissues and transformed cells. Blood platelets in 
particular have the most abundant concentrations of transforming growth factor beta 
suggesting it plays an important role in the normal response to tissue injury. Therefore, 
TGF-β isoform seems to have a strong influence on cellular functions and extracellular 
matrix deposition including proliferation, differentiation and expression of the 
transformed phenotype (Ignotz and Massague, 1986). There is also evidence that  TGF-
β isoforms increases collagen and fibronectin synthesis in various cell types both 
normal and transformed (Ignotz and Massague, 1986).  
TGF-β is also known to exert its effects on cell proliferation, differentiation and 
migration via its modulation of extracellular matrix components, such as fibronectin and 
plasminogen activator inhibitor-1 (PAI-1) (Hocevar et al., 1999), it may also function 
synergistically with pathways involving cannabinoid receptors. There is evidence that 
CB2 selective agonists also negatively control cellular adhesion induced by ICAM-1 
VCAM-1 in a number of cell models (Rajesh et al., 2007) thus not only suggesting that 
endocannabinoids play a role in proliferation but that synthetic HU308 CB2 agonist 
may have a therapeutic application (Ashton and Glass, 2007, Hanus et al., 1999). The 
results from Chapter 2 and 3 suggest that HU308 has an impact on cell migration during 
 134 
 
model wound repair. Thus it is important to examine the effect of HU308 and TGF-β3 
either separately or in combination on MG-63 extracellular matrix up-regulation.  
Recent evidence has shown that protein S-100A6 is up-regulated markedly during 
osteoblast differentiation (Hwang et al., 2004), and that protein S-100A6 is 
overexpressed in human osteosarcoma, furthermore inhibition of protein S-100A6 
resulted in decreased cell adhesion and promoted cell migration and invasion (Luo et 
al., 2008), Conversely, S100A6 overexpression enhanced cell adhesion and inhibited 
cell invasion, therefore protein S-100A6 can be used in identifying oestrogenic cells 
without metastases ability. 
Cytokine-inducible nitric oxide (NO) synthase activities are observed in cultured 
osteoblast-like cells (HOF, 2001, Johnson et al., 1996). NO is involved in various 
pathophysiological events in many diseases and is produced from L-arginine by nitric 
oxide synthase (NOS). NO is also an important signalling molecule in bone and is 
produced by bone cells and organ cultures in response to diverse stimuli such as 
proinflammatory cytokines (Park et al., 2009). Thus this study also aimed at examining 
the levels of nitric oxide expression in response to treatment with HU308, TGF-β3 and 
their combination. 
Matrix Metalloproteinase (MMP) is also an important factor that needs to be considered 
in the process of bone repair. ECM production and degradation by bone cells is critical 
in bone metabolism (Bilezikian, 2002). Mutations of genes encoding type I collagen 
cause bone diseases such as osteogenesis imperfectia (Byers and Steiner, 1992). 
Collagen type I molecules are processed by propeptidases and cross-linked by lysyl 
oxidases into mature collagen. Type I collagens are mainly degraded by matrix 
metalloproteinase (MMPs), which exert their enzymatic activity at a neutral pH in a zinc 
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ion-dependent manner (Andersen et al., 2004). Several MMPs are expressed in bone 
tissue, and these play a significant role in osteoclast bone resorption (Andersen et al., 
2004). Osteoblasts and osteocytes also produce MMPs such as MMP-2 and MMP-13 
(Sasano et al., 2002, Hatori et al., 2004). Both TGF-β3 and CB2 agonists influence cell 
attachment and migration suggesting that they may also play a part in regulating MMP-
2 secretion in osteoblast cells.  
4.2 Aims and Objectives 
In the previous chapters the effects of CB2 selective agonist HU308 and its 
combinations with TGF-β3 on cell behaviour in terms of cell morphology, attachment, 
proliferation and wound repair were investigated. The results of these experiments 
showed that TGF-β3 in combination with HU308 enhanced MG-63 osteoblast bone 
monolayer wound closure. Therefore, immunostaining studies in this chapter will 
concentrate on determining which ECM markers are up regulated by HU308 and TGF-
β3 either individually or in combination. Immunoperoxidase staining will also be used 
to determine if these treatments further modified ECM secretion in the osteoblast bone 
cells quantitatively. This chapter also aims to examine the effect of HU308 and TGF-β3, 
individually and in combination on S-100A6, nitric oxide synthesis and the expression 
of matrix metalloproteinases-2 (MMP-2).  
4.3 Material and Methods 
4.3.1 Immunofluorescence staining for collagen type I, fibronectin and 
protein S-100A6 
Glycine (used to reduce auto-fluorescence) in HBSS was prepared according to the 
suppliers instructions [(0.1M)=0.375g (Glycin +50mL HBSS)] and 4% formaldehyde 
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was also prepared for cell fixation prior to staining by addition of 4 ml formaldehyde to 
32.5 ml HBSS. 1%BSA/HBSS was prepared by addition of 0.5g BSA to 50ml HBSS, 
500μl Goat serum in 25 ml HBSS was used as blocking agent (Sigma, Aldrich). PBS 
was prepared by dissolving 1 tablet per 200 ml distilled water and used for washing 
cells between antibody incubations. Finally, 3μl of dapi was diluted in 30ml HBSS and 
this was used for nuclear staining. Primary anti-body was prepared in 1%BSA/HBSS at 
ratios of 1:500, 1:100 and 1:1000 for collagen type I, fibronectin and S-100A6, 
respectively. Secondary anti-body Ab- Alexor fluor 488nM was diluted by addition of 
5μl into 2ml (1%BSA/HBSS) to block unspecific binding. 
Cells were plated in 25cm2 culture flasks at 10×104 cells/ml and incubated for 48 hours 
until 80% confluency was reached as described in Chapter 2. Cells were then detached 
using trypsin and processed (see chapter 2) to acquire a desired cell suspension for 
further experiments. 
Cells with a total density of 50,000 cells/ml were plated on sterilised coverslips in 
individual petri dishes (3.5 cm2, CORNIA), this was done by applying 2ml of cell 
suspension (10×104 cells/ml) to their surface. Following a 10 minute attachment period 
a further 2ml of complete culture media (see chapter 2) was added to each of the petri 
dish containing cover slips.  
The petri-dishes were then placed in another larger petri-dish and incubated for 48 
hours. After 48 hours dishes were then separated into five treatment cultures, control 
with no treatment and cells treated with 500nM HU308, 2μMHU308, 8nM TGF-β3 and 
a combination of 500nM HU308 and 8nM TGF-β3. Treatment cells were incubated at 
37oC in a 5% CO2 Atmosphere for 30 hours. The experiments were repeated three times.  
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Following the final 30 hour incubation, cells were washed three times in HBSS after 
which cells were fixed in 4% formaldehyde diluted in HBSS for 5-7 minutes at room 
temperature. Following fixation, cells were washed twice with HBSS followed by a 
further wash in the glycine solution. Cells were then permeabilized in 0.1% Triton X-
100 solution in HBSS for 3-5 minutes at room temperature and washed three times with 
HBSS at 15 minutes intervals. To inhibit unspecific staining, cells were treated with 
Image-iTTM FX signal enhancer). After Final incubation with the blocking solution, 
cells were washed further 3 times in HBSS at 5 minute intervals.  
Immunostaining for collagen type 1, fibronectin and protein S-100A6 were achieved by 
incubating cells in either mouse anti-collagen type I or mouse anti-fibronectin or mouse 
anti-s-100A6 diluted in HBSS containing 1% BSA. Negative control cultures (no 
treatment) were incubated in 1% BSA/HBSS only. After 1 hour, the primary antibodies 
were removed and cells were washed 3 times using HBSS at 5 minute intervals. 
Prior to secondary antibody addition, cover slip edges were dried using plotting paper, 
afterwards secondary antibody (Alexa Fluor 488 Goat Anti-mouse IgG) at a 
concentration of 5μg/ml diluted in 1% BSA/HBSS was added to all groups including 
negative control groups for 1 hour at room temperature in the dark. Following this 
incubation with the secondary antibodies, cells were washed 3 times in HBSS at 5 
minute intervals and finally the slides were placed in foil wrapped petri dishes and 
maintained at 0-4oC in a fridge for 4 days. 
Cells were incubated in 10% of dapi (SIGMA) diluted in 1%BSA/HBSS for 15 minutes 
before imaging all in order to identify the nuclei of live cells. Following this incubation 
in dapi cells were washed 2 times in HBSS at 2 minutes intervals. 
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Coverslips were removed from petri-dishes and examined using an Eclipse 80i 
Fluorescence microscope with an objective lens of 60X. 
4.3.2 Elisa based method for detection of collagen type I, fibronectin and 
protein S-100A6 
Cells were cultured in 25cm2 culture flasks under control conditions. On day 3 cells 
were trypsinized and seeded into a 96 well plate and incubated for a further 30 hours in 
medium containing treatments of 500nMHU308, 2μMHU308, 8nMTGF-β3 or their 
combinations HU308/TGF-β3.  Following this 30 hour incubation, cells were stained 
for either collagen type I, fibronectin or protein S-100A6. Cells were washed 3 times in 
PBS and fixed in 4% formaldehyde for 6 minutes.  Cells were washed again in PBS and 
any endogenous peroxide was quenched using 3% hydrogen peroxide (SIGMA) for 5 
minutes.  Following another wash, 1% BSA in PBS was added for 15 minutes to 
prevent non-specific binding. Cells were incubated with the primary mouse anti-
collagen type I, mouse anti-fibronectin and mouse anti-S-100A6 diluted in 1% 
BSA/HBSS at ratios of 1:500, 1:100, 1:1000, respectively.  For negative controls, the 
primary antibody incubation was replaced with a 1% BSA/HBSS incubation.  
Following 1 hour of primary anti-body incubation, wells were rinsed and the secondary 
anti-mouse IgG peroxidise conjugate (8μg/ml, Sigma) was added for a further 30 
minutes at room temperature.  Tetramethylbenzidine (TMB) (SIGMA) substrate was 
then applied and absorbance readings were taken at 630nm after 10 minutes. This 
experiment was repeated three times.  Absorbance readings for control and test groups 
were corrected by subtracting negative control optical density readings.   
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 4.3.3 Nitric oxide quantitative staining 
Seven sets of cells were cultured to reach confluency under normal conditions, after 
which cells were washed three times for 5 minutes in HBSS and wounds were 
initialized as described in chapter 2. Each set of cells were fed with media containing 
either culture media (control), 500nM HU308, 2μM HU308, 8nM TGF-β3 or 500nM 
HU308/8nM TGF-β3, combinations. Following treatment, flasks were incubated at 
37°C in 5% CO2 atmosphere for 30 hours. Every 5 hours supernatants of a single set 
were withdrawn from culture flasks and centrifuged at 1700 rpm for 5 minutes. In a 
coster 96-well plate, 100μl of each supernatant treatment group was mixed with 100μl 
Griess’ reagent and incubated at room temperature for 10 minutes. After incubation 
absorbance was measured using absorbance micro-plate reader ELx 800 (Bioteck 
instruments, USA) at wavelength of 570 nm. This was repeated every 5 hours up to 30 
hours, and experiments were repeated in triplicates.      
4.3.4 MMP-2 immunoassay staining 
Cells were cultured in 25cm2 flasks and left in a 5% CO2 incubator at 37° to reach 
confluancy, after which they were divided into the following treatment groups, control 
(no treatment), 500nMH U308, 2μMH U308, 8nM TGF-β3 and combination treatment 
with 500nM HU308/8nM TGF-β. Conditioned media was aspirated and centrifuged at 
1500 rpm for 5 minutes. An Elisa Kit (Invitrogen,UK) was used and staining steps were 
in accordance with the manufactures supplied protocol. Conditioned media was added 
to pre-treated 96-coster well plates with MMP-2 anti-body and were incubated for 2 
hours. Media was aspirated and washed 4 times with a washing solution; wells were 
then incubated in 100μL of biotin conjugate for a period of one hour at room 
temperature. The wells were again washed 4 times in 1% BSA/HBSS washing solution. 
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After the final wash, wells were incubated in 100μL of streptavidin-HRP for a period of 
30 minutes followed by incubation in stabilized chromogen for 30 minutes in room 
temperature. Stop solution was added and optical density values were obtained using 
ELx 800 (Bioteck instruments, USA) at wavelength of 450nm. 
4.4 Statistical analysis 
Values calculated for quantitative staining were tested for normality using a 
Kolmogorov Smirnov test. Normally distributed data (p > 0.05) were analysed using 
SPSS via oneway analysis of variance (ANOVA) followed by post Hoc Bonferroni 
tests. Kruskal-Wallis test and serial Mann Whitney tests were used for non-normally 
distributed data (p<0.05).  Statistical tests were performed such that a p value of < 0.05 
was considered as indicating a significant difference.  
4.5 Results and brief discussion  
4.5.1 Immunofluorescence staining for collagen type I, fibronectin and 
protein S-100A6: 
Immunofluorescence staining was carried out to determine the effect of 500nM HU308 
and 2μM HU308, 8nMTGF-β and their combination 500nM HU308/8nM TGFβ3 on the 
expression of collagen type I and fibronectin. In the case of collagen Type I, the results 
(Figure 4.1 (A)) indicated that 500nMHU308 and 2μM HU308 promoted enhanced 
staining around the cells dapi stained nuclei as compared with the control. It was also 
apparent that collagen staining following 2μM HU308 was greater than that in cells 
treated with 500nMHU308 and control (figure 4.1 (B, C)).  
Interestingly, immunofluorescence staining of collagen type I after treatment of cells 
with TGF-β3 seemed to induce increased collagen expression (Figure 55(D)) where 
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collagen was uniformly distributed around the majority of all cells in a given area 
compared with control groups and those following HU308 treatment. It was also 
apparent that in most images of control and HU308 treated cells there was minimal 
expression of collagen type I around the nuclei and the periphery of the cells.  
However, collagen type I expression for groups treated with a combination of 500nM 
HU308 and 8nM TGF-β3 seemed to exhibit a similar but seemingly slightly enhanced 
responses as compared with 8nM TGF-β3.  
Immunofluorescence staining was also carried out for fibronectin expression after 
treatment with 500nM HU308; 2μM HU308, 8nM TGF-β3 and 500nM HU308/ 8nM 
TGF-β3 combination, respectively, and they were all compared with control groups. 
Images for the 500nMHU308 treatment groups showed a decrease in fibronectin 
expression indicated by the low staining intensity and less fibronectin expression. In 
contrast treatments with 2μM HU308 seemed to increase expression of fibronectin 
(Figure 4.2(C)). Additionally, it was observed that fibronectin expression in treatment 
groups of 2μM HU308 was more concentrated around the edges of the cells and in-
between cells forming a network of fibronectin connecting cells together and creating a 
layer over which they grew. Interestingly, control groups (no treatment) (Figure 4.2(A)) 
clearly showed fibronectin expression distributed on cell surface and in-between cells, 
yet the ratio of fibronectin stained cells to dapi stained cells  seemed to be quite low 
indicating a decreased fibronectin expression in control cells. In comparison, fibronectin 
expression was increased in cells treated with TGF-β3 and this can be seen in (Figure 
4.2 (D)). In spite of this, it was still lower than that in cells treated with 2μM HU308. 
Also, TGF-β3 seemed to induce fibronectin condensations around cell edges and on the 
culture substrate forming a fibronectin network. This could be as a result of the 
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migrative response that TGF-β3 induces in MG-63 osteoblast cells, as more motile have 
weaker cell attachment with less expression of fibronectin, but they would probably lay 
down ECM as they migrate. 
Interestingly, treatments with combinations of 8nM TGF-β3/500nM HU308 induced 
fibronectin expression that seemed to extend into the spaces between the cells indicating 
fibronectin deposition on the culture substrate. It seemed that fibronectin secretion onto 
the culture substrate was enhanced by the combination treatment giving rise to the 
underlying fibronectin layer becoming uniform throughout. However, the intensity of 
the fibronectin immunestaining following 8nM TGF-β3/TGFβ3 treatment seemed lower 
than that seen in cells treated with 2μM HU308 treatment. 
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immunoperoxidase staining method was used.  Readings of optical densities (OD) were 
compared between control and each treatment used in relation to every protein 
expression. Absorbance readings for non-treatment cell groups for collagen type I, 
fibronectin and S-100A6 were OD = 0.69±0.0014, OD = 0.65±0.0022, OD = 
0.73±0.0019, respectively) (Figure 4.5, 4.6 and 4.7). Primarily observations indicated 
that protein S-100A6 was relatively higher in MG-63 osteoblast control cultures 
compared with collagen type I and fibronectin. However, after treatment with 
500nMHU308 and 2μMHU308, collagen type I expression increased (OD = 
0.76±0.0002, 0.78±0.001 respectively). In contrast, fibronectin expression was 
decreased after treatment with 500nMHU308 to OD= 0.56±0.0025, but was 
significantly increased in comparison to control treated cells (P<0.005) to OD = 
0.70±0.005 for cells treated with 2μM HU308. On the other hand, protein S-100A6 was 
increased in both treatments of 500nM HU308 and 2μM HU308 with OD = 
0.78±0.0015 and OD = 0.84±0.0054, respectively. 
Quantitative staining after treatments of TGF-β3 and TGF-β3/HU308 combinations for 
ECM expressions seemed to increase expression of collagen type I and S-100A6 to OD 
= 0.97±0.0021, OD = 0.93±0.0052 and OD = 0.82±0.0012, 0.80±0.0023) for TGF-3 and 
TGF-β3/HU308, respectively. In spite of this, fibernectin expression was decreased in 
both treatments compared with control groups to OD values of 0.63±0.0021 and 
0.59±0.0041 for TGF-β3 and TGF-β3\HU308, respectively. Figure 4.5, 4.6 and 4.7 
shows expression of collagen type I, fibronectin and protein S-100A6 for each 
treatment. 
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Figure4.5 Optical density readings (630nm) following immunoperoxidase staining of 
deposited collagen type I. Standard error bars are shown, N=9. Standard error bars 
are shown. 
 
 
Figure 4.6 Optical density readings (630nm) following immunoperoxidase staining of 
deposited fibronectin. Standard error bars are shown, N=9. Standard error bars are 
shown. 
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Figure 4.7 Optical density readings (630nm) following immunoperoxidase staining of 
deposited protein S-100A6. Standard error bars are shown, N=9. Standard error bars 
are shown. 
 
4.5.3 Nitric oxide staining 
Quantitative staining was carried out for nitric oxide levels throughout 30 hours; 
readings were taken every 5 hours in order to investigate treatment response by nitric 
oxide synthesis due to wounded/ damaged cells. The results in Figure 4.8 indicate that 
nitric oxide expression in MG-63 osteoblast cell cultures at 0 minute for control, 
500nMHU308, 2μMHU308, TGF-β3 and TGF-β3/HU308 combinations were with 
values OD = 0.75±0.09, OD = 0.74±0.005, OD = 0.76±0.013, OD = 0.785±0.014, OD = 
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optical densities of 0.61±0.0078, 0.62±0.002 and 0.62±0.009, respectively. After 10 
hours, nitric oxide levels were increased and it was notable that nitric oxide elevation 
reached a peak expression at 15 hours for cultures treated with 500nMHU308, TGF-β3 
and TGF-β3\HU308 (OD = 0.94±0.0021, OD = 0.90±0.007, OD = 0.91±.0095, 
respectively). In comparison, nitric oxide levels decreased significantly in control 
treated cells (P<0.05) after 15 hours to OD = 0.75±0.014. Figure 4.8 also shows that 
control treatments and treatment with 2μMHU308 induced similar effect in relation to 
NO synthesis throughout 30 hours, whereas the remaining treatments induced 
significant changes in NO production, especially after 15 to 20 hours indicating a 
possible role for nitric oxide in the acceleration of MG-63 osteoblast monolayer wound 
healing.  
Interestingly, cells treated with higher concentration of HU308 produced lowest NO 
expressions after 30 hours with OD= 0.77±0.0025, suggesting high concentrations of 
HU308 may have anti-inflammatory effects and that these may be mediated by CB2 
receptors.  
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Figure 4.8 Optical density readings (570nm) following immunoassay staining of 
nitric oxide expression. Standard error bars are shown, N=9. Standard error bars are 
shown. 
    
4.5.4 MMP-2 immunoassay staining  
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with HU308 at the higher concentration compared to control treated cells (no treatment 
groups).  
 
Figure 4.9 Optical density readings (630nm) following immunoassay staining of 
matrix metalloproteinase-2. Standard error bars are shown, N=9 
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4.6 Discussion & conclusion    
 
The results of the experiments described in this chapter indicated that HU308 and TGF-
β3 treatment influenced the production of extracellular matrix proteins, MMP-2, 
S100A6 and NO. In the case of collagen type I expressions, 8nM TGF-β3 treatment 
seemed to enhance its expression significantly more than it did for any other treatment. 
Collagen type I levels were increased by approximately 40% compared to control 
treated cells. In comparison combination treatment with 8nM TGF-β3/500nM HU308 
increased expression of collagen type I by approximately 34%. This finding can be 
explained due to the nature of transforming growth factors which have been shown to 
increase differentiation for most type of cells (Miettinen et al., 1994). This is also the 
case in the current investigation with MG-63 osteoblast cells and further confirmed by 
the increase in protein S-100A6 in TGF-β3 treatment cultures. Previous studies have 
indicated that suppression of collagen synthesis resulted in down regulation of genes 
associated with osteoblast mineralization (Owen et al., 1990). Additionally, it was found 
that down regulation of cell proliferation due to increasing doses of ascorbic acid 
induced collagen type I synthesis which in turn increased osteoblast mineralization. 
This finding was further supported in the present study as treatment with 500nMHU308 
significantly induced cell proliferation (see chapter 2) and induced collagen type I 
expression by only 10%, whereas in TGF-β3 treatment groups, proliferation rate was 
relatively lower than those obtained for 500nM HU308 groups (see chapter 2). 
However, the 40% increase in collagen type I expression, is in good agreement and it 
was also observed in higher concentrations at 2μM HU308 which showed lower 
proliferation rates with increasing  levels of  collagen type I expression. It was reported 
that TGF-β3 exerts its multiple activities through type I and II cell surface receptors, 
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and that activation of the TGF-beta signal transduction pathways leads to inhibition of 
cell proliferation and an increase in extracellular matrix production (Miettinen et al., 
1994) leading to a significant increase in collagen type I expression in most tissues. 
Therefore, it can be said that involvement of type I collagen extracellular matrix in the 
developmental expression of osteoblast phenotypic parameters is a physiologically 
responsive manner in response to different stimulants.  
Several studies have also indicated a role for fibronectin in bone repair and remodelling 
(Yamada, 2000).  For example, fibronectin is associated with up-regulation of MMP-2 
activation (Lynch et al., 1995) and the expression of fibronectin in cells can alter levels 
of MMP-2 in culture. This was not the case in the present study as fibronectin 
expression was mainly increased with treatments of 2μM HU308, whilst MMP-2 levels 
were the lowest following the same treatment. This apparent discrepancy could be 
related to the direct action that the synthetic cannabinoid HU308 may have on MG-63 
osteoblast bone cells especially when using higher cannabinoid concentrations. This 
was demonstrated in a previous study (Blazquez et al., 2008) where local administration 
of tetrahydrocannabinol (THC) down regulated MMP-2 expression in Glioma cells. 
There is also evidence that the CB2 receptor agonist JWH-133 also inhibits MMP-2 
expression in mouse gliomas (Blazquez et al., 2008). As a result of the MMP-2 down-
regulation, cell migration and tumour invasion is restricted in carcinogenic cells, 
because down regulation of MMP-2 would lead to increased levels of fibronectin 
expression in culture resulting in maximal force of osteoblast cell adhesion. A similar 
mechanism may operate in MG-63 osteoblast cells treated with 2μMHU308.  
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Interestingly, the expression of fibronectin in cells treated with 500nMHU308 and TGF-
β3\HU308 combinations was decreased by 13.8% and 9.2%, respectively, compared 
with control treated cells (no treatment). 
The expression of fibronectin has also been associated with cell migration in vitro, and 
it has been established in a number of studies that the presence or absence of fibronectin 
deposition around a given cell can determine whether that cell participates in migratory 
movements during development (Ahmed et al., 2000, Brunner et al., 2011). It was found 
that the phenotype of a eukaryotic migrating cell appears to be that of lacking cell 
surface fibronectin in vitro (Ruoslahti, 1984, Ahmed et al., 2000).  This direct relation 
may be the case for MG63 cells treated with 500nMHU308 and TGF-β3\HU308. Both 
treatments seemed to decrease levels of fibronectin expression whilst significantly 
(P<0.05) increasing model wound closure rates. Support for this view comes from the 
results in this chapter indicating that not only did treatment with 500nMHU308 and 
TGF-β3/HU308 decreased fibronectin secretion, but also increased the MMP-2 
production.  
For cells to migrate they must be able to detach from the ECM matrices and correlation 
between ECM protein expressions and cell detachment has been clearly seen in 
(chapters 2 and 3) where higher concentration of synthetic cannabinoid HU308 had the 
least wound healing response with maximal cell detachment time compared to other 
groups, which also induced the highest levels of fibronectin expression, Whereas the 
percentage increase in fibronectin levels in both combination groups 8nM TGF-
β3/500nM HU308 and 8nM TGF-β3 showed accelerated wound closure, though 
percentage of fibronectin increase were only 9.2% and 3%, respectively, compared to 
control groups, thus indicating to a certain threshold for fibronectin expression that 
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could contribute to maximal migratory response, beyond that threshold reduced 
migration would occur. This was further supported by the 16% increase in levels of 
MMP-2 expressions following combination treatment with 8nM TGF-β3\500nM 
HU308 compared with controls resulting in enhanced rate of extracellular matrix 
breakage leading to a decrease in adhesion strength and thus  enhancing cell migration. 
Additionally, a similar increase of 13.3% in 500nMHU308 treatment cultures was also 
observed compared to control groups, emphasising the role and the distinct action of 
MMP-2 in extracellular matrix disintegration resulting enhanced assistance with cell 
movement and detachment for cell traction migratory mechanism. This further highlight 
the crucial role matrix metalloproteinase-2 (MMP-2) plays in bone volume formation 
(Inoue et al., 2006).  
There is evidence that MMP expressions is associated with the mediation of pro-
inflammatory cytokines such as IL-1 and TNF-α which are potent inducers of NF-kB 
(nuclear factor kappa-light-chain-enhancer of activated B cells) (Ben-David et al., 
2012). NF-kB activation results in growth arrest and cell-cycle arrest at G0/G1 (Mogi et 
al., 2004) and plays a key role in regulating the immune response to infection. 
Furthermore, NF-kB activation was found to be responsible for MMP-9 activation but 
not MMP-2 (Ben-David et al., 2012). Therefore, evidence shows that increases in pro-
inflammatory cytokines in osteoblast cell cultures do not seem to affect levels of MMP-
2 in culture (Ben-David et al., 2012), therefore it can be concluded that MMP-2 levels 
found in the current study does not necessarily mirror the inflammation response of 
osteoblasts as a result of wound initiation. However, they are treatment induced. 
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Research has shown that antioxidants inhibit NF-kB, although their exact mechanism of 
action is still not fully understood (Liang et al., 2009, Yagi et al., 2009). CB receptor 
agonists are also considered to act as antioxidants (Moldzio et al., 2012).  
 TGF-β in human body is always in the latent form, and in this form TGF-β is not 
recognized by the signalling receptors, hence, the term latency-associated protein (LAP) 
designates TGF-β as propeptide. In order for TGF-β to take effect, a family of large 
secretory glycoproteins known as latent TGF-β-binding proteins (LTBPs) covalently 
bind to LAP via disulfide bonds. LTBPs are not required for maintenance of TGF-β 
latency but may instead facilitate the secretion, storage, or activation of the TGF-β-LAP 
complex. However, different type of protease, matrix metalloproteinase-2 and -9, which 
are implicated in tumour invasion and angiogenesis as cell surface-bound proteases 
have also been shown to activate latent TGF-β’s (Yu and Stamenkovic, 2000, Walsh et 
al., 2011). This observation indicates that the increased expression of MMP-2 in 
cultures treated with HU308 and combinations of TGF-β3/HU308 may play a 
significant role in activating latent forms of transforming growth factor in vivo.    
S-100A6 (caleyclin), a small acidic calcium binding protein belonging to S-100 protein 
family is expressed in osteoblast cells (Seth et al., 2000). These S-100 binding motifs 
are involved in several regulatory functions that include protein phosphorylation such as 
the activation of enzymes, that regulate the dynamics of the cytoskeleton, various 
transcription factors, cell proliferation, differentiation and Ca2+ homeostasis in the 
skeletal system. Furthermore, Calcyclin is also expressed in epithelial cells and 
fibroblast (Stulik et al., 2000), therefore, it is important to understand its roles in bone 
physiology that are still remain to be fully understood.       
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It was clearly indicated in the present study that treatments with synthetic cannabinoid 
HU308 had a positive effect in a dose-dependent manner on protein S-100A6 levels 
compared to control groups. It was also noted that treatments with higher concentration 
increased expression of S-100A6 compared to control groups by 15%. In contrast, TGF-
β3 and TGF-β3/HU308 combination induced slightly lower increases in S-100A6 
expression in the order of 12.3% and 9.5%, respectively, compared to control treated 
cells. In general, this increase in S-100A6 expression in osteoblast is generally 
associated with the differentiation phase (Hwang et al., 2004), however, for MG-63 
osteoblast bone cells to achieve maximum wound closure rates bone cells should be in 
proliferative and migratory states, therefore if cells start to differentiate into mature 
bone cells with the onset of mineralization, cells would be entrapped inside their own 
extracellular matrix resulting in the suppression of the wound closure response. 
Interestingly this may explain why treatments of MG63 cells with synthetic 
cannabinoids HU308 at higher concentrations decreased wound repair because it may 
have induced progression towards differentiation rather than proliferation and 
Migration. If this is the case, it could indicate the possible use of higher concentration of 
synthetic cannabinoid HU308 for the inhibition of tumour migration and invasion. 
Other proteins probably also play a role. Annexins, a family of proteins present in 
mammalian tissue (AnxAs) are specific markers of chondrocyte hypertrophy; 
significantly increase during progression of osteoarthritis (Mollenhauer et al., 1999) and 
mineralize the ECM. Correspondingly they have been shown to interact with 
homodimeric S100A and S100B proteins (Goossens et al., 1995). The increase of [Ca2+] 
by oscillating fluid flow in osteoblasts was attenuated by the addition of anti-AnxA5 
antibodies, therefore, suggesting that AnxA5 may be involved in the mechano-
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transduction in bone cells leading to terminal differentiation. Homodimeric S100A and 
S100B proteins are shown to interact with AnxA5 and AnxA6, therefore accentuating 
the role of protein S-100(A&B) subunits in the regulation of osteoblast differentiation 
(Balcerzak et al., 2003). 
There is a large body of evidence that NO is involved in several inflammatory disorders, 
and almost all mammalian cells have various immunological parameters that are 
modulated by nitric oxide, despite their paradoxical effects that have shown to be either 
pro-inflammatory (immunostimulatory, anti-apoptotic) or anti-inflammatory 
(immunosuppressive, pro-apoptotic) in various situations (Cirino et al., 2006, Moncada 
et al., 1991). Therefore, it was important to characterize the nitric oxide response on 
MG-63 wounded osteoblast monolayers and to invistigate further showing the effects of 
different treatments with HU308 and TGF-β3. 
It was shown throughout 30hours that different treatments influenced NO levels in 
culture. Treatment with 500nMHU308, TGF-β3 and their combination HU308/TGF-β3 
induced the highest nitric oxide expression at hours 15-20 with optical density values of 
0.94±0.0021, 0.903±0.007, 0.91±0.0095, respectively, and with a percentage increase 
24.4%, 19.3%, 19.6%, respectively, compared to control treated cells after 15 hours. 
However cells treated with higher concentrations of HU308 had significantly lower 
optical density values (P<0.05) at 15 hours compared to other treatment groups 
excluding control cultures. Interestingly, the wound closure experiments (Chapter 3) 
showed that treatment with 500nMHU308, TGF-β3 and their combination HU308/TGF-
β3 increased wound closure more than any other treatment, especially after 15-20 hours 
with a significantly increased proliferation rate. This may be linked to increased nitric 
oxide production in the osteoblast cells resulting in increased proliferation. This is in 
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agreement with evidence that indicated nitric oxide synthases (NOS) inhibitor (NMMA) 
induced a dose-dependent inhibitory effect on the proliferation of the osteoblast-like cell 
lines MG-63 (Riancho et al., 1995). Therefore nitric oxide expression levels in the 
present study due to treatments with either synthetic cannabinoid HU308 and/or TGF-
β3 might have contributed to increasing MG-63 osteoblast cell proliferation in a dose-
dependent manner according to the type of treatment. 
Furthermore, it was clearly indicated that the expression of nitric oxide levels in both 
control groups and higher concentration 2μMHU308 treatment groups, were lower than 
those in cells treated with 500nMHU308, TGF-β3 and HU308/TGF-β3 throughout 25 
hours. This could be due to the fact that proliferation levels in control groups was 
significantly lower than those of 2μMHU308 thus the density of the cells expressing 
NO in control groups was minimal. In contrast, groups treated with higher 
concentrations of 2μMHU308 showed the same decreased levels due to the nature of 
CB2 selective synthetic cannabinoids, being known as anti-inflammatories and being 
mainly responsive to pro-inflammatory mediators such as nitric oxide (HOF, 2001). On 
the other hand, groups with lower concentrations of 500nM HU308 showed increased 
levels of NO, especially around 15-20 hours and this discrepancy might indicate a 
cannabinoid concentration dependant regulatory factor controlling expression of nitric 
oxide levels in MG-63 osteoblast cells. Similar  increased levels of nitric oxide was also 
reported in groups treated with TGF-β3 and its combination TGF-β3/HU308, which was 
in contradiction with a recent study that indicated that TGF-β1 is a negative regulator of 
nitric oxide production stimulated by IL-1β, TNF-α and IFN-γ (Park et al., 2009). This 
contradiction may be due to the difference in the cell lines used in the study or the 
difference in the transforming growth factor isoform used in the current study.  
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It can be concluded that despite the anti-inflammatory nature of synthetic CB2 receptor 
agonist HU308, it might be responsible in the regulation of osteoblast proliferation rates 
and nitric oxide expression levels being dependent on treatment concentration. Overall, 
the present finding indicates that NO levels after 30 hours was the highest in control 
groups indicating that treatment with TGF-β3 and HU308 played a role in the long term 
reduction of NO and/or that after 30 hours accelerated wound closure seen in treatment 
cultures maximized the probability of contact inhibition further leading to a decrease in 
cell proliferation, as a result reducing levels of nitric oxide expressed by the cell 
population. 
4.7 Chapter summery  
Overall, it was found in the present chapter that TGF-β3 treatment groups have induced 
collagen type I significantly compared to treatments with HU308, further establishing 
the role of TGF-β3 in enhancing osteoblast cell maturation leading to mineralization. It 
was also found that fibronectin plays a significant role in the current study in regulating 
osteoblast cell adhesion as a result cell migration was identified, and that cell with 
higher concentration of HU308 had shown increased levels of fibronectin indicating to 
induced attachment, this was in close relation with MMP-2 which was induced with 
higher concentration HU308 confirming literature findings. This further showed that 
synthetic CB2 receptor agonists can be used in a concentration dependent manner in 
reducing tumour spreading in cancer cells. In addition, it was also found that Nitric 
oxide (NO) plays a significant role in increasing MG-63 osteoblast cell numbers which 
was in partial agreement with the literature. 
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Chapter V 
Multilayer models of MG-63 osteoblast cells and the effects of 
HU308, TGF-β3 and their combination on ECM regulation 
 
5.1 Introduction 
Monolayer culture has played a key role in the field of bone and cartilage physiology as 
well as in other fields of cellular biology. Osteogenic and chondrogenic cells have been 
extensively investigated using the traditional 2D culture systems and many researchers 
have employed monolayer cultures to investigate cellular differentiation and 
extracellular matrix (ECM) deposition (Tortelli and Cancedda, 2009). Although these 
traditional cultures can be still useful to investigate the molecular mechanisms 
regulating cell differentiation, it is now evident that this approach cannot be used to 
faithfully mimic bone and cartilage. Indeed, the complex organization between cells and 
ECM is strictly dependent on the three-dimensional environment in which they are 
organized. 
Various techniques have been adopted in the last two decades in order to establish a 3D 
model of osteoblast cells; this is because a 3D model more closely mimics the in-vivo 
environment. Capturing and investigating the complexity of bone and cartilage in three-
dimensional cultures using in-vitro models remains one of the most important 
challenges in the field of tissue engineering. Indeed, the development and the 
optimization of novel culture systems may be necessary to face the next questions of 
bone and cartilage biology. To do this the models should faithfully mimic these tissues, 
resembling their organization, mechanical properties and physiological response to 
different stimuli. 
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Tissue engineering is the process of creating functional three-dimensional tissues using 
cells combined with scaffolds or devices that facilitate cell growth, organization and 
differentiation. The development of models based on the integration between cells and 
biomaterials could help to better understand the basic mechanisms of bone physiology.  
In the present investigation a new approach has been adapted in order to facilitate 3D or 
a pseudo-3D osteoblast model using MG-63 osteoblast bone cells. The temperature-
responsive polymer, poly(N-isopropyl-acrylamide) (PIPAAm) possesses a lower critical 
solution temperature (LCST) at 32°C in water. Below the LCST, PIPAAm is fully 
hydrated and soluble, but collapses extensively and becomes insoluble in the solution 
above the LCST. This unique feature of PIPAAm has been exploited in current tissue 
engineering approaches. More recently a polymer gel was grafted onto cell culture 
dishes using electron beam (EB) irradiation thus enabling temperature-dependent cell 
adhesion/detachment control to be achieved (Okano et al., 1995), thus enabling the 
development of a temperature-responsive culture dish to allow cell adhesion and 
detachment without the need for trypsinization which could potentially enable the 
production of engineered tissue sheets for use in tissue engineering and regenerative 
medical applications (Yamato, 2007). These EB culture dishes allow cell adhesion and 
cell detachment according to environmental temperatures. At cell culture tempratures 
37°C PIPAAm chains on the surface of the dish begins to dehydrate therefore resulting 
in a hydrophobic surface which is acceptable for different cell cultures to adhere and 
spread (Akiyama et al., 2004). However, by reducing ambiant temperature to 20°C 
PIPAAm chains on the surface of TCPS becomes hydrated and the surface becomes 
hydrophilic, as a result cells shrink due to their cytoskeletal reorganization and detach 
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from PIPAAm-TCPS spontaneously. Figure 5.1 shows a schematic illustration of cell 
sheet on poly (N-isopropyl-acrylamide) (PIPAAm) modified surface.   
 
 
 
Figure 51 (a) At 37 °C, cells adhere on dehydrated PIPAAm layer; (b) At 20 °C, cells 
detach from hydrated PIPAAm layer, and form an intact cell sheet. 
 
Interestingly, a recent study adopted a similar technique in seeding cell patches 
retrieved from the thermo-responsive poly (N-isopropylacrylamide) surfaces, which 
aided in the regeneration of in-vitro tissue constructs. In their method they  avoided 
using trypsin and were able to use patch transfer to build up multilayered 3D tissues 
(Kumar et al., 2007). Such systems can be used to examine treatment effectiveness in 
3D models as evidenced by recent work undertaken with bioengineering chondrocyte 
sheets used for cartilage regeneration (Mitani et al., 2009).  
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5.2 Aims and Objectives 
In the previous chapter the effects of treatment with HU308 and TGF-β3 and their 
combination on MG-63 osteoblast 2D monolayers were examined, and quantitative 
staining was carried out to ascertain the impact of these treatments on extracellular 
matrix expressions.  
In this work, MG-63 3D models would be created with the use of UpCell (PIPAAm) 
modified surface petri dishes, and validation tests will be carried out on morphology 
and other cell tissue properties.  
Therefore, the aim of this chapter to examine the effect of treatment with HU308 and 
TGF-β3 and their combination on MG-63 osteoblast in a multilayer culture system in 
relation to collagen type I, fibronectin and protein S-100A6 regulation.                 
5.3 Materials and methods 
5.3.1 Creation of 3D Bone Cultured tissue: 
Cell Seeding into UpCell Temperature Responsive Culture Dish 
Fully confluent MG63 bone cell cultures were trypsinized and detached from culture 
flasks using protocols described earlier in chapters (2 and 3). The resulting cell pellet 
was resuspended in 8ml of media. The UpCell culture dishes as well as normal TCP 
culture dishes of 3.5cm diameter were seeded with 0.5ml cell suspension, followed by 
the addition of 2.5ml of complete culture medium. Under regular change of culture 
medium and overnight incubation the dishes were grown to confluency. As the UpCell 
culture dishes have temperature dependent surface response, the culture medium and 
washing solution had to be pre-warmed to 37°C to avoid detachment of the cells, and 
the processes of medium changing was accomplished as fast as possible.  
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Transferring cell sheet to create a 3D model: 
On the fourth day confluency was reached in each petri-dish. Cell sheets were 
transferred on top of the confluent cell layer in the regular culture TCP dish. This was 
achieved in several steps. Firstly, a single temperature responsive dish was taken out 
from the incubator and the entire medium was discarded. The culture was rinsed twice 
with 1ml of HBSS and a single drop of HBSS was left inside the dish to assist in the 
adhesion of the transfer membrane (supplied by the manufacturer) that was put onto the 
cell sheet. The dish was left for 50 minutes at room temperature allowing the cells to 
detach from the dish, creating a cell sheet that attached to the membrane. The cell sheet 
was detached from the wall of the dish by carefully scratching around the wall of the 
culture dish with a pair of tweezers. The next UpCell culture dish was taken from the 
incubator, the media was drained and the culture was rinsed twice before the first 
UpCell cell sheet was transferred into the second dish. Again after 50 minutes of 
incubation at room temperature, cells detached from the bottom of the second UpCell 
culture dish and cell sheets were left adhered to each other. Both layers were then lifted 
and transferred into the last culture dish and 30 minutes later a drop of media was added 
to aid with the removal of the membrane and the membrane was carefully removed 
forming three layers of MG-63 osteoblast cells. Upon membrane removal 3ml of 
medium was added to this culture dish and the 3D tissue was placed into the incubator. 
Figure 5.2 shows the process of transferring a cell sheet into another culture dish. 
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Figure 5.2 Images of cell sheet detachment and transfer for UpCell culture dishes 
 
    
5.3.2 Data Acquisition 
Cells were imaged using an inverted phase contrast microscope (Optika, XDS-2) 
University of Bradford, and images were taken every 12 hours throughout a period of 
72 hours starting at hour 12. For each image 20 cells were chosen and their 
circumferences were calculated using Image J software, means were calculated (mean 
±SD) for each time interval and were compared with 2D MG-63 osteoblast monolayer 
cell cultures at 0 minute up to 72 hours, to investigate any cell morphology changes. 
 
5.3.3 Elisa based method for detection of collagen type I, fibronectin and 
S-100A6 for 3D multilayer osteoblast tissues 
 
Three layers of MG-63 osteoblast cells were cultured in a six-well culture plate after 
being adhered together using UpCell culture dishes. Osteoblast cells were incubated 
either under control conditions (no treatment) or with either treatments of 
500nMHU308, 2μMHU308, 8nM TGF-β3 or combination of 8nM TGF-β3/500nM 
HU308. After 72 hour period cells were stained for collagen type I, fibronectin and S-
100A6.  Media was used to rinse the multi-layered tissue, after which cells and proteins 
were fixed with 4% formaldehyde for 6 minutes.  Cells were washed again in PBS and 
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any endogenous peroxide was quenched using 3% hydrogen peroxide for 5 minutes.  
Following another wash, 1% BSA in PBS was added for 15 minutes to prevent non-
specific binding.  Cells were incubated with primary antibody i.e. mouse anti-collagen 
type I, mouse anti-fibronectin and mouse anti-S-100A6 diluted in 1% BSA/HBSS with 
ratios of 1:500, 1:100 and 1:1000, respectively.  For negative controls, the primary 
antibody incubation was replaced with a 1% BSA/HSBSS incubation.  Following one 
hour, wells were rinsed and the secondary antibody anti-mouse IgG peroxidise 
conjugate (8μg/ml) was added for a further 30 minutes at room temperature. 
Tetramethylbenzidine (TMB) substrate was added and absorbance readings were taken 
at 630nm after 10 minutes.  This experiment was repeated three times.  Absorbance 
readings for control and test groups were corrected by subtracting the negative control. 
5.4 Statistical analysis    
The statistics package SPSS (IBM) was used to carry out statistical analysis.  Following 
tests for normality, the One-way Anova, followed by the Bonferroni post-hoc test, was 
used to compare more than 2 groups.  The non-parametric Kruskal-Wallis test was used 
if data was not normally distributed.  For comparisons between 2 groups, an unpaired T-
Test and for the non-parametric equivalent, the Mann-Whitney U tests were used.  
Significant differences were taken as *p<0.05, **p<0.01 and ***p<0.001.   
5.5 Results and brief discussion 
5.5.1 Monolayer and multilayer quantifications 
Images obtained from MG-63 osteoblast 3D model (Figure 5.3) suggested clearly a 
change in morphology soon after 12 hours post layer adhesion; cells started to round up 
as compared to elongated cells for 2D monolayers. 
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The changes in cell morphology were recorded every 12 hours starting from hour 12 up 
to 72 hours. Measurements of the surface area of 20 cells were made from each frame at 
a distinct point using Image J software. The recorded measurements from the 3D culture 
were compared with confluent 2D monolayers before cell sheet transfer and after 72 
hours. Images of 2D monolayers and 3D multilayers (Figure 5.3) showed different 
morphology. The cells in the 2D monolayer developed an elongated (and spread) 
morphology with a reduction of cell surface area from 634μm2±16.3SD to 
378μm2±12.65SD after 72 hours. Conversely, the cells in the 3D multilayers were much 
rounded in shape and had a smaller cell surface area (Figure 5.4), and thus cell surface 
area was reduced as the morphology of the cells changed over time. After 72 hours the 
mean surface area of 3D osteoblast cell multilayers had decreased to 168.63 
μm2±5.22SD (P<0.001) compared to 2D monolayer cultures at 378μm2±12.65SD, as 
can be seen clearly in (figure 5.4). 
In order to quantify the dramatic change in MG-63 cell morphology, surface area of the 
cells in the 2D monolayer before sheet transfer were normalized to 100% cell size. It 
seemed that the percentage of the visible surface area of the cells in the 3D multilayer 
reduced dramatically from 100% to 35%±6.12 after 12 hours in the 3D environment. 
This reduction continued such that the surface area decreased to 35.2%±3.24, 
31.4%±5.65, 29.1%±3.42, 28%±2.54 and 27%±4.87 of the original plating surface area 
after 24 hours, 36 hours, 48 hours, 60 hours and 72 hours, respectively. In comparison, 
cell surface area decreased in the 2D environment by only 40% after 72 hours.  
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Time 
(hours) 
MG-63 osteoblast  multilayer model 
Time 
(hours) 
2D monolayer MG-63 osteoblasts 
12hrs 
 
0 hrs 
 
24hrs 
 
72hrs 
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60hrs 
 
  
72hrs 
 
  
Figure5.3  3D cultures of MG-63 osteoblast cells throughout 72 hours (left), 2D 
monolayer cultures at 0 min and 72 hours (right) (scale bar =100μM)  
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Figure 5.4 Reduction of mean cell surface area of MG-63 osteoblast in monolayer 
and multilayer cultured environments. Standard error bars are shown.   
 
        
More interestingly, images from the 3D model of MG-63 osteoblast cells (Figure 5.5) 
clearly indicated a calcified, pseudo-mineralized region or nodules which may have 
been an early indication of osteoblast maturation and differentiation into osteocytic 
phenotype. 
 
Figure 5.5 Multilayer cultured MG-63 osteoblast cells showing nodule formation 
(scale bar =100μM)    
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5.5.2 ELISA based method for detection of collagen type I, fibernectin 
and protien S-100A6: 
Mature osteoblasts secrete bone extracellular matrix containing proteins such as 
collagen type I, fibronectin and S-100A6 and provide an environment that promotes 
osteoblast mineralisation. MG-63 osteoblast pseudo-3D models were treated with either 
HU308 at concentrations of 500nM and 2μM. The 3D cultures were also treated with 
8nM TGF-β3 and combinations of 8nM TGF-β3/500nM HU308. Following 72 hours 
incubation, collagen type I expression following TGF-β3 and TGF-β3/HU308 treatment 
increased significantly by 36% and 33%, respectively (Figure 5.6), compared to control 
groups. On the other hand, the increase in collagen type I for cultures treated with 
HU308 was only 1.5% and 6% for concentrations of 500nM and 2μM, respectively. It 
can be said that significance in collagen type I synthesis was induced in treatments that 
involved treatments with TGF-β3 (P<0.05) (N=9). 
Assessment of fibronectin differed from that of collagen type I after different treatments 
with HU308 and TGF-β3.  It was found that 2μM HU308 induced a 43.5% increase in 
fibronectin expression in comparison to control cultures. This 2μM HU308 induced 
increase in fibronectin expression was similar to the increase in fibronection expressions 
after treatment of 3D cultures with TGF-β3 (OD= 0.89±0.0056, OD=0.86±0.0076 for 
2μM HU308 and TGF-β3, respectively).      
Interestingly, fibronectin expression in 3D cultures treated with 500nMHU308 
increased only by 16% compared to control groups, whereas 3D cultures treated with 
combination of 500nMHU308/8nMTGF-β3 showed a 30% increase in fibronectin 
expression (Figure 5.7).  
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Figure5.6 Optical density readings (630nm) following immunoperoxidase 
staining of deposited collagen type I. Standard error bars are shown, 
N=9. Standard error bars are shown. 
 
 
Figure5.7 Optical density readings (630nm) following immunoperoxidase staining of 
deposited fibronectin. Standard error bars are shown, N=9. Standard error bars are 
shown. 
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Quantification of S-100A6 expressions revealed that treatment with TGF-β3 induced a 
19% increase in this expression compared with control groups, whereas treatments with 
HU308 at concentration of 500nM and its combination HU308/TGF-β3 only increased 
protein S-100A6 to 7 % and 14%, respectively (Figure 5.8). However, treatments with 
HU308 at higher concentrations induced an increase in S-100A6 expression of 15% 
compared to control cultures.  
 
Figure5.8 Optical density readings (630nm) following immunoperoxidase staining of 
deposited protein S-100A6. Standard error bars are shown, N=9. Standard error bars 
are shown. 
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5.6 Discussion & conclusion    
The development of an in vitro model of bone cells or tissue should help in 
understanding the physiology and complexity of bone tissue. These systems could also 
be used in order to test novel drugs that can help with bone metabolism and turnover, 
thus limiting the use of animal models whilst also limiting research cost. An ideal bone 
model should exhibit the main features of the native bone, such as the peculiar 
mechanical and physical properties of the tissue, and should contain various cell types 
involved in the maintenance of healthy bone. Initially, it was important to quantify and 
validate the obtained multilayer system by identification of morphological changes. 
Studies have shown that 2D monolayer osteoblast cells have a flat morphology, and 
once activated in-vivo for differentiation and osteoid formation they become cuboidal 
shaped osteoblasts (Jähn et al., 2010). From this work, it was found that measurements 
of MG-63 osteoblast cells revealed that cell surface area was significantly decreased 
(P<0.05) in 3D culture. This was in agreement with another study that showed immature 
MC3T3-E1 osteoblast cells having a more flat surface then mature MLO-Y4 osteocyte-
like cells (Xu et al., 2012). Additionally, it was shown in this work that all treatment 
groups increased collagen type I expression. Also, 3D cultures treated with TGF-β3 had 
significantly increased level of collagen type I expressions with absorbance readings of 
OD=0.87±0.025 compared with control groups of OD=0.64±0.062. On the other hand, 
treatment of 3D cultures with a combination of TGF-β3/HU308 induced a non-
significant decrease in levels of collagen type I expressions compared to TGF-β3 treated 
cultures. This indicated that treatments with transforming growth factor-β3 combined 
with synthetic cannabinoid (HU308) did not seem to influence expression of collagen 
type I. TGF-β3 had shown to accelerate osteoblast cell maturation and cell 
mineralization because collagen synthesis is considered one of the major milestone 
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regulators in a differentiated osteoblast (Mueller et al., 1999). Nevertheless, collagen 
type I expression with treatments of HU308 with both 500nM and 2μM concentrations 
showed similar expressions as those of control (no treatment).  This contrast also 
reported in chapter 4 for 2-dimenisnal models, clearly suggests that collagen type I 
expression was dependent on HU308 concentration; this observation might indicate that 
mineralizing proteins might have been up-regulated dependent on the multilayer culture 
phase. Another explanation could be due to the low concentration of HU308 with 
limited affinity on multilayer culture, indicating a need for a higher concentration.  
There is evidence that addition of transforming growth factor beta to monolayer cultures 
of adult human osteoblasts induces the formation of 3D structures, inducing 
mineralization progression (Ferrera et al., 2002).    
ECM components most likely fibronectin (FN) are important in regulation and survival 
of osteoblasts (Meredith and Schwartz, 1997), furthermore FN is a heterodimeric ECM 
glycoprotein which has been shown to regulate adhesion, migration and differentiation 
of various mesenchymal cells (Yamada et al., 1992). It was also shown by various 
studies that addition of immature cells of function-perturbing antibodies against FN or 
FN integrin receptors, suppresses the formation of mineralized nodules and expression 
of genes characteristic of mature osteoblasts (Moursi et al., 1996). Moreover, it was also 
suggested that TGF-β and FN together protect osteoblasts from apoptosis in vitro 
(Moursi et al., 1996). Interestingly, fibronectin expression due to addition of TGF-β3 
and its combination with synthetic cannabinoid (HU308/TGF-β3) markedly increased 
by 37% and 30.6%, respectively, compared to control multilayer cultures. Therefore, it 
can be concluded that treatments with TGF-β3 and their combinations with synthetic 
cannabinoid (HU308) as well as higher concentrations of HU308 may have an 
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important yet positive effect on osteoblast differentiation, and that synthetic 
cannabinoid HU308 has a dose dependent effect on fibronectin expression in 3D 
models.   
However, in the present 3D model it cannot be concluded that MG-63 osteoblast cells 
are undergoing differentiation to osteocytes, this is because early markers of 
differentiated osteocyte include reduced expression of collagen type I. In the 
experiments described in this chapter collagen type I expressions was not reduced. 
However, this may be due to the fact that osteocyte markers usually appear after day 7 
of post 3D culture (Boukhechba et al., 2009). There is evidence that increases in 
collagen type I expression is usually observed in the matrix maturation stage before the 
onset of mineralization and terminal maturation (Owen et al., 1990). This finding is 
further supported by results obtained (Boukhechba et al., 2009) where two mouse cell 
lines were examined, with mature MLO-Y4 osteoblast cells and immature MLO-A5 
cells corresponding to immature cells. The authors of this study found that immature 
MLO-A5 cells expressed a lower level of bone sialoprotein (OPN) and higher levels of 
alkaline phosphatase (ALP) and collagen type I compared with the terminally matured 
osteoblast cell line MLO-Y4. It has also been reported that cell death could be initiated 
by a lack of sufficient nutrient flux (Ferrera et al., 2002). To be noted is that in this 
study the 3D cultured cells were only cultured for three days to maximize cell survival.       
A number of studies have suggested that activation of CB2 receptors is more effective 
in mature osteoblastic cells as a result of increased mRNA expression. It has been 
shown that in mature osteoblastic MC3T3-E1 cells, CB2 receptor stimulation by HU308 
up-regulated oateoblast-differentiated functions such as alkaline phosphatase activity 
and exctracellular matrix mineralization (Bab and Zimmer, 2008). In contrast, CB2 
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activation has an opposite effect on osteoclastogenesis, as it inhibits osteoclast 
differentiation (Bab, 2005).           
Calcyclin (S100A6) is a protein that is inducible on differentiation of neuroblastoma 
cells; it was also thought to be a calcium dependent Switch (Seth et al., 2000), and 
seemed to be markedly up-regulated during MC3T3-E1 osteoblast differentiation 
(Hwang et al., 2004). Elisa based staining of S-100A6 protein, revealed in this work that 
MG-63 osteoblast cells treated with TGF-β3 as well as 2μMHU308 had similar protein 
S-100A6 expressions yet significantly higher (p<0.05) than HU308 treatment of 500nM 
concentration and control (no treatment) groups. In contrast, S-100A6 levels in 
combination groups 500nMHU308/8nMTGF-β3 increased by 14% compared to control 
and this results indicates that TGF-β3 and higher concentrations of HU308 treatments 
has a significant (p>0.05) impact on a marker for osteoblast differentiation and thus 
could be used to promote and accelerate bone mineralization in-vitro.  
There is also evidence that show osteosarcoma osteoblast cells experience increase in 
osteoblast adhesion and inhibition of cell invasion is dependent on protein S-100A6 up-
regulation (Luo et al., 2008), therefore identifying the useful role of higher 
concentration cannabinoid (CB2 agonists) in cancer cell metastases treatments.     
This is consistent with studies that have confirmed that transforming growth factors 
modulate osteoblastic differentiation both in-vivo and in-vitro (Chen et al., 2012). Also, 
to be noted is that osteoblast-like cell line MC3T3-E1 from new born mouse calvaria, 
undergoes several and temporal changes throughout differentiation, first few days are 
characterized by the replication of pre-osteoblasts, then followed by a period of growth 
arrest and the expression of mature osteoblastic characteristics such as matrix 
maturation, ending with stages of matrix mineralization (Seth et al., 2000). It is also 
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known that TGF-β is one of the most potent stimulators of the production of 
extracellular matrix in various types of cells including osteoblasts and the most 
pronounced effect of TGF-β in bone is the stimulation of matrix protein synthesis 
including type I collagen, proteoglycans, and fibronectin. However, evidence shows that 
the actions of TGF-β in inducing osteoblast differentiation are suppressed during the 
transition phase from matrix formation to matrix mineralization. Authors also relate this 
phenomenon to collagen matrix accumulation which enhances the differentiation of 
osteoblastic cells and suppresses the actions of TGF-β by reducing the sensitivity of 
TGF-β receptors (Takeuchi et al., 1996). Thus it can be concluded that even though 
TGF-β regulates osteoblast differentiation, it has a feedback mechanism by which it 
controls its effects on cells such as proliferation, migration and cell differentiation.   
5.7 Chapter summery    
Overall, it was found in the current chapter that using UpCell culture dishes, MG-63 
osteoblast multilayer models were established, this was evident from cell surface size 
reduction throughout 72 hours. It was also found that multilayer cells treated with 
combinations of HU308/TGF-β3 increased collagen type I expression due to the 
presence of TGF-β3 and not due to HU308, it was also found that HU308 treatments on 
MG-63 multilayer models would require higher concentration treatments to induce 
significant effects. Furthermore, TGF-β3 and HU308/TGF-β3 combination have shown 
to increase MG-63 osteoblast cell differentiation indicated by the induced expression of 
protein S-100A6. Also it was found that higher concentration of HU308 has increased 
fibronectin expression in agreement with monolayer findings for the same treatment.    
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Chapter VI 
6 Overall Conclusion 
The aims of this thesis were to address the following null hypothesis: 
That CB1 and CB2 receptor agonists and their combination with TGF-β3 had no effect 
on cell replication, model wound closure, cell migration, cell attachment and ECM 
matrix protein secretion. 
However, there was significant differences between control treated cells and 
intervention treated cells (P<0.05), therefore accepting the alternative hypothesis which 
indicates that agonist stimulation for CB1 and CB2 receptors and their combination 
with TGF-β3 facilitate wound healing acceleration by enhancing the speed of migration 
and proliferation of MG-63 osteoblast cells, in relation to their effect on different 
modulators.  These cellular responses are mediated via the up-regulation or down 
regulation of matrix metalloproteinase, collagen type I, fibronectin, protien S-100A6 
and nitric oxide synthesis.   
  
The hypothesis also states that optimum concentration of CB2 receptor agonists and 
their combination with TGF-β3 differ in their effects on cellular response to protein 
deposition.  It is expected that TGF-β3 combination with HU308 will increase the ECM 
expression relative to HU308 culture treated cells, therefore enhancing cell migration 
and accelerating wound repair.           
6.1.1 Specific aims were as follows:  
1. To study the behaviour of cultured osteoblasts (MG-63) cells in response to treatment 
with non-selective (CB1 and CB2 agonist) synthetic cannabinoid Winn55,212-2 and 
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define which receptor (CB1 or CB2) contributes the most in the process of wound 
healing.   
2. Upon identifying which receptor mainly contributes to the process of wound healing, 
selective receptors were investigated either by up-regulation of the specific CB1 agonist 
(2-AG) or by treatment with CB2 specific agonist. 
3. Investigate selective CB2 receptor agonists in combination with TGF-β3 and 
evaluating their relative and joint effects on the process of wound healing.  
4. Study how different treatments with HU308, TGF-β3 and HU308/TGF-β3 
combination influenced cell proliferation and collective migration via cell detachment 
and adhesion.    
5. To qualitatively and quantitatively assess the expression of collagen type I, 
fibronectin and S-100A6 to determine optimal treatments with CB2 specific agonist 
HU308 and its combinations with TGF-β3 isoforms.   
6. To qualitatively determine how CB2 specific agonist HU308 and its combination 
with TGF-β3 influence matrix metalloproteinase (MMP-2) and nitric oxide (NO) 
secretion. 
7. To establish a 3D in-vitro osteoblast model and investigate how treatment with 
HU308 alone and in combination with TGf-β3 influence collagen type I, fibronectin and 
protein S-100A6 expressions in a 3D environment. 
6.1.2 Research output (Findings): 
The experiments performed during this study showed that synthetic cannabinoids 
enhance the wound closure response in osteoblast monolayer wound model. It was 
found in all experiments that treatment with synthetic cannabinoids accelerated wound 
healing starting from hour 15 compared with control treated cells with lower healing 
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rates and without complete wound closure. The fastest wound closure response was 
achieved following treatment with HU308 synthetic cannabinoid at concentration of 
500nM. This was closely followed by treatment with the non-selective cannabinoid 
receptor agonist WINN55,212-2 and URB602 in descending order with relatively small 
differences (p<0.05). However, combination of TGF-β3 with HU308 synthetic 
cannabinoid seemed to induce a better oesteogenic response in terms of optimum cell 
proliferation, cell detachment (enhanced migration) and wound closure in MG-63 
osteoblast cell monolayers.  
 
Concentrations of 500nM, 1μM and 2μM cannabinoid receptor (Winn55,212-2 and 
HU308) agonists were found to influence MG-63 osteoblast cell wound closure in a 
dose-dependent manner. These concentrations also influenced cell proliferation and cell 
migration in agreement with other findings that suggested higher concentration of 
cannabinoids  enters cells into growth arrest (Guzman et al., 2002). Carrier groups of 
0.1% ethanol also increased osteoblast wound healing but at a significantly lower rate 
(p=0.179 at 15 hours) than cells treated with HU308 at optimum concentration of 
500nM. The apparent effect associated with the carrier control could be attributed to the 
decrease of pH medium and there is evidence that pH has some effect on wound healing 
of human fibroblast wounded monolayers cultured at increasing pH values ranging from 
7.2 to 8.4 with induced significant decrease in fibroblast cell migration in wounded 
models alongside a decrease in DNA synthesis (Lengheden and Jansson, 1995). 
Therefore, treatments with 0.1% ethanol is expected to reduce pH (more acidic) hence 
inducing cell migration. The percentage decrease in cell surface area with 500nM and 
1μM HU308 treatment cultures via trypsin was similar to those of control and carrier 
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treatments. This finding indicates potentially that inhibition or activation of CB2 
receptor with concentrations as high as 1μM may have little or no effect on bone cell 
migration.    
Antagonist experiments for blocking cannabinoid receptors before treatment indicated 
that other signalling pathways may be involved downstream and may contribute to the 
action of selective agonists. This was identified through the blockage of CB2 receptors. 
It was found that despite of receptor antagonist action, the CB2 receptor agonist still had 
significant impact on wound closure response in comparison to control treated cells 
(p<0.05). Although signalling pathways have not been examined in the current study, it 
may be useful to identify the individual role of signalling pathways in accelerating bone 
wound healing. This was derived from previous evidence that showed HU308 and 
Winn55,212-2 may act on different yet unidentified subtypes of CB2 receptors (Hanus 
et al., 1999).  
The present study also identified the mechanisms of wound closure based on protein 
expressions and extensive literature comparison in relation to different contributing 
factors. 
It was found in this work that higher concentrations of synthetic cannabinoids, i.e. 
HU308 increased fibronectin expression and down regulated matrix metalloproteinase 
(MMP’s) therefore inducing enhanced cell attachment, further inhibiting cell migration 
response. These findings support the view that higher concentrations of CB2 agonists 
could be used therapeutically to reduce migration of cancerous cells (Blazquez et al., 
2008), whereas low concentrations of cannabinoids could be used therapeutically to 
enhance osteogenesis by either inducing cell proliferation or cell migration. 
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Although the function of the TGF-β family in various cell types has been investigated, 
their function in bone repair is as yet not fully understood and that TGF-β superfamily 
consists of various types of polypeptides such as BMP-2 and TGF-β1, 2 and 3, affecting 
up and down regulation of membrane proteins and consequently inducing cell adhesion, 
proliferation, differentiation, activation, migration and apoptosis (Krauss, 2004). 
Therefore, it is important to note that the interaction of cells (via membrane receptors) 
with ligands expressed by neighbouring cells and cell-cell signalling play an important 
role in cell proliferation in the present study. In fact, cell-cell communication can 
stimulate cell proliferation.  
Interestingly, the current study showed that MG-63 bone monolayers treated with TGF-
β3 demonstrated rapid decrease in wound width during 20-25hrs of wound healing. This 
may be related to TGF-β3 increasing the secretion of ECM molecules at the wound 
edge, which functions by capturing cells via the integrin ECM interactions at the wound 
edge, thus helping migration into the wound site. Also, TGF-β3 treatments induced the 
fastest detachment time from surface suggesting that TGF-β3 decreased cell surface 
attachment which in turn, helped cell migration into the wound site. Such a mechanism 
may be useful in therapeutic procedures by enabling the rapid filling of a wound site 
with large number of bone cells which would presumably enable the deposition of ECM 
proteins across the wound surface enabling cell migration and proliferation into the 
wound. TGF-β isomers have also been found to influence cell morphology and cell 
length. This could be linked to an up-regulation in the production of extracellular matrix 
proteins and extended collagen type-I fibres causing the cells to flatten and occupy a 
larger area which induces cells migration and consequently reduces cell proliferation. 
The trypsinization results (Chapter 3) suggested that TGF-β3 and combination with 
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HU308 do not stimulate bone-ECM protein adhesion. Bone cells cultured in medium 
with TGF-β3 supplementation separately displayed a faster rate of cell/surface 
detachment. There is evidence in the literature that many cell types take on a migratory 
phenotype during wound repair and this migratory phenotype can be associated with a 
change in the degree of cell surface attachment (FOPPIANO et al., 2007). However, no 
clinical research has yet been undertaken on TGF-β3 in combination with synthetic 
cannabinoid, thus this work provided an initial step in evaluating the effects of TGF-β3 
and TGF-β3/HU308 combination in relation to bone wound closure response in-vitro.  
The results of this work showed that in the case of combined TGF-β3 and synthetic CB2 
receptor agonist HU308 treated cells, the rate of wound closure was significantly higher 
(P<0.05) compared to the un-treated controls. This was also observed with both 
500nMHU308 and 8nMTGF-β3 individual treatment cultures which had the same 
significant and positive effects (P<0.05) compared to control and carrier treatments.  
In this study it was found that treatments of cells with HU308 at a concentration of 
500nM significantly reduced fibronectin (p<0.05) secretion compared to control groups 
(no treatment), indicating that HU308 at this concentration potentially decreased 
cell/surface attachment and thus enhanced cell migration.  It was also found that 
collagen type I and S-100A6 secretion was increased by different treatments with 
HU308, TGF-β3 and their combination and this may be an indication of osteoblast 
maturation and increased secretion of ECM proteins, as well as inducing the 
osteoblastic phenotype during wound healing. Cell proliferation has been shown in 
many studies to be involved with integrin/ECM protein interactions and the down 
regulation of collagen type I. Combination treatment with 8nMTGF-β3/500nMHU308 
induced higher levels of fibronectin expression and this could be due to the fact that 
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osteoblast/fibronectin bind via integrins including α3β1 and α5β1 was influenced by 
osteoblast proliferation, which also supports the finding in the present study that 
suggests TGF-β3 treatment groups increased the secretion of fibronectin and hence 
increased proliferation.        
Further investigation also indicated that increasing doses of the synthetic cannabinoid 
HU308 decreased matrix metalloproteinase-2 (MMP-2) expression indicating that lower 
concentrations of synthetic cannabinoid could be associated with higher MMP-2 
secretion and thus associated with higher cell migration rate in comparison to cells 
treated with higher concentrations of HU308. This study found presence of nitric oxide 
(NO) synthesis as a result of which, cell proliferation was influenced throughout 30 
hour treatment window. This effect on MG-63 osteoblast bone cell is in partial 
agreement with literature since there are discrepancies and paradoxical findings on 
nitric oxide effects on osteoblast cells, as some studies indicate that nitric oxide induces 
proliferation; others indicate a suppressive effect on osteoblast as indicated in literature.  
Lastly, evidence from the literature indicates that bone cells behave differently in a 3D 
environment and that the 3D culture systems in vitro mimic the in vivo situation more 
closely than the two-dimensional (2D) cultures (Trojani et al., 2005, Ferrera et al., 
2002). The experiments involving the 3D osteoblast culture model (chapter 5) indicated 
that treatment with TGF-β3 alone and in combination with HU308 initially induced 
osteoblast mineralization. ECM protein expression in the 3D model clearly indicated the 
efficacy of using treatments in combinations in order to promote osteogenesis and 
further confirmed monolayer findings (chapters 2 and 3). The results also indicated that 
TGF-β3 alone and in combination with HU308 promoted osteoblast cell differentiation 
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which could potentially be used in vivo to aid in the restoration of bone integrity in 
wounded sites. 
6.2 Future Work 
 At this point, it is important to acknowledge the limitations of this study as possible 
contributing factors to the differences seen between cannabinoid receptor agonists and 
TGF-β3 and their combination. For all experiments and comparing between all 
treatments, the differences in results could be due to the concentration of treatments 
used.  In order to standardise experiments and obtain optimal results and responses, 
each treatment was used at three concentrations except for TGF-β3 which had been 
identified elsewhere. However, this may not have been the optimal working 
concentration for this study.  In order to identify optimal working concentrations for 
each treatment, experiments should be carried out at a range of concentrations for each 
variable (e.g. wound closure and collagen type I expression) examined.  It would also be 
very useful to investigate the use of primary osteoblast cells, but acquiring primary cells 
is an expensive and lengthy process, furthermore primary cells have different 
characteristics at each passage. The work was also limited in the number of 
experimental repeats in the given time frame.  Using the MG-63 cell line was a 
convenient way in which to produce in vitro models.  The findings from our MG-63 
models provide an indication as to the differences between cannabinoid receptor agonist 
treatments and their combination with TGF-β3 on osteoblast behaviour during the 
process of osteoblast wound regeneration. It is suggested with evidence that MG-63 
osteosarcomic cells have indeed been identified as being a reprehensive model of 
osteoblast cell culture as also suggested by others (Clover and Gowen, 1994, Benayahu 
et al., 2002).               
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The overall findings in this work suggests clearly that addition of CB2 receptor agonists 
and their combination with transforming growth factor beta 3 had a positive effect on 
wound closure in a cell culture environment, whereas control did not have similar 
effects. These results obtained are important for validation of such responses and effects 
and these findings are in good agreement with different studies in literature, with some 
discrepancies which were also identified. Finally, this work is the first step in clinical 
research to evaluate the effect of selective and non-selective CB receptors agonists as 
well as the combination of CB2 selective agonist with TGF-β3 on relation to MG-63 
osteoblast monolayer wound closure.  
However, the results from individual experiments carried out in this work seem to have 
raised some critical questions and therefore there are several lines of future research 
arising from this thesis which should be pursued. 
It is important to fully develop a 3D culture system in which bone cells may be grown 
and in which a model wound could be generated with further in-depth study in the 
mineralization phase using a bioreactor-based approach. 
In the current thesis, TGF-β3 and HU308 combination was investigated in relation to 
wound healing and ECM protein secretion and effect in monolayer cultures. Other 
transforming growth factor isoforms such as TGF-β1and 2 may have different responses 
using manipulated forms with cannabinoid receptor agonists. 
In the present study wound the closure rates were influenced by the migration of cells 
away from the wound margins. This was seen to be following treatment with TGF-β3. 
Similar behaviours have been seen with the overexpression of Slug, a transcription 
factor known to be regulated by TGF-β (Choi et al., 2007).  It may therefore be useful to 
investigate whether the responses seen with TGF-β3 where in fact due to an 
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upregulation of Slug protein and if so, do TGF-β3 isoform differentially regulate Slug 
protein expression. 
The MG63 osteoblast-like cell lines used in this work were derived from osteosarcomas, 
which share certain important features of the osteoblast phenotype. However, it is not 
clear if all the characteristics of MG63 cells are identical to those of bone forming 
osteoblasts in the body. It is possible that MG63 cells have acquired gene mutations that 
make their responses dissimilar to bone cells in vivo. Thus repeat of experiments with 
primary bone cells would be very useful to confirm the findings of this thesis. 
Another important line of action for future work is the fact that the method of the initial 
scratching of the monolayer was non-uniform which could affect the healing rate of the 
MG63 bone cells. Uneven scratching due to human error could contribute to a variation 
in scratch width. A method of uniform scratching for both monolayers and 3D systems 
will therefore be very useful to allow for consistent results and reduced human error to 
allow for consistent results.     
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Effect of Different concentrations of (WIN55,212-2)  in Acceleration of 
MG-63 cell monolayer wound healing 
 
M. Genedy1.2, M. Youseffi1, F. Sefat1.2, A abdeldayem1.2 and M.C.T Denyer2 
1School of Engineering, Design & Technology, 2School of Life Sciences, University 
of Bradford, University of Bradford, BD7 1DP, UK 
 
Abstract 
 
Despite the ongoing political debate regarding the legality of medical marijuana, clinical 
investigations of the therapeutic use of cannabinoids are now more prevalent than at any 
time in history. Cannabinoids have been shown to have analgesic, anti-spasmodic, anti-
convulsant, anti-tremor, anti-psychotic, anti-inflammatory, anti-oxidant, anti-emetic and 
appetite-stimulant properties. There are two receptors well known CB1 and CB2 that 
contribute to the action of cannabinoids and endocannabinoids as they both represent a 
distinctive role in the mediation and regulation in cannabis response. The purpose of 
this investigation was to study the rate of wound healing using a simple scratch assay 
wound model created on osteoblastic MG63 cell-line monolayer and also to investigate 
proliferation and differentiation in the presence of cannbinoid WIN55, 212-2. A wound 
was made (with average scratch width of 300μm±10-30μm SD, 1.7-5μm SEM) on 
confluent monolayer of osteoblastic MG63 bone cells. After wounding, culture flasks 
were treated with a synthetic cannabinoid (WIN 55,212-2) with concentrations of 
0.0006g/mL and 0.0009g/mL and a non-treated control flask was used as reference. It 
was found that in the groups of treated culture flasks aggregations of cells started to 
appear with a slight decrease in the inflammatory response prevalent according to the 
visualization of the number of dead cells on the wound edges and wound bed leading to 
a faster healing rate, thus it was proven that (WIN55,212-2) has a potential advantage in 
wound closure healing rate with an overall future potential in the field of bone tissue 
Engineering.     
 
Keywords: 
MG63 Bone cell monolayer,synthetic cannabinoid (WIN 55,212-2), scratch assay 
wound model. 
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The Effect of Different Concentrations of (R)-(+)-WIN 55,212-2 on 
Wound Healing of Chondrocytes Monolayer 
 
Abdeldayem1, 2, M. Yousseffi1, S.A. Khaghani1, 2, M. Genedy1, 2 and M.C.T. 
Denyer2. 
1School of Engineering, Design & Technology-Medical Engineering, 
2School of Life Sciences, University of Bradford, West Yorkshire, BD7 1DP, UK 
 
Abstract: Number of studies has been conducted to highlight the anti-inflammatory and 
immunosuppressive properties of cannabinoids and also their potentials for prevention 
of cartilage degradation. Various wound healing techniques can be used to investigate 
the mechanisms of chondrocyte repair in monolayer or 3 dimensional tissue. Therefore, 
we investigated the effect of two different concentrations (0.6 and 0.9μg/ml) of the 
synthetic cannabinoid R (+) WIN55, 212-2 on the wound healing of chondrocyte 
monolayers using a simple scratch assay model. WIN55, 212-2 was found to increase 
both the migration and proliferation of chondrocytes cultured in a chondrogenic media, 
with increase in the wound closure rate. These findings highlight the potential use of the 
synthetic cannabinoid for improving the rate of wound closure as well as acting as an 
anti-inflammatory agent, which could be used to enhance tissue engineering protocols 
aimed at cartilage repair.  
 
Keywords: WIN55, 212-2, chondrocyte, monolayer, cartilage, cell migration, cell 
proliferation. 
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Effect Of Cannabinoids (WIN55,212-2)  In Acceleration Of Wound 
Healing In Bone Cell Monolayer 
 
M. Genedy1, 2, N. Hoenig1, M. Youseffi1 and M.C.T. Denyer2 
1School of Engineering, Design and Technology-Medical Engineering Department 
2School of Life Sciences, University of Bradford, Bradford BD7 1DP, UK 
 
Despite the ongoing political debate regarding the legality of medical marijuana, clinical 
investigations of the therapeutic use of cannabinoids are now more prevalent than at any 
time in history. Cannabinoids have been shown to have analgesic, anti-spasmodic, anti-
convulsant, anti-tremor, anti-psychotic, anti-inflammatory, anti-oxidant, anti-emetic and 
appetite-stimulant properties. There are mainly two well-known cannabinoid receptors, 
CB1 and CB2, located in the central (CB1) and peripheral (CB2) nervous systems as 
well as the immune system. More recently, endocannabinoids (ligands) and their 
receptors have also been found in the skeleton which appear as the main body system 
and physiologically regulated by CB2. The purpose of this investigation was to study the 
rate of wound healing using a scratch assay wound model created on MG63 bone cell-
line monolayer and also to investigate proliferation and migration with and without the 
presence of CB1 and CB2 non-selective receptor agonist WIN55, 212-2. Wounds were 
made (average scratch width of 300μm±10-30μm SD, 1.7-5μm SEM) on confluent 
monolayers. After wounding, culture flasks were treated with the synthetic cannabinoid 
(WIN 55,212-2) diluted in ethanol with concentrations of 500nM, 1μM and 2μM, and 
compared to non-treated controls and ethanol only. It was found that addition of 1μM 
synthetic cannabinoid closed the wound completely after 25 hours whereas the control 
showed no sign of complete wound closure even after 30 hours with ~20% of wound 
still remained open. Results were then compared with cannabinoid additions to HaCaT 
cells (Human Keratinocytes monolayer) with only minor effect on wound closure.  The 
rate of wound closure was found to be higher with cannabinoid additions to MG-63 
bone cell monolayers. These findings suggest the potential use of synthetic cannabinoid 
(WIN 55,212-2) for achieving complete   wound closure at a faster rate.    
Keywords: MG63 Bone Cell Monolayer, Synthetic Cannabinoid (WIN 55,212-2), 
Scratch Assay Wound Model, HaCat cell Monolayer. 
 
 206 
 
 
Effect of CB2 Selective Agonist on Wounded Bone Cell Monolayers 
 
M. Genedy1, 2, M. Youseffi1 and M.C.T. Denyer2 
1School of Engineering, Design and Technology-Medical Engineering Department 
2School of Life Sciences, University of Bradford, Bradford BD7 1DP, UK 
 
More recently, endocannabinoids and their receptors have been found in the skeleton 
which appears to be physiologically regulated by CB2 receptor. Previous findings 
indicated non-selective CB1 and CB2 receptor agonist (WIN55,212-2)  accelerated 
wound healing of MG-63 bone cell monolayers. The purpose of this investigation was 
to identify which receptor contributes to the process of wound closure with higher 
acceleration. This was achieved by blocking with either CB1 or CB2 antagonist. Also, 
in this study CB2 receptor agonist HU308 was used on wounded MG-63 bone cell 
monolayers to investigate proliferation and migration as compared to WIN55, 212-2 
additions using the same scratch assay wound model. It was found that addition of 
500nM of CB2 selective agonist (HU308) increased wound healing with 90% of the 
wound closed after 20 hours whereas the control showed no sign of complete wound 
closure even after 30 hours. Results indicated that cannabinoids act mainly via CB2 
receptors in wounded MG-63 bone cell monolayers. These findings indicate the 
potential use of cannabinoids in bone repair. 
 
Keywords: MG-63 Bone cell Monolayer, Synthetic Cannabinoid (HU308), scratch 
Assay Wound Model, CB1 and CB2 receptors, endocannabinoids  
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Cell Traction Force Mapping in MG63 and HaCaTs 
 
Chin Fhong Soon1,a, M. A. Genedy2,b, M. Youseffi2,c, Morgan C. T. Denyer2,d 
1Biosensor and Bioengineering Laboratory, Microelectronics and Nanotechnology-
Shamsuddin Research Center (MiNT-SRC), Universiti Tun Hussein Onn 
Malaysia, 86400 Parit Raja, Batu Pahat, Johor, Malaysia. 
2 School of Life Sciences, University of Bradford, BD7 1DP, Bradford, United 
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Abstract 
The ability of a cell to adhere and transmit traction forces to a surface reveals the 
cytoskeleton integrity of a cell. Shear sensitive liquid crystals were discovered with new 
function in sensing cell traction force recently [1]. This liquid crystal has been 
previously shown to be non-toxic, linear viscoelastic and sensitive to localized exerted 
forces [2,3]. This paper reports the possibility of extending the application of the 
proposed liquid crystal based cell force sensor in sensing traction forces of osteoblast-
like (MG-63) and human keratinocyte (HaCaT) cell lines exerted to the liquid crystal 
sensor. Incorporated with cell force measurement software, force distributions of both 
cell types were represented in force maps. For these lowly contractile cells, 
chondrocytes expressed regular forces (10 – 90 nN, N = 200) around the circular cell 
body whereas HaCaT projected forces (0 – 200 nN, N = 200) around the perimeter of 
poly-hedral shaped body. These forces are associated with the organisation of the focal 
adhesion expressions and stiffness of the LC substrate. From the results, liquid crystal 
based cell force sensor system is shown to be feasible in detecting forces of both MG63 
and HaCaT. 
 
 
 
 
 
 208 
 
The effect of HU308/TGF-β3 combination on MG-63 osteoblast wound 
healing 
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Abstract 
Endocannabinoids (ligands) and their receptors have been identified in the skeleton 
system. It has also been indicated that their functions in bone are physiologically 
regulated by CB2 receptors. The purpose of this investigation was to study the rate of 
wound healing using a scratch assay wound model created on MG63 osteoblast bone 
cell-line monolayers and to investigate their proliferation and migration using CB2 
agonist HU308 in combination with TGF-β3. It is well established that the process of 
osteoblast cell wound healing occurs in three distinct but overlapping stages: (1) The 
early inflammatory stage; (2) The repair stage; and (3) The late remodelling stage, thus 
the use of Inflammatory or cytotoxic medication during the 1st stage of injury may delay 
the inflammatory response which is termed the reactive phase that is responsible for the 
recruitment of various cytokines to the site of injury. One such cytokine is transforming 
growth factor-Beta3 (TGF-β3) which is most abundant in the regulation of bone 
osteoblast cells. Our finding suggested that proliferation rate with 500nM HU308 was 
significantly higher than control and TGF-β3/HU308 combination groups (P<0.005). 
Interestingly, percentage of wound remained open after 15 hours for combination 
groups was 17.6%±1.32 whereas HU308 treatment groups had 20%±2.25 indicating 
that the combination groups took the lead throughout wound healing. It was also 
observed that bridge formation in treatment groups was taking place between 15 to 20 
hour period whereas within control groups bridge formation started to take place after 
25 hours. So far, this is the only investigation with CB2 HU308 selective synthetic 
cannabinoid in combination with TGF-β3 suggesting its synergistic role as a 
combination in the process of MG-63 osteoblast monolayer wound healing. 
Keywords: Cannabinoid, CB2- agonist, inflammatory, transforming growth factor, 
cytokines, migration, proliferation. 
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Abstract 
Endocannabinoid system is known to play an important role in the regulation of bone 
mass and bone remodelling (Idris and Ralston, 2010). One of the main 
endocannabinoids in bone is 2-arachidonoylglycerol (2-AG). Bone osteoblast cells have 
been reported to express type 1 cannabinoid receptor (CB1), type 2 cannabinoid 
receptor (CB2), and orphan G protein coupled receptor 55 (GPR55) which has been 
found to be activated by some cannabinoid receptor ligands (Ross, 2009). However, 
GPR55 does not appear to play a role in regulating bone formation (Whyte et al., 2009). 
Interestingly, CB1 expression in osteoblasts and their precursors is expressed in low 
levels (Tam et al., 2006) and the 2-AG synthesizing enzymes DAGLα and DAGLβ are 
expressed in bone cells since blood 2-AG level is negligible. In the current study the 
effect of monoglycerol lipase (MGL) inhibiter URB602 was investigated on MG-63 
osteoblast scratched monolayers. It is known that MGL hydrolyzes 2-AG to arachidonic 
acid and glycerol, thereby terminating its biological actions. Our results showed that 
MGL inhibitor URB602 accelerated wound healing with concentration of 1μM and 
increased proliferation rate. In contrast, cell migration as indicated by the percentage of 
cell surface reduction, was highest for concentrations of 500nM and 2μM and decreased 
for concentration of 2μM. Immunofluorescence revealed fibronectin and collagen type I 
expression which are related to the mechanisms of wound healing, thus indicating the 
potential role of URB602 in regulation of bone formation.  
 
Keywords: Cannabinoids, Endocannabinoid, URB602, MG63 Osteoblast cell line,  
Immunofluorescence, Fibronectin, Collagen type I. 
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Abstract 
Cannabinoids are compounds from the marijuana plant and their receptors CB1 and 
CB2 have been found in epidermal keratinocytes of normal skin and can be modulated 
through specific ligands [Ständer S, et al, 2005]. Damaged cells secret nitric oxide (NO) 
into the wound area and excess NO inhibits the important proteoglycan synthesis 
necessary for efficient wound repair [Mbvundula EC, et al 2005]. It was also found that 
excessive amount of NO mediates inhibition of epithelial wound closure, especially by 
decreasing cell migration. This study showed that synthetic WIN55,212-2 cannabinoid 
agonist inhibited NO production or at least reduced its negative effects. Addition of a 
cannabinoid antagonist was also found to affect the impact of WIN55,212-2, leading to 
further improved wound closure [Mbvundula EC, et al, 2005 and Pertwee RG, 1997]. 
In this work the effect of WIN55,212-2 additions in two different concentrations of 
1.0μg/ml and 1.5μg/ml using DMSO and ethanol as solvents on healing of scratched 
HaCaT cell monolayers have been investigated. Comparison was therefore made 
between the two solvents, i.e. DMSO and ethanol in terms of the wound healing 
process. The effect of antagonist LY320135 additive (1.5μg/ml in ethanol) in the 
presence of agonist WIN55,212-2 on the healing of scratched HaCaT cell monolayers 
was also investigated. Measurement of wound width was carried out every 2 hrs over a 
period of 12 hrs for the above mentioned experiments. The first 2 hour interval showed 
slight decrease or even an increase in wound width and wound closure after the first 2 
hour was regarded as almost linear. DMSO appeared to reduce wound closure and 
ethanol did not seem to affect wound closure significantly. The cannabinoid agonist 
WIN55,212-2 showed less wound closure after 12 hours than the control even in the 
presence of antagonist LY320135. It was therefore observed that reduction in contact 
inhibition lead to migration and proliferation of cells and that in the first 2 hours after 
scratching, there is an adjustment to the environment with removal of damaged border 
cells. DMSO was found to be an inefficient solvent due to its toxic impact on cells. 
Keywords: WIN55,212-2 agonist, LY320135 antagonist, Healing HaCaT cell 
Monolayer, Scratch assay, DMSO, Ethanol. 
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Abstract 
Cannabinoids have anti-inflammatory effects with production of eicosanoids promoting 
the resolution of inflammation. Cannabinoid receptor type-2 (CB2) appears to be 
responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis. 
Furthermore, CB2 has been identified on chondrocyte membrane. Our previous studies 
showed that treatment of chondrocytes with 1μM of the synthetic non-specific CB1 and 
CB2 agonist WIN55, 212-2 (WIN-2) increased the rate of wound closure in a simple 
scratch assay model. In this study, the effect of three different concentrations of HU-
308 with and without the synthetic CB2 antagonist AM630 on the rate of chondrocyte 
wound closure have been investigated. Chondrocytes were treated with 500nM, 1μM 
and 2μM of HU-308, and 500nM of HU-308 + 500nM of AM630. The rate of 
chondrocytes wound closure was measured and compared to those of untreated 
chondrocytes. Unlike  WIN-2, the concentraion that gave the higest wound closure rate 
was at 500nM. Furthermore, adding 500nM of the CB2 antagonist AM630 to this 
concentration reduced the rate of wound closure suggesting that HU-308 may have 
acted via CB2 receptor pathway. On the other hand, the 1μM of HU-308 treatment 
decreased the rate of wound closure, and the 2μM treatment significantly decreased 
both cell proliferation and migration. 
 
Keywords: HU-308, AM630, Chondrocyte monolayer, Scratch assay technique, Cell 
migration and cell proliferation. 
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Abstract 
Monoglycerol lipase (MGL) terminates the biological ability of endogenous 
cannabinoid receptor 1 (CB1), i.e. MGL hydrolyzes 2-Arachidonoyl Glycerol (2-AG) to 
arachidonic acid and glycerol, thereby terminating its biological actions. On the other 
hand, URB602 is a selective inhibitor of MGL, thus increasing the effects of 2-AG on 
CB1 receptors. Our previous studies showed that treating chondrocytes with 1μM of the 
synthetic non-specific CB1 and CB2 agonist WIN55, 212-2 (WIN-2) increased the rate 
of wound closure in a simple scratch assay model. In this study, the role of two different 
concentrations of URB602 with and without the synthetic CB1 antagonist LY-320,135 
on the rate of chondrocyte wound closure have been investigated. Chondrocytes were 
treated with 1μM and 2μM of URB602, and 1μM of URB602 + 500nM of LY-320,135. 
The rate of chondrocytes wound closure of  was measured and compared to those of 
untreated chondrocytes. Although treating chondrocytes with 1μM of URB602 
increased the rate of wound closure, it was not as significant as treating them with 1μM 
of WIN55, 212-2 (WIN-2). Furthermore, adding 500nM of the CB1 antagonist LY-
320,135 did not affect the rate of wound closure, suggesting that URB602 did not act 
via CB1 receptor pathway. On the other hand, treating chondrocytes with 2μM of 
URB602 lead to a significant decrease in cell proliferation and rate of wound closure. 
 
 
Keywords: Monoglycerol lipase, 2-Arachidonoyl glycerol, URB602, LY-320,135, 
chondrocyte, monolayer, scratch assay technique, cell migration and cell proliferation. 
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Abstract – In vitro Chondrocytes lose their 
chondrocytic morphology producing collagen type 
I instead of collagen type II. In this study 
chondrocyte monolayers treated with 1μM of the 
synthetic cannabinoid WIN55, 212-2  produced 
more collagen type II, and less collagen type I 
compared to control groups. Furthermore, treated 
chondrocytes displayed round chondrocytic 
morphology, while control groups displayed a 
more elongated fibroblastic morphology. These 
results suggested that WIN55, 212-2 encouraged 
chondrocytes dedifferentiation, which could be 
used to reduce scar formation in healing of 
articular cartilage. 
I. INTRODUCTION 
The dramatic increase in the prevalence of cartilage 
disease, injuries and its poor ability to repair [1] due 
to very low (or no) blood  supply [2, 3] has increased 
the need for new engineering cartilage techniques. 
Chondrocytes play a major role in maintaining 
cartilage homeostasis where they maintain the 
balance between cartilage degradation and 
biosynthesis as well as incorporation of matrix 
components [4]. Thus, to improve cartilage healing, 
chondrocytes need to be targeted. Synthetic 
cannabinoids such as Win-55,212-2 and HU-210 
have been found to affect the metabolism of 
chondrocytes reducing cartilage breakdown [5]. 
Moreover, their anti-inflammatory and analgesic 
properties [6] make them an attractive option for 
treating cartilage degradation diseases; such as 
osteoarthritis. 
II. METHODS 
Chondrocytes isolated from Sprague-Dawley rats (3-
6 days old) were cultured at humidified atmosphere 
(95% air and 5% CO2) at 37ºC till the 3rd passage. 
After that, 2 groups of chondrocytes were prepared. 
The first group was treated with 1μM WIN55, 212-2, 
and the second group was untreated (control), where 
each group consisted of two samples. Cells were left 
for 24 hours, and then the first and the second sample 
of each group were stained for collagen type I and 
collagen type II, respectively. Stained samples were 
viewed under the immunofluorescence microscope 
after incubating at 5 ºC for 1 week. 
Immunoperoxidase was also used as a quantitative 
staining technique to confirm the 
immunofluorescence staining results. Finally, SPSS 
was used for statistical analysis of the quantitative 
data obtained. 
III. RESULTS AND DISCUSSION 
By comparing (a) and (c) in Figure 1, it can be seen 
that the staining intensity of collagen type I in the 
control group is much higher, whereas the staining 
intensity of collagen type II is higher in (b) WIN-2 
than (d) control. Therefore, treating chondrocytes 
with 1μM WIN-2 increased collagen type II 
secretion, while reducing collagen type I secretion, 
which was confirmed with quantitative staining 
(P<0.05).  
(a) (b) 
(C) (d) 
Figure 3.  immunofluorescence images of (a) WIN-2 CO I, (b) WIN-
2 CO II, (c) Control CO I, and (d) Control CO II, 20 X 
magnifications. 
III. CONCLUSION 
Treating chondrocyte monolayers with 1μM of the 
synthetic cannabinoid WIN55, 212-2 encouraged 
chondrocytes dedifferentiation, which could be used 
to reduce scar formation in healing of articular 
cartilage. 
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